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INTRODUCTION 
                      The siddha system of medicare is one of the most ancient systems 
contemporaneous with those of the submerged lands, Egyptian, Mesopotamian, Chinese 
and Grecian medicines. It is the holistic health care system, perfected many thousands of 
years ago in the Tamil speaking peninsular India.  
The granite rocks of the southern peninsula belong to the category of Archaic 
Rocks and are estimated to be around 2.5 to 4 billion years old. The historical, 
Anthropological, Archeological and Geographical evidences currently available confirm 
the antiquity of human civilization in this region. This antiquity also places the Siddha 
system of health science of this region as the oldest. 
Siddha system of medicare is also being called as Tamil Maruthuvam, 
Chinthamani Maruthuvam and Arivan Maruthuvam. The word Siddh means realized and 
perfected. Siddhar means perfected or realized saints. Siddhar implies an expert in 
occultism, alchemy and so on with divine power. Since the advent of Thirumoolar who 
denotes Siddhi as super natural powers in his text Thirumanthiram, this is popularly 
called as Siddha system. 
 Siddha system is associated with Siddhars – the enlightened seekers. Who aimed 
for ageless body to achieve their highest spiritual goal. Though the system of medicine is 
associated with Tamilnadu the originators of the system, Siddhars have transcended to 
different parts of the world.   
           The principles of siddha system are based on five basic elements, called Earth 
matter (Mann), Space (Aagayam), air (Vali), fire (Thee) and water (Neer). The formation 
of the five classical elements as per the Tamil literature  
ÁñÊ½¢ó¾ ¿¢ÄÛõ 
¿¢Ä§Áó¾¢Â Å¢ÍõÒõ 
Å¢ÍõÒ¨¾ÅÕ ÅÇ¢Ôõ 
ÅÇ¢ò¾¨ÄþÂ ¾£Ôõ 
¾£ ÓÃ½¢Â ¿£Õ ¦ÁýÈ¡íÌ 
³õ¦ÀÕõ â¾ò¾¢Âü¨¸ §À¡Ä. 
- ÒÈ¿¡ÛÚ 
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       "¿¢Äõ ¿£÷¾£ÅÇ¢ Å¢Íõ§À¡¨¼óÐõ 
            ¸Äó¾ÁÂì ¸ÓÄ¸ Á¡¾Ä¢ý"     
-¦¾¡ø¸¡ôÀ¢Âõ 
It means the world is formed of the five elements. 
 
 The concepts of the five element constituting macrocosm (universe level) all the 
way down to the microcosm (sub atomic or even meta physical-level). This is better 
described by the verse of Siddhar Chattamuni. 
 
 “«ñ¼ò¾¢ø ¯ûÇ§¾ À¢ñ¼õ 
  À¢ñ¼ò¾¢ø ¯ûÇ§¾ «ñ¼õ 
  «ñ¼Óõ À¢ñ¼Óõ ´ý§È 
  «È¢óÐ ¾¡ý À¡÷ìÌõ§À¡§¾”     
   -  ºð¼ÓÉ¢ »¡Éõ. 
This is very basic of understanding that the seven physical constituents (Udal 
thathus) and three biological humors (Uyir thathus) are all based of the five elements. 
Change in life style i.e.  Food habits and physical activities will make an imbalance of 
three biological humors leads to pathological changes in the body and mind. 
“Á¢¸¢Ûí Ì¨ÈÂ¢Ûí  §¿¡ö ¦ºöÔ á§Ä¡÷ 
ÅÇ¢ Ó¾Ä¡ ¦Åñ½¢Â ãýÚ”    
-  ¾¢ÕìÌÈû 
 
 Disharmony with environment is the cause of most of the diseases. Both extrinsic 
and intrinsic factors are responsible for the manifestation of diseases. Uyir Tathus when 
deranged become thodams resulting in various diseases numbering 4448 as per Siddha 
text. 
 Kunmam is a disease one among them occurs due to the derangement of Uyir 
tadhu Vali as per Siddhar Theriyar  
 
“¦¾¡¼÷ Å¡¾ Àó¾ÁÄ¡Ð ÌýÁõ ÅÃ¡Ð” 
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Siddhar Yugi in his Yugi Vaithiya Chinthamani classified Kunmam in to eight 
types. One among them is Vaayu kunman. Melnokku kaal and Keezh nooku kaal are 
primarily affected in Vaayu kunmam. The signs and symptoms of Vaayu kunmam may be 
correlated to Gastritis in modern system of Medicine. The symptoms are as follows. 
Indigestion, Nausea or Vomiting, Aversion to food, Flatulence, Gripping abdominal pain 
and Generalized weakness. 
 In the Siddha Text ‘Yakoobu Vaidhiya Chinthamani 700’ the drug “Vediyuppu 
Kattu” is indicated specifically for Atta Kunmam and Vaayu. The main ingredients of 
Vediyuppu Kattu are Vediyuppu and Seenam. As per the Siddha literature Pathartha 
Guna Chinthamani Vediyuppu and Seenam are found to be very efficacious in the 
treatment of ‘Vaayu Kunmam’. 
 The above mentioned formulation has not undergone any clinical trial so far. 
Hence i selected Vediyuppu Kattu for further clinical evaluation in Vaayu Kunmam. 
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AIM AND OBJECTIVES 
 
AIM 
The aim of the study is to evaluate the safety and therapeutic efficacy of the 
Siddha formulation “Vediyuppu Kattu” (Internal Medicine) in the treatment of “Vaayu 
Kunmam”(Gastritis). 
 
OBJECTIVES 
1. PRIMARY OBJECTIVE 
To evaluate the therapeutic efficacy of the Siddha formulation “Vediyuppu Kattu” 
(Internal Medicine) in the treatment of “Vaayu Kunmam” (Gastritis). 
2. SECONDARY OBJECTIVE 
n To evaluate the safety profile of the trial drug (Acute and Long term toxicity studies) to be 
carried out as per W.H.O guidelines 1993. 
n To conduct a clinical trial with a well defined proforma on the patients identified with 
“Vaayu Kunmam” 
n To screen the biochemical constituents of the trial drug “Vediyuppu Kattu”. 
n To study the influence of other co factors such as age, sex, dietary habits, family history, 
socio economic status, habitat etc on the disease. 
n To find out the side effects / adverse effects of the drug “Vediyuppu Kattu” if any. 
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SIDDHA ASPECT 
KUNMAM 
SYNONYM: 
Kunmam, Vaittrul puralal, Vaittru puraludan nothal. 
DEFINITION: 
Kunmam is a form of dyspepsia with burning sensation and gnawing pain in 
gastrium, gastric eructation, nausea, vomiting and indigestion. These terms refer to 
deterioration of both body and mind due to pain.  
NOI VARUMVAZHI (ETIOLOGY)       
ACCORDING TO THERIYAR PINI ANUGA VIDHI:                                                
 “¦¾¡¼÷ Å¡¾ Àó¾ÁÄ¡Ð ÌýÁõ ÅÃ¡Ð”  
- §¾¨ÃÂ÷ 
As per the Theriyar Text, Kunmam occurs due to the repeated derangement of 
Vaatham. Primarily Udhanan vaayu, Abanan vaayu and Samanan vaayu gets affected. 
ACCORDING TO YUGI VAIDHYA CHINTHAMANI  800: 
 “¦ºöÂ¡É ÌýÁò¾¢ §¾¡üÈó ¾ý¨Éî 
¦ºôÀ¢¼§Å ÐÅ÷ôÀ¡É ¦À¡º¢ôÀ¢ É¡Öõ 
¨ÁöÂ¡É Áí¨¸Ô¼ý ÁÕÅ Ä¡Öõ 
Å¨¸Â¡Ìí ¸¢ÆíÌ Å¨¸ ÂÕó¾ Ä¡Öõ 
¯öÂ¡É Á¢ÇÌ Å¨¸ Ô¨ÃôÀ¢ É¡Öõ 
¯ÕÀº¢¨Â Â¼ì¸¢Îõ Áó¾ò ¾¡Öõ 
¨¾Â¡Ç ºñ¼¡Ç §¸¡Àò ¾¡Öõ 
ºÄ¢ôÀ¡Öõ ÌýÁõ Åó¾¨¼Ôõ À¡§Ã”. 
- ä¸¢ ¨Åò¾¢Â º¢ó¾¡Á½¢ 
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    “À¡÷ì¸§Å ÌÕ¿¢ó¨¾ Àñ½¢ §É¡÷ìÌõ 
À¡Ä¸¨Ãî º¢Í¨ÅÀðÊÉ¢¨Åò §¾¡÷ìÌõ 
Á¡÷ìÌõÁ¡ ¾¡¨ÅôÀ¢ ¾¡¨Å ¿¢ó¨¾ 
Åïº¨É¾¡ý ¦ºö§¾¡÷ìÌ Á¼ó¨¾ ¾ý¨É 
¸¡÷ì¸§Å ¸üÀÆ¢ò¾ ¸¡Ó¸÷ìÌõ 
¸Õ¾¢§Â º¢Å¿¢ó¨¾ Àñ½¢ §É¡÷ìÌõ 
¬÷ì¸§Å Â‰¼ ÌýÁ ÁÏÌ ¦ÁýÈ 
«Ãý¦º¡øÄò §¾Å¢¦º¡ýÉ¡Ç È¢óÐ À¡§Ã”. 
      - ä¸¢¨Åò¾¢Â º¢ó¾¡Á½¢ 
 
Yugi said that, there are two main reasons for the onset of Kunmam 
1. Seiyal maarupadugal  (Change in personal habits) 
2. Manamarupadugal  (Altered mental status) 
1. Personal habits: 
  
· Intake of contaminated food and water 
· Excessive intake of foods that produces indigestion and flatulence 
· Excessive intake of tubers  
· Excessive intake of spicy items 
· Starvation 
· Excessive sexual indulgence 
2. Mental status: 
· Increased anger 
· Mental depression 
· Disobedience towards God, Teacher, and Parents.  
· Ill treating the parents,  
· Letting the children and infants in a starving condition,  
· Involving in the antisocial activities such as rape etc. 
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AGASTHIYAR VAITHYA KAVIYAM-1500: 
 “§ÁÅ¢Â ÌýÁó¾¡ý ¦ÉØó¾§¾¡÷ Å¢¾í¸û ¦º¡ø§Å¡õ 
       À¡Ã¢Â À¢ò¾§¾¡Îõ Å¡¾Óõ ÀÃ¢óÐ §ºÃ¢ø 
       À¡¸¢Â Åñ½ ¿£Õõ Å¡ó¾¢Â¡Ìõ À¡§Ã”. 
- «¸ò¾¢Â÷ ¨Åò¾¢Â ¸¡Å¢Âõ 1500 
According to ‘Agasthiyar vaithya kaviyam’ the combination of Pitham with 
Vaatham induces Kunmam leads to vomiting of food and water. 
AGATHIYAR GUNA VAGADAM: 
“¾¡É¡É ÌýÁ Å¨¸ ±ðÎ Á¢ó¾ò 
¾¡Ã½¢Â¢ Öñ¼¡É Å¢¾ò¨¾ì §¸Ç¡ö 
°É¡É «º£Ã½ó ¾¡Éó¾ §Ã¡¸õ 
¯üÀò¾¢Â¡Ì ¦Áý§È ¯Ú¾¢ ¦º¡øÖ". 
- «¸ò¾¢Â÷ Ì½Å¡¸¼õ 
Agathiar assures all the eight types of Kunmam are caused by indigestion of food. 
AGATHIYAR KANMA KANDAM: 
“ÌýÁõ Åó¾ ¸¡Ã½ó¾¡§É§¾¡¦ÅÉ¢ø 
ÌÊì¦¸Îò¾ ÅÂ¢ü¦ÈÃ¢îºø ¦¸¡ñ¼À¡Åõ 
¿ý¨ÁÂ¢øÄ¡ ÁÉì¸ºÎ ¦ÀÕò¾À¡Åõ 
¿ø§Ä¡¨Ã ÁÉõ §¿¡¸ô ÀÆ¢ò¾ À¡Åõ 
¾ý¨ÁÂ¢øÄ¡ À¢È÷Àº¢ì¸ ×ñ¼À¡Åï 
ºñ¼¡Ç ¾òÐÅ§Á ¦ºö¾ À¡Åõ 
þõ¨ÁÂ¢§Ä þôÀ¡Åõ ÅóÐ ÍüÈ¢ 
Â¾É¡§Ä ÌýÁ¦ÁÉ ¦ÅÎò¾ Å¡§È”. 
- «¸ò¾¢Â÷ ¸ýÁ ¸¡ñ¼õ 
 
Agathiar in his Kanma kandam states the cause for Kunmam as 
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· Sin pertaining to those who have deprived the dwellings of others and 
humiliating elders. 
· Consuming food in the presence of starved people. 
· Slanderers acquire the disease by their action and covetous mind in the 
past. 
PARARASA SEKARAM: 
“¸ÂÁ¡É Ì¼Ä¢ Ûû§Ç 
¸øÖÁ¢ ¦¿øÖ Á¡§Á 
¸ø¦Ä¡Õ ÁÂ¢Ã¡ ÔûÇ 
¸º¼Ð Ì¼Ä¢ü ÀüÈ¢ 
ÅøÄÀ¡í ¸ÐÅ¡ ÂýÉï 
¦ºÃ¢Â¡¾ Á¡º¢ É¡§Ä 
¦ÁøÄ¢Â ¸¢ÕÁ¢ ¦¸¡ñÎ 
ÌýÁ §¿¡ö ÁÕ×í ¸¡§½". 
-  ÀÃÃ¡º §º¸Ãõ 
 
Intake of food contaminated with stones, rice husks, hair causes indigestion which 
in turn leads to infection by microorganisms results in Kunmam.  
THIRUMOOLAR KARUKKADAI VAITHYAM: 
“²üÈ¢Â ÌýÁõ ¦ÀÕò¾ Å¢¾í§¸û 
§¾¡ýÈ¢Â À¢ò¾Óõ Å¡Ô×õ ¦¾¡ó¾¢ì¸¢ø 
§ºüÈ¢Â ÅýÉõ ¦ºÃ¢ì¸¢ø ÅÉô¦ÀÚõ 
Á¡üÈ¢Â ¿£Õ¾¢ Å¡ó¾¢ÔÁ¡§Á”. 
   -  ¾¢ÕãÄ÷ ¸Õì¸¨¼ ¨Åò¾¢Âõ 
If Azhal and Vali together affected it leads to Kunmam. 
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RESTRICTIONS OF BODY FUNCTIONS: 
"Å¡¾ò¨¾ ¾¨¼ ¦ºö¾¡§Ä¡ 
 Á¡÷À¢§É¡ö ÌýÁõ Å¡Ô" 
- «Úº£÷ Å¢Õò¾õ 
As a result of prevention of the movement of vaatham, kunmam will occur. 
“Å¢Æ¢Â¢É¢ø ¿£Ã¼ì¸¢ø Å¢¾Á¡É þÕòÐ§Ã¡¸õ 
ÅÆ¢ÂÎ À£¿¢ºí¸û Åó¾¢Îõ §¿òÃ§Ã¡¸õ 
«Ø¸¢Îõ º¢Ãº¢ý §Ã¡¸õ «¾Û¼ý Å¡¾õ ÜÊø 
ÀØÐ¼ø Àñ½¢ì ÌýÁõ ÀüÈ¢Îõ Ì½ÓÓñ§¼” 
- «Úº£÷ Å¢Õò¾õ 
Preventing tears leads to disease of Heart, sinuses, eye and head. when vaatham 
adds to it causes Kunma noi. 
PATHARTHAGUNA CINTHAMANI: 
"°ÛìÌ Óý ¿£Õñ¼¡ü 
Å¢ÛìÌ ÌýÁõ Å¢¨ÇÔí¸¡ñ" 
Intake of water before taking food leads to the genesis of Kunmam. 
AAVIYALLIKUM AMUTHAMURAI CHURUKKUM BY SIDDHARS: 
According to the text aaviyallikum amuthamurai churukkum, Kunma noi there 
will be excess secretion of Analapitham (Hcl) which induce gastric eructation, dyspepsia, 
flatulence with pain. 
 
CLASSIFICATION OF KUNMAM: 
         
   YUGI CLASSIFICATION: 
           Yugi classified the Kunmam into 8 types 
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                1. Vaayu kunmam 
                2. Vatha kunmam 
                3. Pitha kunmam 
                4. Eri kunmam 
                5. Vali kunmam 
                6. Satthi kunmam 
                7. Sanni kunmam 
                8. Sethuma kunmam 
 
THIRUMOOLAR CLASIFFICATION: 
Classified the kunmam into 8 types 
Due to derangement of vali: 
                      1. Vatha kunmam 
                      2. Soolai kunmam 
                      3. Vali kunmam 
   Due to derangement of pitham: 
                       1. Eri kunmam 
                       2. Pitha kunmam 
                       3. Satthi kunmam 
  Due to dearangement of kabam: 
                        1. Iya kunmam 
                        2. Sanni kunmam 
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ACCORDING TO T.V.SAMBA SIVAM PILLAI DICTIONARY: 
Kunmam is classified into 13 types 
1. Eri kunmam 
2. Vali kunmam 
3. Satthi kunmam 
4. Kasa kunmam 
5. Thontha kunmam 
6. Sanni kunmam 
7. Valineer kunmam 
8. Purattal kunmam 
9. Pitha kunmam 
10. Vatha kunmam 
11. Kari kunmam 
12. Silethuma kunmam 
13. Pulippu kunmam                      
 
ACCORDING TO DANVANTHRI VAITHYAM: 
Danvanthri says that 108 diseases arise from the abdomen; eight among them are 
kunmams which are as follows 
                       1. Vatha gknmam  
                       2. Vali kunmam 
                       3. Satthi kunmam 
                       4. Soolai kunman 
                       5. Pitha kunmam 
                       6. Susai kunmam 
                       7. Kaba kunmam 
                       8. Eri kunmam 
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ACCORDING TO YUGI VAITHIYAKAVIYAM: 
Classified the kunmam into 11 types 
                       1. Vali kunmam 
            2. Maha kunmam 
                       3. Bethi kunmam 
                       4. Vatha kunmam 
                       5. Soolai kunmam 
                       6, Pitha kunmam 
                       7. Eri kunmam 
                       8. Satthi kunmam 
                       9. Kabala kunmam 
                      10. Ratha kunmam 
                      11. Susai kunmam 
 
AATHMA RATCHAMIRTHAM ENNUM VAITHYA SARASANGIRAKAM:   
Classified the kunmam into 8 types 
1. Vatha kunmam 
2. Pitha kunmam 
3. Silethuma kunmam 
4. Vali kunmam 
5. Satthi kunmam 
6. Eri kunmam 
7. Soolai kunmam 
8. Kabala kunmam 
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VAAYU KUNMAM 
Å¡Ô ÌýÁõ 
§ÅÚ ¦ÀÂ÷:  
À¡ÔÕ ÌýÁõ,  
Ý¨Ä ÌýÁõ. 
 
 AS PER YUGI VAITHYA CHINTHAMANI 
"À¡÷ì¸§Å Å¡Ô ÌýÁõ À¸Ãì §¸Ç¡ö 
 ÀÕ¸¢Â§¾¡÷ À¾¡÷ò¾í¸û ¦ºÃ¢ò¾¢¼¡Ð 
§¾÷ì¸§Å ÂºÉó¾¡ý ¦ºøÄ¡ ¾¡Ìõ 
 ÐÕò¾¢¦¸¡ñ ¸¡üÈÐ§À¡ø ÅÂ¢Ú ÓôÒõ 
°÷ì¸§Å ¯û¦ÀÄÛõ ¦¸ÎôÀ ¾¡Ìõ 
 ¯¼ÖÄÕõ ¿¨¼Ì¨ÈÔõ µöîºÄ¡Ìõ 
§Å÷ì¸§Å ÂÊÅÂ¢Ú ¾É¢§Ä ÅóÐ 
 Á¢¸ôÒÃñÎ Å¢øÖô§À¡ø Å¢Ìò¾Ä¡§Á" 
      - ä¸¢ ¨Åò¾¢Â º¢ó¾¡Á½¢ 
 
CLINICAL FEATURES: 
· Indigestion,  
· Vomiting the residues of last food intake,  
· Aversion to food,  
· Flatulence,  
· Fatigue,  
· Generalized weakness,  
· Sweating  
· Gripping abdominal pain,  
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AS PER NAADI NOOL: 
"À¡ÃôÀ¡ Å¡ö× Å¡¾õ 
 ÀÃ¢×¼ý «À¡É §É¡í¸¢ 
µÃôÀ¡ ÌõÀ¢ ¾ýÉ¢ø 
 ¯ÕñÎ¾¡ý Á¢¸§Å §¿¡Ìõ 
§¸¡ÃôÀ¡ ¦¿ïÍ ÌòÐí 
 Ì¼¨ÄÔ ÓÚì¸¢ì ¦¸¡ñÎ 
Å¡ÃôÀ¡ ÅÄ¢ìÌ ¦Áò¾ 
Å¡ºÁ¡ö ÅÆíÌõ Å¡ö§Å" 
     - ¿¡Ê áø 
CLINICAL FEATURES: 
· Increased vaatha humor 
· Flatulence with painfull abdomen. 
· Pricking pain of the chest. 
· Gripping abdominal pain, 
 
In T.V.S Dictionary description: 
Vaayu Kunmam is one of the classifications of Kunmam disease. 
A form of dyspepsia marked by following symptoms viz- Upper abdominal pain, 
unusual secretion of saliva, indigestion, belching, etc… 
YUGI VAITHYA KAAVIYAM: 
Å¡Ô ÌýÁõ (Ý¨Ä) ÌýÁò¾¢ý þÂøÒ: 
 
" §ÁøÅÂ¢Ã ¾¢§ÄÅóÐ Á¢¸ôÀ¼ÅÄ¢ò¦¾Ã¢òÐ 
º¡Ä§ÅÅ¡ö¿£÷°È¢ò ¾Ã¢ò¾¢¼¡ §¾ôÀõ ¯ñ¼¡ö 
º£Ä Á¡õ ÌÇ¢÷ ±ØõÀ¢î º¢Ú¸×û ¦ÅÐõÒõ ±ýÉ 
§¸¡ÄÁ¡õ ÌÆÄ¢É¡§Ç Ý¨Ä ÌýÁõ ±ýÉÄ¡§Á" 
    - ä¸¢ÓÉ¢ ¨Åò¾¢Â ¸¡Å¢Âõ  
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1. Pain in the upper abdomen 
2. Excessive salivation in mouth 
3. Belching 
4. Rigor  
5. Raised body  temperature 
AATHMA RATCHAMIRTHAM ENNUM VAITHYA SARASANGIRAKAM: 
1. Burning sensation in the upper abdomen 
2. Excessive salivation, Nausea 
3. Belching 
4. Shivering 
5. Pain in the joints. 
MUKKUTRA VERUPADUGAL (Pathogenesis) 
Disease occurs due to the derangement in 
· Uyir thathukkal  
· Udalthathukkal   
· kaala marupadu (seasonal changes) 
· Thinai (living lands) and 
· Udal vanmai. 
Mukkutra Iyal  
The function of the three uyir thathus:  
a) Vali   –  (Kattru + Veli) 
b) Azhal  – (Thee) 
c) Iyyam – (Neer + Mann) 
The alteration of three thathu in their reaction to extrinsic or intrinsic factors 
results in disharmony. This altered harmony and balance variation of the three thathus 
results in disease. Their natural ratio (1 :½:¼) to each other is discerned by the physician 
at the wrist and each naadi is individually assessed for its strength, speed and regularity. 
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The following poem describes the origin of three uyir thathus 
‘,Ug;ghd ehb vOgNjhBuh 
 apukhd Njfj;jpy; Vyg; -ngUehb 
 xf;fj; jrkj; njhopiy a+f;f jrthAf;fs; 
 jf;fgbahdNj  rhu;G” 
‘rhUe; jrehb jd;dpy; %yk; %d;W 
 NgUkplkp gpq;fiyAk; gpd;dYld;-  khWk;  
 ciuf;ftpuw; fhw;nwhl;Lzu;j;J Nkehrp 
 tiur;Rop Nahikaj;jpy; te;J” 
‘te;jfiy %d;wpy; tha;thkghdDld; 
je;j gpuhzd; rkhdDk; re;jKwf; 
$l;Lwtpy; Nurpj;jy; $Wk; thjk; gpj;jk;; 
ehl;Lq;fgNk ahk; ehL” 
 
- fz;Zrhkpak; 
The three thathus are manifested at the wrist and are individually and collectively 
assessed. These three humour are divided in to various types and have their functions 
specifically. 
FUNCTIONS OF VALI  
‘xOq;Fls; jhNjo;%r; Nrhq;fp ,aq;f 
vOr;rpngw vg;gzpAk; Mw;w - vOe;jpupa 
Ntfk; Gyd;fSf;F Nktr; RWRWg;G 
thfspf;Fk; khe;ju;f;F thA” 
- kUj;Jt jdpg;ghly;   
According to the physiological function, vali is classified into ten types. They are  
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1. Uyir Kaal (Pranan)       
This is the first of ten vital airs. According to Yugimuni, pranan starts from 
moolatharam and comes through the nostrils and causes the act of inspiration and the 
expiration. The inspiration and expiration are not equal and their ratio is 8:12. This is 
responsible for the respiration of the tissues, controlling knowledge, mind and five sense 
organs and helps in the digestion of ingested food. 
2. Kizhnokkumkaal (Abanan)      
Abanan, the downward air, starts from swathittanam and descends towards the 
pelvis and is responsible for excretion of urine and faeces ejaculation of semen and 
menstruation. This is green in color. It contracts the anus. It helps to take the essence of 
the digested food to the different parts of the body which requires food. The god 
attributed is varadarajan. 
3. Paravukaal (Viyanan) 
Viyanan arises from the shoulders and go through all the 72,000 nerves and thus 
activate voluntary and involuntary movements of the body and thus make them to extend 
and contract. This is responsible for the motor and sensory function of the entire body. 
This appreciates the sense of touch, helps to take the essence of the food to the strategic 
points of the body and guards the body. 
4. Melnokkumkaal (Udhanan) 
Udhanan starts from the umbilical region (Udarakkini) and takes the essence of 
food and stations it at appropriate places. It helps in digestion and assimilation of food. It 
is   responsible for all the upward movements. 
5. Nadukkaal (Samanan) 
Samanan starts from the umbilical cord and spread out up to the lowerlimb. This 
is responsible for the balance of the other four vathas. It equalizes the six tastes, water, 
food etc and helps in assimilation. 
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6. Naagan 
Naagan is responsible for higher intellectual functions, hearing, thinking etc. It 
causes closing and opening of the eye lids. Its derangement causes impaired memory, 
lack of coherent thinking. 
7.  Koorman 
Koorman starts from the mind and causes winking of the eyelids, yawning and 
closure of mouth.It gives strength to the body and helps to visualize things and causes 
lacrimal secretion 
8. Kirukaran 
Kirukaran lies in the tongue and causes nasal and salivary secretions. Hunger, 
concentration of the mind on one particular thing, Sneezing and cough are attributed to 
kirukaran. It is black in colour 
9. Devadaththan 
Laziness is attributed to devadaththan. Occular movements and human passions 
are attributed to this vaatham. It stays at the anus or at urinary orifice. 
10. Dhananjeyan 
Dhananjeyan functions from the nose and it is responsible for the bloating of the 
body after death and also for the foul smell. 
In Vaayu Kunmam, Pranan, Samanan and Udhanan will be mainly affected due to 
poor appetite, gastro intestinal symptoms and indigestion respectively.  
Abanan and Viyanan may also be affected due to changes in bowel movements 
and poor assimilation. 
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FUNCTIONS OF AZHAL 
‘grpjhfk; Xq;nfhspfz; ghu;itgz; lj;J 
Urpnjup rj;jp ntk;ik tPuk; - crpj 
kjp$u;j;j Gj;jptdg; gspj;Jf; fhf;Fk; 
mjpfhup ahq;fh doy;” 
-  kUj;Jt jdpg;ghly;  
Azhal is functionally divided in to five types. They are 
1. Aakkanal (Anala pitham) 
It lies between the stomach and the intestine and causes digestion and dries up 
moist ingested substances. Its derangement produces indigestion, acidity, burning 
sensation in the middle of the chest, throat and stomach. 
2. Vanna eri (Ranjaga pitham) 
This fire lies in the stomach and gives red colour to the chyme and produces 
blood. It improves blood. Its derangement causes disease of the liver and spleen and 
disease of the blood. 
3. Attralangi (Sadhaga pitham) 
This fire lies in the region of intellectual function and helps for the 
accomplishment of desired functions. 
4. Nokku Azhal(Alosaga pitham) 
It lies in the eyes and causes the faculty of vision. It helps to visualize things 
5. Ollolithee (Prasaga pitham) 
It gives color and complexion and brightness to the skin. 
In Vaayu Kunmam Anala Pitham is mainly affected due to indigestion, acidity, 
burning sensation in the middle of the chest. In later stage Attralangi and Vannaeri will be 
affected. 
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FUNCTIONS OF IYAM 
‘jplkPA nkd;gpizg;Gj; jpz;ikAw;w ahg;Gk; 
 
mlNyu; tOtOg;Gk; Mf;iff; - fplu;f;F 
 
ntUthg; nghWikAk; Nkyhd fhg;ghk; 
 
ngUikj;jh ikankdg; NgR” 
- kUj;Jt jdpg;ghly;  
It is of five types. They are 
1. Alli Iyyam (Avalambagam) 
It lies in the lungs and helps in respiration. It causes firmness of the limbs. This is 
vital among all types of kapham. It controls the other four kapham and maintains 
equilibrium 
2. Neerpi Iyyam (Kilaethagam) 
It lies in the stomach. It mixes the consumed food and water and promotes the 
digestive process. Protects the upper and middle abdomen from hot, irritant and cold food 
as well as from the secretions of anala pitham. 
3. Suvaikanna Iyyam (Pothagam) 
It lies in the tongue and helps to realize the taste of the consuming food. 
Potentially harmful substances are initially rejected by this taste screen. 
4. Niraivu Iyyam (Tharpagam) 
Sustaining in the head, this gives refrigerant effect to cool the eyes and other sense 
organs. 
5. Ondri Iyyam (Santhigam) 
Sustaining in the joints this makes them more freely and easily. 
In Vaayu Kunmam, Kilaethagam may be affected due to altered digestive process 
and Pothagam may be affected due to altered taste sensation. 
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PARUVAKALAM (SEASONS) 
According to ancient Tamilians, the one year is divided in to six seasons and each 
season consists of two months and the year starts from Margazhi 
1. Munpani -   Early winterseason from Markazhi to thai (Dec16 to Feb15) 
2. Pinpani  -   Latter winter season  from Masi to panguni (Feb16 to Apr15) 
3. Elavenil  -   Early summer season from Chithirai to vaikasi (Apr16-Jun15) 
4. Mudhuvenil  -   Latter summer season  from Aani to aadi (Jun16 to Aug15) 
5. Kaar -   Early rainy season  from Aavani to puratassi (Aug16 to Oct15) 
6. Koothir  -   Latter rainy season  from Iypasi to karthigai (Oct to  Dec15) 
 
The disease Vaayu kunmam mostly aggravated during the seasons Elavenil 
(early summer) and Muthuvenil (Late summer).  
 
The winter season gives good health to the man, early summer and latter rainy 
gives moderate health. Whereas early rainy and latter summer are more prone to diseases, 
that’s why siddhars called it as Aanaga kalam 
 
THINAI (LAND) 
Siddhars classified the lands in to five types. They are 
1. Kurungi  - Mountain range 
2. Mullai  - Pastoral area of the forest 
3. Marudham - The fertile river bed 
4. Neidhal  - The coastal region 
5. Paalai  - Arid desert                                                                     
 
· Marudha nilam is the fertile area where no disease occurs 
· It is reportedly higher in Palai, Neithal and Mullai area’s when compared to 
others. 
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Relation between Mukkutram, Kaalangal and Thinnaigal 
Mukkutram 
Paruvakalam (Seasons) 
Thinai Thannilai 
vazharchi 
(Accumulation) 
Vetrunilai 
vazharchi        
(Aggravation) 
Thannilai 
adaithal             
(Alleviation) 
Vaatham Mudhuvenil 
kalam 
Kaar kalam Koothir kalam Vatha disease is 
more prevalent in 
Neithal land 
Pitham Kaar kalam Koothir kalam Munpani Pitha disease is 
more prevalent in 
Mullai land 
Kapham Pinpani Elavenil kalam Mudhuvenil 
kalam 
Kaphadisease is 
more prevalent in 
Kurunchi land 
 
Gnanenthriyam: 
Mei       -          feels all types of sensation.  
Vaai      -   for identifying taste.  
           Kan   -  for vision  
           Mooku  -  for identifying the smell 
           Sevi   -  for hearing    
In Vaayu kunmam, mei was affected due to the presence of epigastric tenderness 
and vaai may affected due to impairment of taste sensation          
Kanmenthriyam: 
Kai  -  majority of normal works done by hand 
            Kaal  -  for walking 
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           Vaai  -  for speaking 
           Eruvai –  for defeacation 
           Karuvai -  for reproduction 
 In Vaayu Kunmam, Eruvai may be affected due to variation in bowel habits.  
UDAL VANMAI (IMMUNITY) 
Siddhars classify Udal vanmai as three types. They are 
1. Iyarkai vanmai 
2. Kala vanmai 
3. Seyarkai vanmai 
Since Vaayu Kunmam patients are suffering with epigastric pain, nausea, 
indigestion as principal symptom, we came to understand that it is because of alteration in 
Vali thathu and Vali should be the primary causative factor (Muthanmai kutram). It can 
be confirmed by the words of great Siddhar Therayer 
“¦¾¡¼÷ Å¡¾ Àó¾ÁÄ¡Ð ÌýÁõ ÅÃ¡Ð”  
- §¾¨ÃÂ÷ 
 
EZHU UDAL KOORUGAL (SEVEN PHYSICAL CONSTITUENTS) 
‘,rukpuj; je;jir nea; epznkd;G kr;irtPe;njd;NwOk; KiwNa” 
rujnkhL nka;kdj;J epiwTjUk;capUl;Lj;jhq;fp apUf;Fk; 
 cuKjTk; NkLgs;sk; epuTk; nea;g; gira+l;Lk; Xq;fp epWj;Jk;  
gue;njd;gpd; JisfnlhWk; epuk;gpLq;fs; KisNjhd;wg; gz;Zk; njuptha;” 
                                                          - rpj;j kUj;J}thq;fr; RUf;fk;  
The human body is made of seven basic physical constituents. These constituents 
should be in harmony and function normally. Any variation in them will lead to their 
functional deviations. The Natural characters of the seven physical constituents are 
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1. Saaram (Chyle)   
 This gives mental and physical perseverance 
2. Senner (Blood)  
 Imparts color to the body, nourishes the body and is responsible for the ability and 
intellect of an individual 
3. Oon (Muscle)  
 It gives shape to the body according to the physical activity and covers the bones 
4.  Kozhuppu (Fat)  
 It lubricates the joints and other parts of the body to function smoothly 
5. Enbu (Bone)  
 Supports the frame and responsible for the postures and movements of the body 
6. Moolai (Bone marrow) 
It occupies the medulla of the bones and gives strength and softness to them 
7. Sukkilam/Suronitham (Sperm / Ovum)  
It is responsible for reproduction 
THE VARIATIONS OF THE PHYSICAL CONSTITUENTS 
1. SAARAM  
Increased Saaram: Leads to diseases of increased kapham like loss of appetite etc. 
Decreased Saaram: Leads to loss of weight, tiredness, lassitude, dryness of the 
skin and diminished activity of the sense organs. 
2.  SENNER 
Increased Senner: Causes boils in different parts of the body throbbing pain, 
anorexia, mental disorder, splenomegaly, Colicky pain, increased blood pressure, reddish 
eye and   Skin, jaundice, haematuria etc. 
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Decreased Senner: Leads to anaemia, tiredness, neuritis and lassitude, Pallor of 
body. 
3. OON  
Increased Oon: Oon in excess causes cervical lymph adenitis, venereal ulcer, 
tumor in face, abdomen, thigh genitalia etc are the signs of increased Oon. 
Decreased Oon: Leads to impairment of sense organs, joints of jaw, thigh and 
genitalia gets shortened. 
4. KOZHUPPU 
Increased Kozhuppu: Identical to that of increased Oon associated with Dyspnoea 
and loss of acidity. 
Decreased Kozhuppu: Leads to pain in the hip region and diseases of the spleen. 
5. ENBU 
Excess Enbu: Growth in bones and teeth 
Decreased Enbu: Loosening of teeth and nails and Splitting and falling  of hair 
6. MOOLAI 
Increased Moolai: Causes heaviness, swollen eyes, swollen phalanges, Oliguria 
and non healing ulcers. 
Decreased Moolai: Causes osteoporosis and sunken eyes 
7. SUKKILAM / SURONITHAM 
Excess Sukkilam/Suronitham: Causes lust towards women and cause Urinary 
calculus. 
Decreased Sukkilam/Suronitham : Causes failure in reproduction, pain in the 
genitalia. 
In Vaayu Kunmam  Saaram (Generalised weakness), Senner (Pale conjunctiva) 
and Oon ( loss of Weight) may be affected. 
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PINIYARI MURAIMAI (DIAGNOSIS) 
           It means the method of diagnosing the disease.           
‘kjpj;jplw;fUik tha;e;j 
khz;gupfhunky;yhe; 
Jjpj;jpl Tzu;e;jhNdDe; 
Jfswg; gpzpapd;wd;ik 
gjpj;jpl Tzuhdhfpw; 
 gaDwhdhfyhNd 
tpjpj;jpL gpzpj;jpwj;ij 
tpsk;GJ Kjw;fz;kd;Ndh” 
- rpfpr;rh uj;jpdjPgk; - gf;fk; 3                                         
The above poem describes that diagnosis is very important for the physician to 
treat the disease. 
Four steps are followed in diagnosing the disease. They are, 
a. Poriyaal arithal 
b. Pulanal therthal 
c. Vinaathal 
d. Envagaithervu  
In detail, 
a. PORIYAAL ARITHAL 
In this the physician should carefully observe the changes that occur in the five 
sensory organs (Porigal) of the patient. 
b. PULANAL THERTHAL 
The physician carefully applies his five senses of perception, smell, taste, vision, 
touch and sound to understand the condition of the patient. 
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c. VINAATHAL 
The physician should interrogate about the patients name, age, occupation, socio 
economic status, food habits, history of past illness, history of present illness, family 
history, marital status, menstrual history and frequency of pain. 
d. ENVAGAI THERVUKAL 
‘ehb guprk; eh epwk; nkhop tpop  
ky%j;jpuk; kpit kUj;JtuhAjk;” 
- ÁÕòÐÅ áø Åø§Ä¡÷  
‘ehbahy; Kd;Ndhu;nrhd;d ey;nyhypguprj;jhYk; 
ePba tpopapdhYk; epd;w ehf;Fwpg;gpdhYk 
thba NkdpahYk; kynkhL ePupdhYk; #ba  
tpahjpjd;idr; RfKld; mwpe;JghNu” 
- «Úº£÷ì ¸Æ¢¦¿ÊÄ¡º¢Ã¢Â Å¢Õò¾õ 
  Nowadays advanced diagnostic tools have been developed by modern bio-medical 
scientists. But Siddhars have given eight diagnostic methodological tools. They are called 
as Envagai thervu. 
Eight Fold Systems of Clinical Assessments 
Siddhars have given eight diagnostic methodological tools. They are, 
1. Naa 
2. Niram 
3. Mozhi 
4. Vizhi 
5. Malam 
6. Moothiram 
7. Naadi 
8. Parisam 
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GENERAL FINDINGS 
1. NAA 
i. Signs and symptoms in the tongue are noted here. 
ii. Color, salivary secretion, ulcers, coating, inflammation, taste changes, and its 
nature are generally noted. 
In VaayuKunmam the Naa may be affected due to the pallor and dryness of the 
tongue with Sour / Bitter taste sensation. 
2. NIRAM 
i. The color of the skin is noted here. 
In VaayuKunmam the Niram may be affected due to the Pale / Yellowish colour 
of the body. 
3. MOZHI 
i. Character of the speech is noted, mainly uratha olli (high pitched), thazhntha olli 
(low pitched), or resembles the sound of any instrument. 
In VaayuKunmam the Mozhi will be affected to the patients who have severe 
epigastric pain leading to the thazhntha olli (Low and soft). 
4. VIZHI 
i. Character of the eye is noted. Color, warm, burning sensation, irritation, visual 
Perception.   
In VaayuKunmam the Vizhi may be affected due to the pale in colour and burning 
sensation of the eyes. 
5. MALAM 
i. The stools are examined for Erugal (constipation), Elagal (Loose stools), Color 
(Niram) and Froth (Nurai). 
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In VaayuKunmam the Malam will be affected (either constipation or diarrhea). 
Nurai may not present. 
6. MOOTHIRAM 
a. Neerkuri 
 The urine is examined for its 
(i) Niram (Colour)    
(ii) Adarthi (Specific gravity)   
(iii) Manam (Odour)    
(iv) Nurai (Froth) 
(v) Enjal (Deposits) . 
b. Neikuri 
‘mUe;J khwp ujKk; mtpNuhjkjha;  
mf;fy; myu;jy;mfhyt+d; jtpu;jow; 
Fw;wstUe;jp cwq;fp itfiw 
Mbf;fyrj; jhtpNa fhJnga; 
njhUK$u;j;jf; fiyf;Fl;gL ePupd; 
epwf;Fwp nea;Fwp epUkpj;jy; flNd” 
- §¾¨ÃÂ÷ ¿£÷ìÌÈ¢ ¦¿öìÌÈ¢ áø 
The early morning freshly voided urine of the patient is analyzed by dropping a 
drop of gingili oil on the surface of the urine sample. The accumulation, formations, 
changes, and dispersal under the sunlight without any external disturbances of the urine 
sample can be noted.  
· Vatha neer - The oil spreads like snake 
· Pitha neer - The oil spreads like ring 
· Kapha neer - The oil stood like pearl 
· If the oil spreads gradually, it indicates good prognosis 
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· If the oil spreads fast or gets mixed completely with urine or sinks in urine, it 
suggests bad prognosis. 
Since VaayuKunmam is due to the derangement of vaatham and pitham the 
neikuri will be in snake pattern and ring like. 
7. NAADI 
Naadi is a Unique Siddha Pulse reading method and it should be felt and not read. 
Different characters of Vazhi , Azhal, Iyam  like branching, jumping, mixing, rotating and 
compression can be identified in diseased conditions. 
Characters of the Naadies 
Identification (finger) Index Middle Ring 
Strength (In unit) 1 ½ ¼ 
Pattern 
(Male) Hen Tortoise Snake 
(Female) Snake frog Swan 
 
‘ghu;f;fNt ngz;fSf; fplJgf;fk; 
  gjpthfg; ghu;j;jplNt gfugf;NfSk; 
  fhu;fNt thjkJ ru;g;gk; Nghyha; 
  fdkhd gpj;jkJ jtis NghyhQ; 
  Nru;f;fNt iaankd;w ehbjhDQ; 
  rpWeilah td;dk; Nghw; nropg;gha;f; fhDk;” 
-gjpnzd; rpj;ju; ehbrhj;jpuk; (gupG+uz ehb)-  gf;fk;2 
 
In VaayuKunmam the Naadi nadai will be as follows; 
 
1. Vaatha Naadi 
 Å¡¾¦ÁÛõ ¿¡ÊÂÐ §¾¡ýÈ¢ø 
º£¾Áó¾¦Á¡Î ÅÂ¢Ú ¦À¡ÕÁø ¾¢Ãðº¢ Å¡ö× 
º£¾ÓÚí ¸¢Ã¡½¢ Á§¸¡¾Ãõ ¿£Ã¡¨Á 
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¾¢ÃûÅ¡ö× Ý¨Ä ÅÄ¢¸ÎôÒò ¾£¨Ã 
¿£¾ÓÚí ¸¢ÕÁ¢ÌýÁõ «ñ¼ Å¡¾õ 
..................................................
..................             
                                        - º¾¸¿¡Ê 
2. Pitha Vaatham 
 º¢ÈôÀ¡É À¢ò¾ò¾¢ø Å¡¾ ¿¡Ê 
§ºÃ¢ÖÚ ¾¡Ð¿ð¼ Ó¾Ã À£¨¼ 
¯¨ÈôÀ¡¸î ¦ºÃ¢Â¡¨Áì ÌýÁï Ý¨Ä 
...........................................................................  
- º¾¸¿¡Ê 
3. Sethuma Vaatham 
 
¦¾¡ó¾¢ò¾ §ºòÐÁò¾¢ø Å¡ÔÜÊò ¦¾¡¼÷ó¾ 
 ÌýÁõ¦¿ï º¨¼ôÒ ÍÅ¡º¸¡ºõ 
     ...................................................................    
      - º¾¸¿¡Ê 
In VaayuKunmam any one of the following naadies will be observed vatha naadi, 
vatha pitham, vatha kappam, pitha vaatham, kappa vaatham, kappapitham. 
8. PARISAM  
In parisam the following observations such as temperature, sensory impairment, 
mass, nodes, swelling, and texture of the skin, pain, hardness, edema will be noted 
through palpitation.. 
In VaayuKunmam the parisam may be affected (tenderness in the Epigastric 
region). 
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NOIKANIPPU VIVAATHAM: 
Vatha Kunmam is differentiated from other types of Kunmam as follows: 
1. ERI KUNMAM: 
“¾¢ÎìÌÁ¡ ¦ÁÃ¢ÌýÁî ¦ºÂ¨Äì §¸Ç¡ö 
º¢ÚÅÂ¢üÈ¢ ¦ÄÃ¢óÐ§Á Ì¼ø ÌÓÚõ 
ÅÎìÌõÅ¡ö ¿£÷ÍÆüÚû  ¾¨ÄÅ Ä¢ìÌõ 
 
ÅÂ¢ÚôÀ¢ì ¸¢Ú¸¢Úò§¾ ²ôÀÁ¡Ìõ 
¦ÅÊìÌÁÂ¢÷ ¸¡ø§¾¡Úõ Å¢Â÷¨ÅÂ¡Ìõ 
Á¢¸ô¦À¡ÕÁ¢ ÅÂ¢Ú¸Æ¢ó ¾¢¨ÃîºÄ¡Ìõ 
±ÎìÌ§Á Ì¼Ä¢¨ÇìÌ Á¢Èí¸¡ ¾ýÉõ 
±Ã¢Ô§Á Ô¼¦ÄíÌ Á¢ÕÁÄ¡§Á". 
                            - ä¸¢¨Åò¾¢Âº¢ó¾¡Á½¢  
1. Burning sensation in the stomach 
2. Borborygmus 
3. Excessive salivation 
4. Headache  
5. Giddiness 
6.  Belching 
7. Perspiration 
8. Diarrhoea 
9. Emaciation 
10. Loathing of food 
11. Burning sensation all over the body 
12. Cough 
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2. SILETHUMA KUNMAM: 
 
“¯ñ¼¡Ìõ Å¡ö¿£÷¾¡É¢¨ÇôÒñ¼¡Ìõ 
¯¼øÅüÈ¢ ¸Õò¾Æ¢Ô ÓÃò¾¢¨ÃìÌõ 
¦Åñ¼¡Ìõ ¦ÀÄý¦¸ÎìÌ ÁºÉó ¾ûÙõ 
Á¢ì¸¡É ¾¨ÄÂÃ¢ìÌõ ¦ÅÇ¢Õ §ÁÉ¢ 
¦¾ñ¼¡Ì ¦¿ïº¾É¢ü Ò¨¸îº Öñ¼¡õ 
¾¢Îì¸¢ðÎ ¿Îì¸ÖÁ¡ó §¾¸ó¾¡Ûõ 
¾¢ñ¼¡Ìó ¾¨Ä¦ÂíÌõ À¡Ã Á¡Ìõ 
º¢§ÄðÎÁÁ¡í ÌýÁ¦Áý§È ¦ºôÀÄ¡§Á”. 
- ä¸¢¨Åò¾¢Âº¢ó¾¡Á½¢  
-  
1. Excessive salivation 
2. Emaciation 
3. General weakness 
4. Loathing of food 
5. Generalised Tremor 
6. Heaviness of head 
7. Pallor of the skin  
8. Dyspnoea 
9. Heart burn sensation 
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3. PITHAKUNMAM: 
“§¿¡õÀ¢ò¾ ÌýÁò¾¢ ÑðÀí §¸Ç¡ö 
ÑÉ¢Áïº ½¢Èõ§À¡Ä Ó¸Ó Á¡Ìõ 
Å¡ïºò¾¢  Å¡ó¾¢Ôñ¼¡ö ÁÉÁÚìÌõ 
ÁÂì¸Á¡ö ¦¿ïº¾É¢ü §¸¡¨Æ ¸ðÎõ 
¸¡Á¦¿ÕôÀ¡öò ¾¡É¢ÕìÌí ¨¸¸¡§Ä¡Ôõ 
¸Î¦ÅöÂ¢ü ¸ñ¼×¼ý È¨ÄÍ ÆüÚõ 
ãò¾¢Ãï º¢Åó¾¢ÕìÌó ¾¡¸í ¸¡Ïõ 
Óì¸¢§Â ÁÄõÅ£Øõ ãîÍñ ¼¡§Á”.   
- ä¸¢¨Åò¾¢Âº¢ó¾¡Á½¢ 
1. Yellowish discolouration of face 
2. Nausea and Vomiting 
3. Reeling of head 
4. Phlegm in the chest 
5. Thirst 
6. Haematuria 
7. Constipation 
8. Excessive body heat 
9. Weariness of limb 
10. Fainting 
11.  Dyspnoea 
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TREATMENT: 
Siddhars have designed line of treatment into 3 phases for all disease, they are given 
below         
1. Kaappu (Prevention) 
2. Neekam (Treatment) 
3. Niraivu (Restoration) 
“§¿¡ö¿¡Ê §¿¡öÓ¾ø ¿¡Ê «Ð ¾½¢ìÌõ 
     Å¡ö¿¡Ê Å¡öôÀî ¦ºÂø” 
- ¾¢ÕìÌÈû 
LINE OF TREATMENT: 
Ø Purgation 
Ø Internal medicine 
Ø Dietary advice 
Purgation: 
         “Å¢§ÃºÉò¾¡ø Å¡¾õ ¾¡Øõ” -  
      “«È¢ó¾¢Îõ Å¡¾õ «¼íÌ ÁÄò¾¢É¢ø”  
- ¾¢ÕãÄ÷ 
Here Vaayu Kunmam, vatha humour is mainly deranged. Administration of 
purgatives is done to normalize the vitiated vaatham and eliminate other toxic products of 
digestion, metabolism and catabolism. 
Purgative medicine: 
Agasthiyar kuzhumbu-130 mg (Ref: Siddha vaithya thirattu) with 15 ml ginger 
juice at early morning on the first day of treatment. 
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INTERNAL MEDICINE:  
Vediyuppu kattu - 800mg 
with 
Thiru kadugu Chooranam – 400mg 
With Butter milk, after food twice daily. 
Dietary advice: 
Restricted diet: 
1. As per saint Yugi: 
                      Excessive intake of food having Thuvarppu taste 
                      Milagu vagai uraippu (excessive intake of spicy diet) 
                      Kilanguvagaigal (Tuberous diet) 
2. As per literature Noigalukku Siddha parikaram: 
                      Kollu, ulunthu, maamisam, sea foods like fish, dry fish… 
DO’S: 
v Butter milk is also recommended as one of the best home remedy for the treatment 
of gastric ulcer. 
v Coconut water is considered as one of the best health drink. It keeps the body 
temperature cool, helps indigestion. 
v Patient suffering from gastric ulcer should drink plenty of water (8-10 glasses   of 
water/day). 
v Having a small meal every 3 hours is recommended. 
v Honey is also considered as an effective home remedy for the treatment of gastric 
ulcer. 
v Foods to include: Leafy vegetables, carrot juice, fresh fruits, vegetable salads. 
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 DON’TS: 
v Alcohol, black pepper, chilli powder should be avoided. 
v Tea, coffee, chocolate should not be taken. 
v Do not eat full stomach 
Prevention: 
v Eat slowly by chewing the food thoroughly; this will help in proper digestion and 
prevention of gastric ulcer. 
v Do not eat full stomach. 
v Having a small meal every 3 hours is recommended. 
v Avoid spicy foods. 
v Avoid stress 
v A proper diet for gastric ulcer combined with stress managing methods and life 
style changes can help in preventing gastric ulcer. 
Niraivu (restoration):  
Yogam techniques to be observed by the Vaayu Kunmam patients: 
· Kiriya Gnayiru Vanakkam (Kiraiya Pose of Sun Salutation) 
· Meditative postures 
o Thamarai Asanam (Padmasanam) 
o Mandi Uruthi Asanam (Vajrasanam) 
· Paranayamams 
o Mathrika Pranayamam  
o Omkhara Pranayamam  
o Nithirai Pranayamam 
· Shanthi Asanam (Savasanam) 
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DIGESTIVE SYSTEM 
ABDOMEN 
The abdominal cavity is an extensive space which extends upwards, deep to the 
costal margin, into the concavity of the diaphragm; and projects downwards and 
backwards into the bony pelvis as the pelvic cavity. 
NINE REGIONS OF THE ABDOMEN 
 For the purpose of describing the location of viscera, the abdomen is divided into 
nine regions by four imaginary planes, two horizontal and two vertical. The horizontal 
planes are transplloric and trans tubercular planes. The vertical planes are the right lateral 
and lelt lateral planes. 
STOMACH 
The stomach is a muscular bag forming the widest and most distensible part of the 
digestive tube, it is connected above to the lower end of the oesophagus and below to the 
duodenum. 
LOCATION:                  
      The stomach lies obliquely in the upper and left part of the abdomen, occupying 
the epigastric, umbilical and hypochondriac regions. 
 SIZE:    
The stomach is about 25cm long and is 6 inches (15.2 cm) wide at its widest part. 
SHAPE AND POSITION: 
            The shape of the stomach depends upon the degree of its distension and that of the 
surrounding viscera. 
            When empty, the stomach is somewhat J-shaped (vertical). 
            When partially distended it become pyrifom in shape. 
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CAPACITY: 
§ At birth - 30 ml 
§ Puberty - 1000 ml 
§ Adults - 1500 – 2000 ml 
ANATOMY OF THE STOMACH                                                      
The stomach has two orifices, two curvature, and two surfaces 
ORIFICE: 
Cardiac orifice:  The cardiac orifice is joined by the lower end of the oesophagus. 
Pyloric orifice:   The pyloric orifice opens into the duodenum. 
CURVATURES: 
Lesser curvature:  The lesser curvature is concave and forms the right border of the 
stomach. 
Greater curvature:  The greater curvature is convex and forms the left border of the 
stomach. 
SURFACES: 
The Anterior or Antero superior surface faces forwards and upwards. 
The Posterior or Postero inferior surface faces backwards and downwards. 
PARTS OF STOMACH: 
The stomach is divided in to two parts 
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1. Cardiac part:     
Ø This is upper opening of the stomach. 
Ø Cardiac part is further subdivided in to the fundus, body. 
2. Pyloricpart:   
Ø This is lower opening of the stomach. 
Ø Pyloric part is subdivided in to the antrum, pyloric canal. 
Fundus: 
Fundus is the portion above the horizontal line drawn across the oesophago-
gastric junction. 
            It is commonly distended with gas which is seen clearly in radiographic 
examination under the left dome of diaphragm. 
Body of the stomach:  
It lies between the fundus and the pyloric antrum. 
STRUCTURE OF WALL OF THE STOMACH 
The wall of the stomach has four layers. 
Outer serous layer: It consists of the peritoneal covering.  
Muscular coat: This consists of three layers of smooth muscles fibers namely, inner 
oblique, middle circular and longitudinal layer. 
Sub mucosa layer: It is made of connective tissue, arterioles and nerve plexus. 
Inner mucosa layer:  The glands of the stomach are situated in the mucous membrane. 
The gastric glands are mainly mucous secreting. 
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The glands of the fundus and most part of the body contain three types of cells 
a. The mucous neck cells 
b. The chief cells or zymogenic or peptic cells 
c. The parietal cells or oxyntic cells 
          The glands of pyloric region mainly produce mucous and alkali. 
Arterial supply:    
Right gastric artery 
Left gastric artery 
Right gastroepiploic artery 
Left gastroepiploic artery 
Short gastric arteries 
Venous supply: 
Right gastric vein 
Left gastric vein 
Right gastroepiploic vein 
Left gastroepiploic vein 
Short gastric vein 
NERVE SUPPLY: 
Stomach is supplied by both parasympathetic and sympathetic nerves. 
 Sympathetic: 
Greater splanchnic nerve 
 Parasympathetic: 
            Right vagus and Left vagus. 
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STOMACH FUNCTIONS: 
1. Storage function: It is a reservoir for food. 
2. Absorption: It has limited power of absorption.Substances like water, alcohol and 
drugs acetylsalicylic acid etc.are absorbed from the stomach. 
3. Digestive function: Secretion of gastric juice. 
4. Haematinic function: Secretion of intrinsic factor (glycoprotein) which is 
necessary for the absorption of vitamin B12. 
GLANDS OF STOMACH: 
The glands of the stomach or gastric glands are divided in to three types 
1. Fundic glands: 
The different cells of these glands are, 
a) Chief cells or pepsinogen cells: These cells secrete pepsinogen, rennin and 
gelatinase. 
b) Parietal cells or oxyntic cells: These secrete HCL and intrinsic factor of castle. 
c) Mucous neck cells which secrete mucin. 
 
2. Pyloric glands:   
These glands secrete mostly mucin and gastrin. 
3. Cardiac glands:    
These glands secrete alkaline mucus and small quantity of pepsinogen. 
GASTRIC JUICE 
Gastric juice is the mixture of secretions from different glands of the stomach. 
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Composition:    
Gastric juice contains 99.5% water and 0.5% solids 
Organicsubstances of gastric juice:    
1. Gastric enzymes:  
Pepsin, rennin, gastric lipase and othe enzymes. 
2. Gastric mucus:    
Mucus is a glycoproptein it is like a flexible gel covering the gastric mucus 
membrane 
3. Intrinsic factor:  
This is necessary for absorption of the extrinsic factor (old name for vitamin B12).    
Inorganic substances of gastric juice:      
Hcl, Sodium, Calcium, Potassium, Chloride, Bicarbonate, Phosphate       
SECRETION OF HCL 
Hcl secretion is an active process taking place in the canaliculi of parietal cells in 
fundic glands of stomach. 
Factors regulating the secretion of Hcl 
1. Gastrin:  
i. Gastrin is one of the gastrointestinal hormones 
ii. It stimulates acid secretion 
2. Enterogastrone: 
i. Enterogastrone is another gastrointestinal hormone 
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ii. It inhibits the acid secretion 
3. Histamine:  
i. It is an excitatory neurotransmitter sunstance secreted in spinal cord. 
ii. It stimulates the acid secretion 
4.Vagal stimulation: 
Increases acid secretion 
REGULATION OF GASTRIC SECRETION 
Secretion of gastric juice occurs when the food is taken in the mouth. The neural 
and hormonal mechanism is involved in the secretion of gastric juice. The secretion 
occurs in three phases 
1.Cephalic phase : This phase is under nervous control. 
2.Gastric phase : This phase is under nervous and hormonal control. 
3.Intestinal phase : when the chyme leaves the stomach and enters the  
intestine, initially the secretion of gastric juice is increased 
and later it is inhibited. 
GASTRITIS 
Definition: 
Gastritis is an inflammation or irritation of the lining of the stomach, is not a 
single disease. The term gastritis should be reserved for histologically documented 
inflammation of the gastric mucosa. Gastritis is not the mucosal erythema seen during 
endoscopy and is not interchangeable with "dyspepsia."  
The etiologic factors leading to gastritis are broad and heterogeneous. Gastritis has 
been classified based on time course (acute vs. chronic), histologic features, and 
anatomical distribution or proposed pathogenic mechanism. 
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Classification of Gastritis 
I. Acute gastritis 
A. Acute H. pylori infection 
B. Other acute infectious gastritis 
a. Bacterial (other than H. pylori) 
b. Helicobacter helmanni 
c. Phlegmonous 
d. Mycobacterial 
e. Syphilitic 
f. Viral 
g. Parasitic 
h. Fungal 
II. Chronic atrophic gastritis 
A. Type A: Autoimmune, body- predominant 
B. Type B: H. pylori–related, antral-predominant 
C. Indeterminant 
III. Uncommon forms of gastritis 
A. Lymphocytic 
B. Eosinophilic 
C. Crohn's disease 
D. Sarcoidosis 
E. Isolated granulomatous gastritis  
Incidence: 
Sex : No sexual predilection   
Age : Gastritis affects all age groups        
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ACUTE GASTRITIS 
Acute gastritis is a term covering a broad spectrum of entities that induce 
inflammatory changes in the gastric mucosa. The different etiologies share the same 
general clinical presentation. However, they differ in their unique histologic 
characteristics. The inflammation may involve the entire stomach (eg, pangastritis) or a 
region of the stomach (eg, antral gastritis). Acute gastritis can be broken down into two  
categories: erosive (eg, superficial erosions, deep erosions, hemorrhagic erosions) and 
nonerosive (generally caused by Helicobacter pylori).  
The bacteria Helicobacter pylori accounts for 90% of cases of acute gastritis. If 
not treated, this picture will evolve into one of chronic gastritis. Hypochlorhydria lasting 
for up to one year may follow acute H. pylori infection. 
No correlation exists between microscopic inflammation (histologic gastritis) and 
the presence of gastric symptoms (eg, abdominal pain, nausea, vomiting). In fact, most 
patients with histologic evidence of acute gastritis (inflammation) are asymptomatic. The 
diagnosis is usually obtained during endoscopy performed for other reasons. Acute 
gastritis may present with an array of symptoms, the most common being nondescript 
epigastric discomfort.  
Other symptoms include nausea, vomiting, loss of appetite, belching, and 
bloating. Occasionally, acute abdominal pain can be a presenting symptom. The diagnosis 
of acute gastritis may be suspected from the patient's history and can be confirmed 
histologically by biopsy specimens taken at endoscopy.  
Pathophysiology 
Acute gastritis has a number of causes, including certain drugs; alcohol; bile; 
ischemia; bacterial, viral, and fungal infections; acute stress (shock); radiation; allergy 
and food poisoning; and direct trauma. The common mechanism of injury is an imbalance 
between the aggressive and the defensive factors that maintain the integrity of the gastric 
lining (mucosa).  
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Causes for acute gastritis 
1 .Diet and personal habits: 
Ø Highly spiced food 
Ø Excessive alcohol consumption 
Ø Malnutrition 
Ø Heavy smoking 
2.  Infections: 
v Bacterial infections e.g H.Pylori, H.heilmanii, streptococci, staphylococci, 
Proteus species, Clostridium species,  Escherichia coli, Diphtheria, Salmonellosis 
and pneumonia,  
v Viral infections, e.g Cytomegalovirus (CMV), viral hepatitis, influenza, 
infectious mononucleosis. 
v Fungal (yeast) infections – eg Candida albicans, Histoplasmosis and Gastric 
phycomycosis. 
v Parasites and worms - Anisakidosis 
3. Drugs: 
Intake of drugs like Non steroidal anti-inflammatory drugs (NSAIDs), asprin, 
indomethacin cortisone, preparation of iron and chemotherapeutic agents. 
4. Chemical and physical agent: 
Intake of Corrosive chemicals such as caustic soda, phenol, Lysol. 
Gastric irradiation. 
5. Severe stress: 
Emotional factors like shock, anger, etc.  
Trauma and Surgery 
Extensive burns. 
6. Bile:  
The reflux of bile (an alkaline medium important for the activation of digestive 
enzymes in the small intestine) from the small intestine to the stomach can induce 
gastritis.  
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CHRONIC GASTRITIS 
Chronic gastritis is a histopathologic entity characterized by chronic inflammation 
of the stomach mucosa. Gastritis can be classified on the basis of the underlying cause 
(eg, Helicobacter pylori, bile reflux, nonsteroidal anti-inflammatory drugs [NSAIDs], 
autoimmunity, or allergic response) and the histopathologic pattern, which may suggest 
the cause and the likely clinical course (eg, H pylori –associated multifocal atrophic 
gastritis).  
Etiology 
Chronic gastritis may be caused by either infectious or noninfectious conditions. 
Infectious forms of gastritis include the following:  
Ø Chronic gastritis caused by H pylori infection – This is the most common cause of 
chronic gastritis 
Ø Gastritis caused by Helicobacter heilmannii infection  
Ø Granulomatous gastritis associated with gastric infections in mycobacteriosis, 
syphilis, histoplasmosis, mucormycosis, South American blastomycosis, 
anisakiasis, or anisakidosis  
Ø Chronic gastritis associated with parasitic infections -Strongyloides species, 
schistosomiasis, or Diphyllobothrium latum 
Ø Gastritis caused by viral (eg, CMV or herpesvirus) infection 
Noninfectious forms of gastritis include the following: 
Ø Autoimmune gastritis 
Ø Chemical gastropathy, usually related to chronic bile reflux or NSAID and aspirin 
intake 
Ø Uremic gastropathy 
Ø Chronic noninfectious granulomatous gastritis – This may be associated with 
Crohn disease, sarcoidosis, Wegener granulomatosis, foreign bodies, cocaine use, 
isolated granulomatous gastritis, chronic granulomatous disease of childhood,  
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eosinophilic granuloma, allergic granulomatosis and vasculitis, plasma cell 
granulomas, rheumatoid nodules, tumoral amyloidosis and granulomas associated 
with gastric carcinoma, gastric lymphoma, or Langerhans cell histiocytosis  
Ø Lymphocytic gastritis, including gastritis associated with celiac disease (also 
called collagenous gastritis) 
Ø Eosinophilic gastritis 
Ø Radiation injury to the stomach 
Ø Graft-versus-host disease (GVHD) 
Ø Ischemic gastritis 
Ø Gastritis secondary to drug therapy 
Chronic gastritis: 
Older people tend to suffer more frequently with chronic gastritis. Chronic 
gastritis involves the long-term inflammation of the mucosal lining of the stomach. This 
inflammatory condition of the upper digestive system can last for years. There are many 
possible causes, though in 90% of all patients who suffer with chronic gastritis the 
Helicobacter pylori bacteria is the primary culprit.  
Type A gastritis: (autoimmune gastritis) 
             Type A gastritis involves mainly the body-fundic mucosa. It is also called auto 
immune gastritis due to the presence of circulating antibodies and is sometimes associated 
with other auto immune diseases such as Hashimoto’s thyroiditis and Addison’s disease. 
As a result of the antibodies against parietal cells and intrinsic factor, there is 
depletion of parietal cells and impaired secretion of intrinsic factor, these changes may 
lead to significant gastric atrophy where intestinal metaplasia may occur, and a small 
proportion of these patients may develop pernicious anemia. Due to to depletion of gastric 
acid-producing mucosal area, there is hypo-or achlorhydria, and hyperplasia of gastrin-
producing G cells in the antrum resulting in hyper gastrinaemia. 
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Type B: (H.pylori-related) 
              TypeB gastritis involves the region of antral mucosa and is more common. It is 
also called hypersecretory gastritis due to excessive secretion of acid, commonly due to 
infection with H.pylori. These patients may have associated peptic ulcer. 
Type AB: (Environmental gastritis, Chronic atrophic gastritis) 
Type AB gastritis affects the mucosal region of A as well as B types. This is the 
most common type of gastritis in all groups. It is also called environmental gastritis 
because a number of as yet unidentified environmental factors have been implicated in its 
etio-pathogenesis. 
Chronic atrophic gastritis is also used synonymously with type AB gastritis 
because in advanced stage, there is progression from chronic superficial gastritis to 
chronic atrophic gastritis, characterized by mucosal atrophy and metaplasia of intestinal 
or pseudopyloric type. 
Sydney system of recording of Histologic changes in gastritis is more acceptable 
since it takes into account following multiple parameters: 
i. Etiology (H.pylori, autoimmune, NSAIDs, infections) 
ii. Location (Pangastritis, Predominant antral, predominant body-fundic) 
iii. Morphology (depth of inflammation-superficialor deep, severity of   
inflammation, type of inflammation, atrophy, metaplasia). 
iv. Somespecialfeatures 
(e.Granulomas,Eosinophilicgastritis,Erosions,Necrosis,Haemorrhages). 
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CLINICAL FEATURES: 
1. Pain in the abdomen: 
i. Onset  : Sudden   
ii. Location : Epigastric  area of the abdomen 
iii. Radiation :  Gastritis pain occurs in the left upper portion of the  
abdomen and in the back. The pain seems to "go right  
straight through" a person as it travels from the belly to  
the back.  
iv. Nature of pain : People often use the terms burning, aching, gnawing,  
or sore to describe the pain. Usually, a vague sense of 
discomfort is present, but the pain may be sharp, stabbing 
or cutting.   
  2.  Other symptoms of gastritis include the following: 
 Belching  
 Nausea and vomiting  
 Bloating  
 Feeling of fullness or burning in the upper part of the belly  
 
PROGNOSIS 
The prognosis of chronic gastritis is strongly related to the underlying cause. 
Chronic gastritis as a primary disease, such as H pylori- associated chronic gastritis, may 
progress as an asymptomatic disease in some patients, whereas other patients may report 
dyspeptic symptoms. The clinical course may be worsened when patients develop any of 
the possible complications of H pylori infection, such as peptic ulcer or gastric 
malignancy.  
H pylori gastritis is the most frequent cause of MALT lymphoma. Patients with 
chronic atrophic gastritis may have a 12- to 16-fold increased risk of developing gastric 
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carcinoma, compared with the general population. Approximately 1 in 6 infected persons 
develop peptic ulcer, and, in the United States, approximately 25% develop 
hypochlorhydria or achlorhydria. The lifetime risk of gastric cancer is in the range of 1-
3%.  
Eradication of H pylori results in rapid curing of the infection with disappearance 
of the neutrophilic infiltration of the gastric mucosa. Disappearance of the lymphoid 
component of gastritis might take several months after treatment. Data on the evolution 
of atrophic gastritis after eradication of H pylori have been conflicting. Follow-up for as 
long as several years after H pylori eradication has not demonstrated regression of gastric 
atrophy in most studies, whereas others report improvement in the extent of atrophy and 
intestinal metaplasia.  
Another important question is whether H pylori eradication in a patient with 
atrophic gastritis reduces the risk of gastric cancer development. Limited data are 
available, but a prospective study in a Japanese population reported that H pylori 
eradication in patients with endoscopically resected early gastric cancer resulted in the 
decreased appearance of new early cancers, whereas intestinal-type gastric cancers 
developed in the control group without H pylori eradication.  
These findings support an intervention approach with eradication of H pylori if 
the organisms are detected in patients with atrophic gastritis; the goal is to prevent the 
development of gastric cancer. 
In patients with autoimmune gastritis, the major effects are consequent to the loss 
of parietal and chief cells and include achlorhydria, hypergastrinemia, loss of pepsin and 
pepsinogen, anemia, and an increased risk of gastric neoplasms. Autoimmune gastritis 
represents the most frequent cause of pernicious anemia in temperate climates. The risk 
of gastric adenocarcinoma appears to be at least 2.9 times higher in patients with 
pernicious anemia than in the general population. 
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Laboratory Studies 
A number of laboratory tests are usually ordered. 
Ø CBC count to assess for anemia, as acute gastritis can cause gastrointestinal 
bleeding 
Ø Liver and kidney function tests 
Ø Gallbladder and pancreatic function tests 
Ø Pregnancy test 
Ø Stool for blood 
Special investigation: 
During the endoscopy, a thin, flexible probe with a tiny camera on the end is sent 
into your stomach for a direct look. 
At the same time, samples of stomach lining can be taken to test for a wide 
variety of conditions 
Histologic Findings 
Histologic examination of a biopsy specimen can help in establishing the etiologic 
agent of gastritis.  
Other investigation: 
Gallbladder and pancreas functions 
H pylori tests:   
 Blood antibody test 
          Urea breath test 
         Stool antigen test          
 54 
 
Differential Diagnosis: 
Gastritis is often interpreted as primary, although it is frequently an expression of 
a more general disease. The following diseases present with gastric complaints and must 
always be considered in differential diagnosis. 
1. General disease condition: 
Any serious general disease can show symptoms indicating a stomach disease, 
such as nausea, belching, loss of appetite, and possibly vomiting. 
2. Chronic uremia: 
These symptoms are particularly frequent in chronic uremia. 
3. Acute or chronic liver diseases: 
Acute or chronic liver diseases (e. g., due to chronic alcohol abuse) are frequently 
accompanied by gastric complaints. 
4. Congestive gastritis: 
Congestive gastritis as a manifestation of cardiac insufficiency or portal 
hypertension must be considered in patients with cardiac or hepatic disease. 
5. Digitalis gastritis: 
Among drugs, “digitalis gastritis” in cardiac patients disappears a few days after 
stopping therapy. 
6.  Allergic gastritis: 
           Allergic gastritis, as a consequence of hypersensitive reactions to food, 
particularly milk, chocolate, yeast, nuts, citrus fruit, strawberries, shellfish, etc., occurs 
primarily as part of a generalized gastrointestinal reaction with diarrhea and pain, in 
some cases combined with systemic symptoms (e. g., tachycardia, drop in blood 
pressure, asthma, headache, urticaria). 
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Diagnosis: 
Diagnosis of gastritis is made by examination (clinical symptoms, physical 
examination) habits and lifestyle, and the medications history along with endoscopy and 
biopsy findings. 
Complications of Gastritis: 
If gastritis isn't treated, it may lead to stomach ulcers and stomach bleeding. There 
are also some forms of chronic gastritis that may increase your risk of stomach cancer.  
Other complications include:  
v Gastrointestinal bleeding  from an erosion or ulcer 
v Gastric erosion  
v Gastric outlet obstruction due to edema limiting the adequate transfer of food from 
the stomach to the small intestine 
v Anemia  
v Dehydration  from vomiting 
v Renal insufficiency as a result of dehydration 
v Stomach perforation. 
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¦ÅÊÔôÒì¸ðÎ 
 
¬¾¡Ãõ: Â¡§¸¡Ò ¨Åò¾¢Â º¢ó¾¡Á½¢ - 700 
 
ÌýÁòÐìÌ  ¦ÅÊÔôÒì¸ðÎ : 
 
“º£É§Á¡÷ ÀÊ¦ÃðÊ ¦ÅÊÔôÀ¢ðÎ 
¦ºÚºðÊ ¾ýÉ¢Ä¢ðÎ «ÎôÀ¢ø¨ÅòÐ 
§Á¡ÉÁ¡ó ¾£¦ÂÃ¢ì¸ ¯ÕÌõÀ¡Õ 
Óì¸¢ÂÁ¡öî  º¡öò¦¾ÎòÐ ¨ÅòÐòÐÇ¡ö 
»¡ÉÁ¾¡öò ÐðÊ¨¼¾¡ ¦¿ÎòÐì§¸Ù 
¿ý¨Á¦ÀÈò ¾¢Ã¢¸Î¸¢ü È¢Ã¢¿¡Ùñ½ 
®ÉÓûÇ Å¡ö×ÌñÁ ¦ÁðÎó¾£Õõ 
²¸¡ó¾ Â¡§¸¡Ò Â¢¾ï¦º¡ýÉ¡§Ã” 
- Â¡§¸¡Ò ¨Åò¾¢Â º¢ó¾¡Á½¢ - 700 
 
¦ºöÓ¨È: 
 
´ÕÀÊ º£Éõ, þÃñÎÀÊ ¦ÅÊÔôÒ ´Õ º¢È¢Â ºðÊÂ¢ø þðÎ «ÎôÀ¢ø 
¨ÅòÐ ¦ÁÐÅ¡¸ò ¾£¦ÂÃ¢ì¸ þÃñÎõ §º÷òÐ ¯ÕÌõ. ºðÊ¨Â þÈì¸¢ 
º¡öòÐ ¨ÅòÐ ÌÆõÒ ¬È¢Â À¢ý àÇ¡É¨¾ ´Õ ¸¡¦º¨¼ ±ÎòÐì¦¸¡ñÎ 
¾¢Ã¢¸ÎÌî ÝÃ½ò¾¢ø ¯ð¦¸¡ûÇ ±ðÎ Å¨¸ì ÌýÁ §Ã¡¸í¸Ùõ Å¡ö×õ 
¿£íÌõ. 
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VEDIYUPPU (POTASSIUM NITRATE) 
 Vediyuppu occurs naturally as efflorescence on the soil. is mixed with water, 
boiled and egg white is added to remove its impurities and get purified. 
¦À¡ÐÌ½õ 
" ÁøÄ¡Õ Áð¼ÌýÁ Á¡¾Õ¾ Ãì¸ðÊ 
  ¸øÄ¡ Á¨¾ôÒ¿£÷ì ¸ð¼Õ¸ - ¦ÄøÄ¡§Á 
  ¸õÀ¢ ¸õÀ¢ ¦ÂýÚí  ¸Õ×ñ¼¡ Áí¸¢¿¢ýÈ 
  ¸õÀ¢ ¸õÀ¢ ¦ÂýÚ¨ÃìÌí ¸¡ø" 
 
"Ý¾¸ Å¡Ô¦Å¡Î  §º¡½¢¾ò¾¢ý Å¡¾Óõ §À¡õ 
 Å¡¾ÅÄ¢ ÌýÁÁ¢¨Å Á¡Õí¸¡ñ - Á£¾¡í 
 ¦¸¡ÊÂ ÅÂ¢È¢Æ¢Ôí ¸¡¨Æ¸À §ÁÌõ 
 ¦ÅÊÔôÒò ¾ý¨É Å¢ÇõÒ" 
     - À¾¡÷ò¾ Ì½º¢ó¾¡ÁÉ¢ 
Organoleptic charcters 
Taste      : Pungent 
Potency :  Hot 
Division   : Pungent 
Action  : demulcent, diuretic, and diaphoretic. 
Medicinal uses : In the form of solution it is a refrigerant, efficient diuretic 
and disphoretic. It acts on the vascular system and reduces 
the pulse. 
   As per the siddha text vediyuppu is used in the treating 
eight types of Gunmam, Utrine tumours,  
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  SEENAM (ALUMINIUM POTASSIUM SULPHATE) 
¦À¡ÐÌ½õ  
 
" º£É¦ÁÛí ¸¡ÃÁÐ º£È¢ÅÕ ÀøÄÃ¨½ 
  ¬¨Éì¸¡ø ¸ñ§½¡ö «É¢Ä¦Á¡Î - Á¡¿¢Äò¾¢ø 
  ÐýÁ¡í¸¢ºõÅ¡Ô §¾¡Ä¡¾ ¯ûÇÆ¨Ä 
  ÌýÁÁ¢¨Å §À¡ìÌ¦ÁÉì  ÜÚ" 
    - À¾¡÷ò¾ Ì½º¢ó¾¡ÁÉ¢ 
 
Taste              :          sour, sweet and astringent. 
Characters        :          Colourless, transparent crystals, with acid, sweetish astringent taste. 
Action   : Astringent, caustic, haemostatic, anti spasmodic and anti septic. 
   Irritant and purgative in large dose. 
   Emetic in repeated doses. 
 
Medicinal uses: It is used in the treatment of Leucorrhea, Haematuria, Haemoptysis, 
Menorrhagia, Gastric and intestinal catarrh and other 
Haemorrhages. 
 
In the form of lotion it is used internally to check Haemorrhage 
from stomach, lungs, kidneys and other organs. 
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CHUKKU 
¦À¡ÐÌ½õ 
‘#iy ke;jk; neQ!nrupg;G NjhlNkg;gk; moiy 
 %yk; ,iug;gpUky; %f;F ePu; - thyfg 
 Njhlkjp rhue; njhlu;thj Fd;kePu;j; 
 Njhlk; Mkk; Nghf;FQ; Rf;F” 
- À¾¡÷ò¾ Ì½º¢ó¾¡ÁÉ¢ 
Botanical name   : Zingiber officinale, Roscoe. 
Family     : Zingiberaceae 
Parts used  : Scraped and Dried rhizome 
Organoleptic charcters 
Taste     : Pungent 
Potency    : Hot 
Division  : Pungent 
Action   : Stimulant to the gastro intestinal tract, stomachic, 
carminative, aromatic, silagogue and digestive. 
Constituents : Camphene, phellandrene, cineol, zingiberine, borneol, 
gingerol a yellow pungent body and an oleo resin Gingirin.  
Medicinal uses : Dry ginger is much used as a carminative adjunct. It is 
extremely valuable in dyspepsia, flatulence, colic, cough, 
asthma, dyspepsia and indigestion. 
  It is also used in nervous disorders, strengthens memory, 
removes obstruction in the vessels and restricts incontinence 
of urine. 
  Dry ginger is generally used as a corrective adjunct to 
purgatives to prevent nausea and griping. 
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MILAGU 
¦À¡ÐÌ½õ 
 ‘rPjRuk; ghz;L rpNyj;Jkq; fpuhzpFd;kk; 
 thjk; mUrpgpj;jk; kh%yk;-XJrd;dp 
 ahrk g];khuk; mlu;Nkfk; fhrkpit 
 ehrq; fwpkpsfpdhy;” 
  - À¾¡÷ò¾ Ì½º¢ó¾¡ÁÉ¢ 
Botanical name   :  Piper nigrum, Linn. 
Family    :  Piperaceae 
Parts used   :  Dried unripe fruit 
Organoleptic charcters 
Taste      : Pungent, Bitter. 
Potency :  Hot 
Division   : Pungent 
Action  :  Black pepper is acrid, pungent, hot, carminative, 
Stimulant, Anti periodic, Antidote and Anti pyretic. 
 
Constituents :  A volatile oil Piperine and Piperidin, a balsamic 
volatile essential oil, soluble pungent resin chavicine, 
starch,lignin, gum, fat, proteids and ash.. 
Medicinal uses :  Black pepper is prescribed in cholera, dyspepsia, 
flatulence, diarrhea and various gastric ailments. 
    It is also used in the treatment of piles, constipation, 
colic, gastric troubles, ascities, anemia, worms, 
asthma, etc. 
    Black peper is also used in the treatment of venereal 
disease, tuberculosis and rheumatism. 
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THIPPILI 
¦À¡ÐÌ½õ 
 ‘,Uky; Fd;kk; ,iug;G fag;gpzp 
  <is ghz;L re;ahrk; mNuhrfk; 
  ngUkhiyg; GupNkfk; gplfKk; 
  NgUe; jpg;gpypg; Nguq;Fiuf;fNt” 
  - À¾¡÷ò¾ Ì½º¢ó¾¡ÁÉ¢ 
Botanical name      : Piper longum, Linn. 
Family  : Piperaceae 
Parts used : Dried unripe fruit  
Organoleptic charcters 
Taste  : Sweet 
Potency : coolant 
Division : Sweet 
Action  : Infusion is stimulant, carminative and alternative tonic. It 
acts also as an aphrodisiac, vermifuge, emmenagogue and 
diuretic. 
Constituents : Resins, volatile oil, alkaloid Piperine, starch, gum, fatty oil 
and inorganic matter. 
Medicinal uses : Old long pepper is more efficacious in medicine. It relives 
cough, cold, asthma, hoarseness and hiccup. 
   Thippili is valuable alternative tonic in paraplegia, asthma, 
chronic bronchitis, chronic cough, enlargement of spleen 
and other abdominal viscera etc. 
   It is also used in the treatment of anorexia, piles and 
rheumatism. 
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INGREDIENTS OF VEDIYUPPU KATTU 
 
VEDIYUPPU     SEENAM 
 
 
 
 
 
\ 
 
INGREDIENTS OF THIRIKADUGU CHOORANAM 
CHUKKU    MILAGU                   THIPILI 
 
 
 
 
 
PREPARED MEDICINES 
      VEDIYUPPU KATTU       THIRIKADUGU CHOORANAM 
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STANDARD OPERATING PROCEDURE FOR 
VEDIYUPPU KATTU & THIRIKADUGU CHOORANAM 
 
The required raw drugs were purchased from a well reputed country shop .The 
raw drugs were authenticated by the concerned Head of the Department, of NIS. The raw 
drugs were purified and the medicine was prepared in Gunapadam lab of NIS. The 
prepared medicine was again authenticated by the concerned Head of the department. 
 
PREPERATION OF VEDIYUPPU KATTU  
 
Required raw drugs: 
 
      1. Vediyuppu – Pottasium Nitrate  
2. Seenam – Aluminium Potassium Sulphate 
 
Purification of the raw drugs 
 
1. VEDIYUPPU - Pottasium Nitrate  
 
Pottasium Nitrate and water is mixed in the ratio of 1:4 taken in a pot and allowed 
to boil in mild flame. When the salt and water content is about to boil, add egg white in a 
ratio of 4 egg: 1400 grams of Potassium Nitrate salt. Now the impurities accumulated 
over the water surface are removed with the help of wooden spoon. When the salt water 
mixture is about to freezing transfer it into a separate mud pot and kept out of reach 
without aeration. The next day water content in the mixture is drained and the salt is dried 
under sunlight. The above said procedure is repeated for seven times to get the purified 
Potassium Nitrate salt.  
  
2. SEENAM (Alum) - Aluminium Potassium Sulphate  
 The alum is dissolved in water, filtered, boiled when it attains the jelly 
consistency. It is allowed to cool to get it in a purified form.  
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Method of Preparation: 
 
Two parts of purified Vediyuppu and one part of purified Seenam are powdered 
and mixed. This mixture is taken in an earthen vessel and heated in mild flame till it 
melts. This colloid mixture is then allowed to cool till it becomes hard. Then it is 
powdered well and stored in an air tight glass container. 
 
 
PREPERATION OF THIRIKADUGU CHOORANAM 
 
 Required raw drugs: 
 
1. Chukku (Dried Ginger) – Zingiber officinale, Rosc  
2. Milagu (Black Pepper) – Piper nigrum. Linn  
3. Thippili (Long Piper) - Piper longum.Linn  
 
Purification of the raw drugs 
 
1. Chukku (Dried Ginger)- Zingiber officinale, Rosc  
Double the proportion of lime stone [calcium carbonate] solution is poured to the 
dried ginger and boiled for three hours, then wash it, dry and remove the peel. 
 
 
2. Milagu (Black Pepper) – Piper nigrum. Linn  
Soak it in sour butter milk for three hours then dry it in sunlight. 
 
3. Thippili (Long Piper) - Piper longum, linn  
Soak it in Plumbago zeylanica,Linn leaf juice for twenty four minutes(1 Nazhigai) 
and dry it in sunlight. 
 
 Method of Preparation:  
 
Equal parts of purified Chukku, Milagu and Thippili are powdered separately and 
mixed thoroughly and stored in an air tight container. 
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DRUG STORAGE:  
 
The drug thus prepared is stored in a clean and dry glass bottles. 
 
DISPENSING:  
 
The Prepared Medicine was dispensed in sachets. 
 
DOSAGE:  
 
Kaasu edai [800mg]  
(Twice / day) after food.     
 
VEHICLE:  
Thirikadugu Chooranam 
 
COURSE:  
1 Mandalam [48 days] 
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STUDY DESIGN AND CONDUCT OF THE STUDY 
 
STUDY TYPE : An Open Clinical Trial 
 
STUDY PLACE : OPD and IPD of Ayothidasar  Pandithar Hospital, 
National Institute of Siddha, 
Tambaram Sanatorium, Chennai-47. 
 
STUDY PERIOD : 12 Months. 
 
SAMPLE SIZE :  40 patients. 
 
TRIAL DRUG : VEDIYUPPU KATTU 
           
DOSAGE  : Kaasu edai [800mg]  
                          (Twice / day) after food.     
 
VEHICLE  : Thirikadugu Chooranam 
 
COURSE  : 1 Mandalam [48 days] 
 
 
SUBJECT SELECTION: 
                 
As and when patients reporting at OPD of Ayothidasa Pandithar Hospital, 
National Institute of Siddha with clinical symptoms of Indigestion, Vomiting the residues 
of last food intake, Aversion to food, Flatulence, Fatigue, Generalized weakness, 
Sweating Gripping abdominal pain, Pricking pain of the chest were subjected to screening 
test & documented using screening proforma. 
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SELECTION CRITERIA 
 
INCLUSION CRITERIA 
· Age 20-55 of both sexes. 
· Patient willing to undergo blood investigation and willing to be admitted in 
the hospital or attend the OPD once in 7 days. 
· Patients with clinical symptoms of Indigestion, Vomiting the residues of last 
food intake, Aversion to food, Flatulence, Fatigue, Generalized weakness, 
Sweating Gripping abdominal pain, Pricking pain of the chest. 
· Patient willing to sign the informed consent stating that he/she will 
conscientiously stick to the treatment during 48 days but can opt out of the 
trial of his/her own conscious discretion. 
 
EXCLUSION CRITERIA  
Patient’s with a known  
· History of Gastric Carcinoma 
· History of complicated Peptic Ulcer 
· History of Cardio vascular disease 
· History of Liver disorders 
· History of Worm infection 
· Abnormal spinal curvature of thoracic vertebrae (kypho scoliosis) 
· History of Diabetes mellitus 
· History of Hyper tension 
· Pregnancy 
· Lactation 
· History of Appendicitis  
· History of pancreatitis 
were excluded. 
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WITHDRAWAL CRITERIA 
· Intolerance to the drug, and development of adverse reactions during the drug 
trial  
· Severe abdominal pain 
· Profuse vomiting and occurrence of Haematemesis. 
· Incidence of diarrhea, dysentery 
· Any other acute illness 
· Poor patient compliance and defaulters 
· Patients turned unwilling to continue in the course of clinical trial 
· Any other unforeseen circumstances rendering the patient unable to continue 
in the trial were withdrawn from the study. 
 
ASSESSMENTS AND INVESTIGATIONS: 
        A) Clinical assessment 
             Siddha assessment 
        B) Routine investigations 
  Modern parameters 
  Siddha parameters 
        C) Special investigations 
    
A) CLINICAL ASSESSMENT: 
· Indigestion 
· Vomiting with residues of food intake lastly 
· Aversion to food 
· Griping epigastric pain 
· Flatulence 
· Fatigue 
· Generalized weakness 
· Sweating 
· Excessive thirst 
· Headache  
· Loss of weight 
· Regurgitation 
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 SIDDHA ASSESSMENT 
 
Ennvagaithervu (Eight types of Examination): 
 
§ Naadi 
§ Sparisam 
§ Naa 
§ Niram 
§ Mozhi 
§ Vizhi 
§ Malam 
§ Moothiram 
                                
B) ROUTINE INVESTIGATION 
Modern Parameters: 
BLOOD  
§ Hb (gm/dl) Total WBC Count( Cells/cumm) ,  
§ DC - (Polymorphs (%), Lymphocytes (%) Eosinophils (%), Monocytes (%), 
Basophils (%),   
§ Total RBC count (Million cells / cu mm), 
§ ESR (mm/hr) 
§ Blood glucose ( mg/dl) ( Fasting, Post Prandial or Random) 
 
LIPID PROFILE 
§ Serum cholesterol (mg/dl), HDL cholesterol (mg/dl), LDL cholesterol (mg/dl)-
VLDL cholesterol (mg/dl), Serum triglycerides (mg/dl).    
KIDNEY FUNCTION TESTS 
§ Blood urea(mg/dl), Serum Creatinine (mg/dl) 
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LIVER FUNCTION TESTS 
§ Serum total bilirubin (mg/dl) , Serum Direct bilirubin (mg/dl) , Serum Indirect 
bilirubin (mg/dl), Serum Alkaline phosphate (u/l) , SGOT (u/l), SGPT (u/l), 
Serum Total Protein   ( g/dl) , Serum Albumin( g/dl), Serum Globulin( g/dl), 
Serum Calcium (mg/dl), Serum Phosphorous (mg/dl), Serum Uric Acid (mg/dl). 
URINE 
§ Urine sugar (F)&(PP) or (R), Albumin, Deposits 
MOTION 
§ Ova, Cyst, Occult blood. 
Siddha parameters 
  
                   Malam  -  Niram 
     Elakal / Erukal 
     Muraigal  
 
                   Moothiram    
Neerkuri    - Niram 
   Edai 
   Manam 
   Nurai 
   Enjal 
     
Neikuri - 
 
C) SPECIAL INVESTGATIONS 
· Endoscope 
 
· USG  - Abdomen  
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PATIENT SCREENING         
INCLUSION / EXCLUSION 
INCLUSION CRITERIA 
EXCLUSION CRITERIA 
 EXCLUDED FROM TRIAL 
       STUDY NUMBER 
      HISTORY TAKING 
   LAB INVESTIGATION 
        TRIAL DRUG  
GENERAL     
TREATMENT 
CLINICAL ASSESSMENT 
OUTCOME 
INFORM ABOUT STUDY AND 
TRIAL DRUG 
 INFORMED COSENT FORM 
12.0 METHODOLOGYY 
IF ANY ADVERSE REACTION 
REFERED TO PHARMACO VIGILANCE 
DEPT OF NIS 
   TREATED IN OPD 
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STUDY ENROLLMENT 
§ In this Open Clinical Trial, patients reporting at the OPD with the clinical 
symptoms of Indigestion, Vomiting the residues of last food intake, Aversion to 
food, Flatulence, Fatigue, Generalized weakness, Sweating Gripping abdominal 
pain, Pricking pain of the chest etc., were examined clinically for enrolling in the 
study based on the inclusion and exclusion criteria.  
§ The patients enrolled were informed (Form IV) about the study, trial drug, 
possible outcomes and the objectives of the study in the language and terms 
understandable to them. 
§ After ascertaining the patient’s willingness, informed consent was obtained in 
writing from them in the consent form (Form IV-A).                                                                                                             
§ All these patients will be given unique registration card in which patient’s 
Registration number of the study, Address, Phone number and Doctors phone 
number etc. had be given, so as to report easily, if any complications arise. 
§ Complete clinical history, complaints and duration, examination findings-- all 
were recorded in the prescribed Proforma in the history and clinical assessment 
forms separately. Screening Form- I will be filled up; Form I-A,  
Form –II and Form –III were used for recording the patient’s history, clinical       
examination of symptoms and signs and laboratory investigations respectively. 
§ Patients were advised to take the trial drug with appropriate dietary advice (Form 
IV-D). 
 
CONDUCT OF THE STUDY: 
 
           As per Siddha literature, before starting the treatment for VAAYU KUNMAM, 
purgation was given with Agathiar kulambu 130 mg with palm jaggery 5gm, early 
morning, in empty stomach for one day. 
           The trial drug “VEDIYUPPU KATTU” was given with THIRIKADUGU 
Chooranam continuously for 48 days. OP patients visited the hospital once in 7 days. At 
each clinical visit clinical assessment was done and prognosis was noted. For IP patients 
the drug was provided daily and prognosis was noted. For IP patients, clinical 
assessments were carried out daily. 
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            Laboratory investigations were done at 0th day and 48th day of the trial. For IP 
patients, who were not in a situation to stay in the hospital for a long time was advised to 
attend the OPD for further continuation of the treatment. 
 Patients with previous Endoscopic investigations were included and after 
completion of the treatment they were subjected to endoscopic evaluation and changes 
were noted.  
 After the 35th day (6th visit), a card containing Symptom tables were given to each 
patient. The patients were advised to mark a tally mark for each occurrence of symptoms 
during the last two weeks of the treatment (36th – 48th day). These data’s were analyzed 
using symptom score according to vaezl, Grading and Staging in Gastroenterology, for 
outcome measurement.  
            During the course of the treatment, patient was advised not to take coffee, tea, 
curd, root tubers, sour and spicy foods, and advised to, take the diet as given in Form IV- 
D.  After the end of the treatment also, the patient was advised to visit the OPD for 
another 2 months for follow-up. If any of the trial patients who fail to collect the trial drug 
on the prescribed day but wants to continue in the trial, from the next day or two was 
allowed, but defaulters of one week and more were excluded from the study.  
 
DATA MANAGEMENT 
 
· After enrolling the patient in the study, a separate file for each patient was opened 
and all forms were filed in the file. Study No. and Patient No. were entered on the 
top of file for easy identification. Whenever study patient visits OPD during the 
study period, necessary recordings were made at the assessment form or other 
suitable form of the respective patient’s file. 
· The screening forms were filed separately. 
· The Data recordings were monitored for completion by Faculties, HOD and SRO 
(statistics). All collected data were entered in the computer using Microsoft Office 
software. Data entries were 100% cross checked manually. 
· All forms were further scrutinized in presence of Investigator by Senior Research 
Officer (Statistics) for logical errors and incompleteness of data to avoid any bias. 
No modification in the results was permitted for unbiased reports. 
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OUT COME OF TREATMENT 
Primary Outcome: 
Primary Outcome was mainly assessed by reduction in the clinical symptoms of 
Gripping abdominal pain, Flatulence and Regurgitation assessed by Symptom score 
according to vaezl. 
 According to the score obtained by the patient before and after treatment they are 
categorized as Level I (0 – 5), Level II (6 – 10) and Level III (11 – 15). 
 
Secondary Outcome: 
           Secondary outcome was assessed by comparing the following parameters, before 
and after the treatment. 
1) Reduction  in other clinical symptoms 
2) Changes in Endoscopic study (5 Patients) 
 
 ADVERSE EFFECT / SERIOUS EFFECT MANAGEMENT 
If the trial patient develops any adverse reaction, he/she will be referred to the 
pharmacovigilance department of NIS. The members of this department will assess the 
adverse event and recorded in the prescribed adverse reaction form. For any adverse 
effect the investigator will give the proper management in NIS OPD with free of cost. 
 
ETHICAL ISSUES 
1. Informed consent was obtained from the entire patient after explaining about the 
study in the understandable language to them. 
2. After getting the consent of the patient (through consent form) only, they were 
enrolled in the study.  
3. Treatment was provided free of cost.  
4. While collecting blood sample from the patient, only disposable syringes, 
disposable gloves, with proper sterilization of lab equipments were used to prevent 
infections.                          
5. The data collected from the patient were kept confidential. The patient’s were    
informed about the diagnosis, treatment and follow-up.  
6. The patients excluded [as per the exclusion criteria] from the study were given 
proper treatment, with full care at NIS. 
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19.0 ASSESSMENT FORMS 
 
Form – I             Screening and Selection Proforma 
Form – IA          History Proforma on enrollment 
Form - II            Clinical Assessment on enrollment  
Form - IIA          Clinical Assessment during and after the trial 
Form – III          Laboratory investigations on enrollment during and after the trial. 
Form - IV           Information sheet 
Form – IV A       Consent form 
Form - 1V-B       Withdrawal form 
Form - IV-C       Drug Compliance form 
Form – IV- D      Dietary Advice form. 
Form – IV-E       Adverse Reaction form  
 
 
 
 
 
 
 
 75 
 
Observations and Results are tabulated under the following headings, 
1. Age incidence. 
2. Sex distribution 
3. Gunam 
4. Body constitution 
5. Paruva Kaalam  
6. Nilam 
7. Diet 
8. Habit of Smoking and Alcohol 
9. Occupation 
10. Socio-economic status  
11. Positive family history for the disease 
12. Chronicity of illness 
13. Derangement in Vatham. 
14. Derangement in Pitham 
15. Derangement in Kabam. 
16.  Gnanenthriyam. 
17. Kanmenthiriyam  
18. Kosangal 
19. Udal thathukkal 
20. .Envagai thervugal 
18.a. Naadi 
18.b.Naa 
18.c.Vizhi 
18.d. Malam 
18.e.Neikkuri  
21. Clinical features 
22. Blood Grouping 
23. Statistical Analysis. 
24. Lab investigations. 
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OBSERVATION AND RESULTS 
1. AGE INCIDENCE: 
Table: 1 
AGE (YEAR) NUMBER OF CASES PERCENTAGE 
21-30 7 17.5 % 
31-40 19 47.5 % 
41-50 12 30 % 
51-60 2 5 % 
Total 40 100 % 
 
 
Fig:1 
 
 
Observation:  
As per table 1 & fig 1: The prevalence of the disease was found to be higher in 19 
cases (47.5 %) in the age group of 31 - 40 years, 12 cases (30%) in the age group of 41 - 
50 years, 7 cases (17.5 %) in the age group of 21 - 30 years and 2 cases (5 %) in the age 
group of 51 - 60 years. 
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2. SEX DISTRIBUTION:     
Table: 2 
GENDER NUMBER OF CASES PERCENTAGE 
Male 25 62.5 % 
Female 15 37.5 % 
Total 40 100% 
 
 
 
Fig:2 
 
 
 
Observation: 
As per table 2 and fig 2, Among the 40 patients selected, prevalence of the disease 
was found to be higher in males i.e. 25 cases (62.5%) then the female cases of 15              
( 37.5%). 
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3. GUNAM  
Table: 3 
GUNAM NUMBER OF CASES PERCENTAGE 
Sathuva gunam 0 0 % 
Rasatha gunam 40 100 % 
Thamo gunam 0 0 % 
Total 40 100 
 
 
Fig:3 
 
 
Observation:  
As per table 3 and fig 3: Among the 40 patients selected all were found to possess 
Rasatha gunam. 
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4. BODY CONSTITUTION: 
Table 4: 
 
 
Fig 4 
 
 
Observation:  
As per table 4 and fig 4: Among the 40 patients selected, all were found to be 
Vaatha thegi. 
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5. PARUVA KAALAM (SEASON)  
Table: 5 
PARUVA KAALAM NUMBER OF CASES PERCENTAGE 
Kaar        (Aug 16 – Oct 15)                     
) 
8 20 % 
Koothir    ( Oct 16 – Dec 15) - - 
Munpani  (Dec 16 – Feb 15) - - 
Pinpani    (Feb 16 – Apr 15) - - 
Ilavenil    (Apr 16 – Jun 15) 22 55 % 
Mudhuvenil (Jun 16 –August 15) 10 25 % 
Total 40 100 
 
 
Fig 5 
 
 
 
 
 
 
 
 
Observation:  
As per table 5 and fig 5: Among the 40 cases, in 22 cases (55%) the incidence of 
the disease seems to be higher in  Ilavenil kaalam (Apr 16 – Jun 15) , 10 cases (25%) in 
Muthuvenilkaalam (Jun 16 – August 15) and 8 cases ( 20 %) in Kaar kaalam. 
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6. THINAI: 
Table: 6 
THINAI NO OF PATIENTS PERCENTAGE 
Kurinji Nil Nil 
Mullai Nil Nil 
Marutham 28 70 % 
Neithal 11 27.5% 
Paalai 1 2.5% 
Total 40 100% 
 
FIG: 6 
 
 
Observation:  
As per table 6: The incidence of the disease was more in 28 (70 %) cases reported 
in Marutham Thinai, 11 (27.5%) cases in Neithal thinai and only 1 ( 2.5%) case from 
Paalai Thinai. 
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7. DIET 
Table: 7 
DIET 
NUMBER OF 
CASES 
PERCENTAGE 
Vegetarian 2 5 % 
Non-Vegetarian 38 95 % 
Total 40 100 
 
 
FIG: 7 
 
           
Observation:  
  As per table 7 and fig 7: Among 40 cases the incidence of the disease was higher 
in 38 (95%) cases, who were non vegetarians and lower in vegetarians 2 cases (5%). 
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8. Habits of Smoking and Alcohol 
Table: 8 
Habit 
NUMBER OF 
CASES 
PERCENTAGE 
Smoking and Alcohol 8 20 % 
Smoking only 1 2.5 % 
Non users 31 77.5 
Total 40 100 
 
 
Fig: 8 
 
 
Observation:  
  As per table 8 and fig 8: Among 40 cases the habit of consuming Smoking and 
Alcohol was found to be in 8 (20%) cases and only Smoking was found to be in 1 (2.5%). 
Remaining 31(77.5%) were non users of smoking and alchol. 
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9. OCCUPATION STATUS 
Table: 9 
OCCUPATION 
NUMBER OF 
CASES 
PERCENTAGE 
Field Work 24 60 % 
Desk work 8 20 % 
Others 8 20 % 
Total 40 100 
 
 
FIG: 7 
 
 
Observation:  
  As per table 9 and fig 9: Among 40 cases, 24 cases( 60%) were doing Field work, 
8 cases (20%) were doing Desk work and 8 cases (20%) were found to be with other 
works. 
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10. SOCIO-ECONOMIC STATUS 
Table: 10 
SOCIO-ECONOMIC STATUS         
(In terms of Income status) 
NUMBER OF 
CASES 
PERCENTAGE 
Lower 13 32.5 % 
Middle 27 67.5 % 
Higher - - 
Total 40 100% 
 
FIG: 10 
 
 
Observation:   
As per table 10 and Fig 10, the incidence of the disease was found to be higher in 
27 (67.5 %) cases belonging to Middle class, lower in 13 (32.5 %) cases belonging to 
lower class. 
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11. POSITIVE FAMILY HISTORY FOR THE DISEASE 
Table:11 
FAMILY HISTORY FOR THE 
DISEASE 
NO. OF CASES PERCENTAGE 
IN I DEGREE RELATIONSHIP 4 10 % 
NO POSITIVE FAMILY HISTORY 36 90 % 
Total 40 100% 
 
 
FIG 11 
 
 
Observation:  
As per table 11 and Fig 11. Among the 40 cases, Positive familial history  was 
seen in 4  (10 %)  patients and no history of family involvement was found in 36 cases 
(90 %).   
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12. CHRONICITY OF ILLNESS AT THE TIME OF RECRUITMENT: 
Table: 12 
CHRONICITY OF 
ILLNESS 
NO OF CASES PERCENTAGE 
Less than 6 months 4 10 % 
Six months – 1 year 4 10 % 
1 – 2 years 3 7.5 % 
2-5 years 21 52.5 % 
5-10 years 4 10 % 
More than 10 years 4 10 % 
Total 40 100 
FIG:12 
 
Observation:  
As per table 12 and Fig 12. The chronicity of illness before recruitment for the 
study was more in 21(52.5%) cases with 2-5 years of illness then 4(10%) cases in the 
category within 6 months, 6-12months, bet 5-10 years and above 10 years. 3(7.5%) the 
chronicity of illness was found to be bet 1 – 2 years. 
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13.  DERANGEMENT IN VATHAM: 
CLASSIFICATION OF VALI NUMBER OF CASES PERCENTAGE 
Pranan 40 100 % 
Abanan 19 47.5 % 
Samanan 40 100 % 
Udhanan 32 80  % 
Viyanan 3 7.5  % 
Nagan - - 
Koorman - - 
Kirukaran 4 10 % 
Devadhathan - - 
Danajeyan - - 
Table 13:   FIG 13 
 
Observation:  
As per table 13 and Fig 13 Samanan and Pranan were affected in all the 40 
(100%) Patients. In 32 (80 %) cases Udhanan was affected and Abanan was affected in 19 
(47.5%) of the cases. Viyanan was affected in 3 (7.5%) cases and Kirukaran was affected 
in 4 (10%) cases.  
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14.  DERANGEMENTS IN PITHA KUTRAM: 
Table 14: 
CLASSIFICATION OF AZHAL 
NUMBER OF 
CASES 
PERCENTAGE 
Analam 40 100  % 
Ranjagam 3 7.5 
Sathagam - - 
Alosagam - - 
Prasagam 1 2.5 % 
 
Fig 14 
 
Observation:  
As per table 14 and Fig 14, Among the 40 (100%) cases, Analam was affected in 
all the 40 (100%) cases as a result of epigastric tenderness, indigestion, abdominal 
discomfort and Flatulence. Ranjagam was affected in 3 (7.5%) cases as a result of pale 
conjunctiva. Prasagam was affected in 1(2.5%) cases due to dull skin texture. 
Analam Ranjagam Sathagam Alosagam Prasagam
Pitham 100% 7.50% 0 0 2.50%
40
3
0 0 1
0%
20%
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60%
80%
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15. DISTURBANCES IN KABA KUTRAM: 
Table 15: 
CLASSIFICATION 
OF KABAM 
NUMBER OF CASES PERCENTAGE 
Avalambagam 40 100 % 
Kiledhagam 40 100 % 
Pothagam 2 5 % 
Tharpagam - - 
Santhigam 1 2.5 (3) % 
 
FIG 15 
 
Observation:  
As per table 15 and Fig 15, Among 40 cases Avalambagam and Kiledagam were 
affected in all the 40 (100%) cases as a result of epigastric tenderness, indigestion, 
abdominal discomfort and Flatulence.  Pothagam was affected in 2 (5%) cases with poor 
taste sensation and Santhigam was affected in 1 (2.5 %) as a result of pain in both limbs. 
Avalambag
am
Kiledagam Pothagam Tharpagam Santhigam
Kabham 100% 100% 5% 0 3%
40 40
2 0 1
0%
20%
40%
60%
80%
100%
120%
Kabham
Kabham
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16. DISTURBANCES IN GNANENTHRIYAM: 
Table 16: 
SL.NO GNANENDRIUM NO OF CASES PERCENTAGE 
1 Mei 40 100 
2 Vai 8 20 % 
3 Kan 3 7.5% 
4 Mooku - - 
5 Sevi - - 
 
Fig: 16 
 
 
Observation:  
As per table 16 and Fig 16, Among 40 cases all 40 (100%) cases had Mei affected 
(Epi gastric tenderness).  8 (20%) cases had Vaai affected (mouth ulcers) and in 3 (7.5%) 
cases Kan was affected (pallor). 
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17. KANMENTHIRIYAM INVOLVEMENT: 
Table 17 
KANMENTHIRIYAM NO.OF CASES PERCENTAGE 
Kai 1 2.5 % 
Kaal 1 2.5 % 
Vai 8 20 % 
Eruvaai 19 47.5 % 
Karuvaai 1 2.5 % 
 
FIG 17 
 
Observation: 
As per table 17 and Fig 17.Among the 40 cases, Eruvaai was affected in 19 (47.5 
%) cases (variable in bowel habits). Vaai was affected in 8 (20 %) cases (Stomatitis). Kai 
(pain), Kaal (pain) and Karuvaai (white discharge) were affected in 1 (2.5 %) case.  
 
 
 
0
5
10
15
20
Kai Kaal Vai Eruvai Karuvai
2.5% 2.5%
20%
47.5%
2.5%N
o 
of
 P
at
ie
nt
s
Kanmenthireyam
 93 
 
18. KOSANGAL: 
Table: 18 
KOSANGAL NO OF CASES PERCENTAGE 
Annamaya kosam 40 100 % 
Pranamaya kosam - - 
Manomaya kosam 1 2.5% 
Vignana mayakosam 1 2.5% 
Anantha mayakosam 1 2.5% 
 
FIG: 18 
 
 
 
 OBSERVATION:  
As per table 18 and Fig 18, In all the 40 cases Annamaya kosam was affected due 
to clinical symptoms like epigastric pain, flatulence, vomiting, indigestion and gripping 
abdominal pain. Manomaya kosam (depression), Vignanamaya kosam (pain) and 
Anantha maya kosam (White discharge) were affected each in 1 (2.5%) cases. 
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19. DISTURBANCE IN UDAL THATHUKKAL 
Table 19: 
UDAL THATHUKKAL NUMBER OF CASES PERCENTAGE 
Saaram 40 100 % 
Senneer 3 7.5 % 
Oon 3 7.5 % 
Kozhuppu - - 
Enbu 1 2.5 % 
Moolai - - 
Sukkilam/Suronitham 1 2.5 % 
 
FIG: 19 
 
Observation: 
As per table 19 and Fig 19, Saaram, was affected in all the 40 cases due to 
generalized weakness, Oon (weight loss) and Senner (pale conjunctiva) were affected in 3 
(7.5 %) cases. Enbu (pain in joints) and Suronitham (white discharge) were affected in 
1(2.5%) cases. 
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20.  ENVAGAI THERVUGAL (EIGHT DIAGNOSTIC METHODS) 
Table 20 
ENVAGAI THERVUGAL NUMBER OF CASES PERCENTAGE 
Naadi (Vaatham & 
vaathapitham) 40 100% 
Naa (Coating & Fissured) 25 62.5% 
Niram (Pallor & Yellow) 8 20% 
Mozhi (Reduction) 8 20% 
Vizhi (Pallor & Yellow) 16 40% 
Sparisam (Warmth) 26 65% 
Malam (Constipation & 
Diarrhea) 19 47.5% 
Moothiram (Dysurea) 2 5% 
FIG 20 
 
Observation  
As per table 20 and Fig 20, Naadi was altered in all the 40 cases. Naa was affected 
in 25 (62.5%) cases, Vizhi was affected in 16 (40%) cases, Malam was affected in 19 
(47.5%), Sparism was affected in 26 (65%) cases due to warmth and Niram & Mozhi 
were affected in 8 (20%) and Moothiram was affected in 2(5%) cases. 
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20. a. NAADI 
Table 20 a 
NAADI NUMBER OF CASES PERCENTAGE 
Vatha predominat 30 75% 
Vaatha pitham 10 25% 
Total 40 100 
 
FIG 20 a 
 
 
Observation:  
As per the table 20a and Fig 20a, Majority of the cases 30 (75%) revealed 
predominantly Vatha naadi and 10 (25%) with Vatha pitha tontha naadi.  
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20. b. NAA 
Table 20 b 
NAA NUMBER OF CASES PERCENTAGE 
Coated 18 45 % 
Coated with 
Fissured 
7 17.5% 
Normal 15 37.5 % 
Total 40 100 
 
FIG 20 b 
 
 
Observation:   
As per the table 20 b and Fig 20 b, Among the total of 40 patients Coated tongue 
is noted in 18(45%) of cases and Coating with Fissured tongue was noted in 7 (17.5%). 
15 (37.5%) cases were found to be with normal tongue. 
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20. c. VIZHI 
Table 20 c 
VIZHI NUMBER OF CASES PERCENTAGE 
Pale 3 7.5 % 
Yellow 13 32.5 % 
Normal 24 60% 
Total 40 100 
 
 
FIG  20 c 
 
 
Observation:   
As per the table 20 c and Fig 20c, among the total of 40 patients Yellow 
conjunctiva is noted in 13 (32.5%) of cases, Pale colored conjunctiva was noted in 3 
(7.5%) and normal Vizhi was observed in 24 (60%). 
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20. d. MAALAM 
Table 20.d 
MALLAM NUMBER OF CASES PERCENTAGE 
Constipated 16 40 % 
Diarrhea 3 7.5 % 
Normal 21 52.5 % 
Total 40 100 
 
FIG  20 d 
 
 
 
Observation:   
As per the table 20 d and Fig 20d, among the total of 40 patients Constipation was 
noted in 16 (40%) of cases and Diarrhea was noted in 3 (7.5%). Remaining 21(52.5%) 
cases had normal bowel habits. 
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20. e. NEIKKURI  
Table 20 e. 
PATTERN NUMBER OF 
CASES 
PERCENTAGE 
Aravenaneendathu 
Vathaneer (Spreading  like a snake) 
28 70 % 
Aazhipolparaviathu 
Pitha neer (Spreading like a ring) 
8 20 % 
Muththothu Ninrathu 
Kabaneer (Stands  like a  pearl) 
4 10 % 
Total 40 100 
 
FIG 27 
 
Observation: 
As per the table 20 e and Fig 20 e, Among the total of 40 patients Vaatha neer was 
observed in 28 (70%) cases, Pitha neer was observed in 8 (20%) and Kabha neer was 
observed in 4 (10%) patients. 
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TABLE NO 21. CLINICAL FEATURES: 
CLINICAL 
FEATURES 
BEFORE AFTER 
NO  OF 
CASES/40 
% RELIEVED % REDUCED % NO 
IMPROV
EMENT 
% 
Indigestion 40 100% 34/40 85% 6/40 15% - - 
Vomiting with 
residues of food 
33 82.5% 30/33 91% 3/33 9% - - 
Aversion to food 40 100% 36/40 90% 4/40 10% - - 
Griping epigastric 
pain 
40 100% 34/40 85% 4/40 10% 2/40 5% 
Flatulence 31 77.5% 28/31 90% 2/31 6.5% 1/31 3.5% 
Fatigue 28 70% 26/28 93% 2/28 7% - - 
Generalised 
weakness 
39 97.5% 39 100% - - - - 
Sweating 2 5% ½ 50% - - ½ 50% 
Excessive thirst 3 7.5% 3/3 100% - - - - 
Headache 9 22.5% 8/9 89% 1/9 11% - - 
Loss of weight 3 7.5% 2/3 67% 1/3 33% - - 
Regurgitation 6 15% 4/6 67% 2/6 33% - - 
 
Observation: 
 As per the table 21, Indigestion, Gripping epigastric pain and aversion to food 
were found in all the 40 (100%) patients. Vomiting, flatulence and generalised weakness 
were present in majority of patients 33 (82.5%), 31 (77.5%) and 39 (97.5%) respectively. 
28 (70%) patients had fatigue, 9 (22.5%) patients had Headache, 6 (15%)patients were 
affected by regurgitation,3 (7.5%) patients were found to have loss of weight and 
excessive thirst and 2 (5%) patients have increased sweating. 
After treatment there was a considerable reduction in all symptoms, except  2 
(5%)patients showed no reduction in griping epigastric pain and 1 showed no reduction in 
flatulence.  
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FIG  21 a 
 
 
FIG  21 b 
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22. BLOOD GROUPING 
Table 22 
BLOOD 
GROUPING 
NUMBER OF 
CASES 
PERCENTAGE 
A + 11 27.5% 
A - 1 2.5% 
B + 8 20% 
O+ 18 45% 
O- 1 2.5% 
AB+ 1 2.5% 
TOTAL 40 100% 
 
Fig 22 
 
Observation: 
As per the table 22, among the 40 patients, 18(45%) belongs to the O+ Blood 
group, 11(27.5%) belongs to the A+ Blood group, 8(20%) belongs to the B+ Blood group 
and 1(2.5%) each belongs to the blood groups AB+, A- and O- respectively.  
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Observation with reference to symptom score according to vaezl , Grading and 
Staging in Gastroenterology: 
Level 1 – marks scored between 0 – 5 
Level 2 – marks scored between 6 – 10 
Level 3 – marks scored between 11 – 15 
Table 23: 
LEVELS 
(SCORES) 
SYMPTOM SCORE BEFORE TREATMENT SYMPTOM SCORE AFTER TREATMENT 
NO. OF CASES PERCENTAGE NO. OF CASES PERCENTAGE 
I (0-5) 0 0 % 28 70 % 
II (6-10) 1 2.5 % 7 17.5 % 
III(11-15) 39 97.5 % 5 12.5 % 
TOTAL 40 100 40 100 
 
FIG 23 
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Observations: 
 According to Vael’s symptom score of Grading and Staging in Gastroenterology, 
(Table 22)  
Among the 40 patients 
Before treatment 1(2.5%) patient was found to be in level 2 and 39 (97.5%) 
patients were found to be in Level 3.  
After treatment 28 (70%) patients were in level 1, 7(17.5%) patients were in Level 
2 and  5(12.5%) patients were in Level 3.  
 
STATISTICAL ANALYSIS: 
Symptom score Paired Samples Statistics 
SYMPTOM SCORE         MEAN ± SD     t VALUE p VALUE 
Before treatment         14.33 ± 1.185 18.930 P <0.001 
After treatment         5.40 ± 3.037 
 
The mean± standard deviation of symptom score of patients before and after 
treatment were  14.33 ± 1.185 and 5.40 ± 3.037 respectively which is statistically 
significant (t= 18.930  p<0.001). 
 
Haemoglobin Paired Samples Statistics 
    HAEMOGLOBIN         MEAN ± SD     t VALUE p VALUE 
Before treatment         13.85 ± 1.8 -2.714 P <0.010 
After treatment         14.55 ±1.97 
 
The mean± standard deviation of Haemoglobin of patients before and after 
treatment were  13.85  ± 1.8 and 14.55 ± 1.97 respectively which is statistically 
significant (t= -2.714  p<0.010). 
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LAB INVESTIGATIONS: 
ENDOSCOPIC EVALUATION 
Among the 40 patients screened 12 patients were found to have endoscopic study 
before treatment itself. After the completion of drug administration for 48 days, 5 patients 
willing to undergo endoscopic study were undergone the procedure and compared. 
S.No of 
Patient 
Before treatment After treatment 
1. Duodenal ulcers (healing), 
Duodinitis, Gastritis.  
Normal Gastro- Deodenoscopy 
2. Antral Gastritis Normal study 
3. Antral Gastritis Normal 
4. Multiple Duodenal ulcer with 
Duodenitis, Gastritis 
Normal Gastro- Deodenoscopy 
5. Gastritis Normal mucosal study 
 
Observations: 
Endoscopic evaluation of the 5 patients after treatment shows no inflammation in 
the gastric mucosa and they were found to be normal.  
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DISCUSSION 
Vaayu Kunmam is one among the eight types of Kunmam as mentioned by 
Siddhar Yugi in his ‘Yugi  Vaithia chinthamani’  The signs and symptoms of Vaayu 
Kunmam are Indigestion, nausea or Vomiting, aversion to food, flatulence, gripping 
abdominal pain and generalized weakness. These are similar to Gastritis in modern 
system of medicare. The aim of the study is to evaluate the safety and therapeutic efficacy 
of the trial drug Vediyuppu Kattu in the treatment of Vaayu Kunmam. 
In the siddha literature ‘Yakoobu Vaidhiya Chinthamani 700’ the drug Vediyuppu 
Kattu is mainly indicated for Atta Kunmam and Vaayu. Vediyuppu Kattu comprises of 
two mineral drugs namely vediyuppu and seenam which are found to be very efficacious 
in the treatment of vaayu Kunmam as per the text ‘Patartha Guna Chinthamani’. 
The raw drugs were purchased from reputed country drugs stores and 
authenticated by the concerned department. The trial drug was prepared by the standard 
operating procedure as mentioned in the protocol in the Dept of Gunapadam, National 
Institute of Siddha under the direct supervision of lecturers. 
              The safety of the trial drug usage and standardization of the trial drug through 
biochemical analysis were also ensured during the study. 
               The preclinical toxicity studies (Acute and long term toxicity) for the above said 
trial drug was carried out at National Institute of Siddha after getting the proper 
acceptance and permission from the Institutional Animal Ethical Committee. The trial 
drug was proved to be safe for human beings from the observations made from the study. 
The biochemical qualitative and quantitative analysis were done at the 
Biochemistry lab of NIS. SEM analysis and Trace metal detections were carried out at 
Sophisticated Analytical Instrument Facility, IIT, Chennai. It revealed the presence of 
effective minerals and the existence of the drug molecules at micro level. 
             After the approval of the Institutional Ethical Committee of NIS, the clinical 
study was conducted with a well defined protocol with a proper proforma under the direct 
supervision of faculties of Dept of Maruthuvam. After screening 70 cases reporting at the 
OPD, 40 cases were selected for induction to the trial. The patient who satisfied the 
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Inclusion and Exclusion criteria were admitted to the trial. The patients were well 
explained about the clinical trial and informed consent was obtained from them. 
The enrolled patients were subjected to lab investigations before and after 
treatment. On the day one of the treatment the patients were advised to take Agasthiyar 
kuzhumbu 130 mg with ginger juice, at early morning for purgation to normalize the 
deranged thodams. From the 2nd day onwards the patients were treated with the trial drug 
Vediyuppu Kattu 800mg with Thirikadugu Chooranam 400 mg, internal twice daily  for a 
period of 48 days. 
For OP patients, they should visit the hospital once in 7 days. At each clinical visit 
clinical assessment was done and prognoses were noted. For IP Patients clinical 
assessment was done daily and prognosis was noted. 
 For IP patients, who were not in a situation to stay in the hospital for a long time 
were advised to attend the OPD for the continuation of the treatment. All the patients 
were put under observation for 2 months as follow up period without the trial drug 
treatment. 
The observations are summarized below. 
1. Incidence with Age distribution: 
Among the 40 patients 
· 7(17.5%) cases were observed to be in the age group of 21 to 30 years 
· 19 (47.5%) cases were observed to be in the age group of 31 to 40 years. 
· 12 (30%) of cases were observed to be in the age group of 41 to 50 years. 
· 2 (5%) cases were observed to be in the age group of 51 to 60 years. 
Inference: In this study the prevalence was more in the age group 31 - 40 years. i.e the 
middle decade of life is mostly suffered with more stress.  
2. Incidence with Sex distribution: 
Out of 40 patients, 25(62.5%) cases were males and 15(37.5%) cases were 
females.  
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Inference: In this study the prevalence was more in males than the females, which clearly 
states the prevalence and predominance of the disease in males who may have irregular 
dietary habits and may consume alcohol or smoking.  
3. Incidence with reference to Gunam: 
     All the 40 cases were observed with Rasatha gunam. 
4. Incidence with reference to constitution of the body: 
     All the 40 (100%) cases were observed with Vaatha predominant. 
5. Incidence with reference to Paruvakalam: 
     Among the 40 cases observed, 
· 22 cases (55%) the incidence of the disease was observed in  Ilavenil kaalam  
· 10 cases (25%) the incidence of the disease was observed in Muthuvenilkaalam  
· 8 cases (20%) the incidence of the disease was observed in Kaar kaalam.  
6.  Incidence with reference to Thinai:  
Among the 40 cases observed  
· 28 (70%) cases were observed to be from Marutham. 
· 11 (27.5%) cases were observed to be from Neithal 
· 1 (2.5%) case was observed to be from Paalai. 
Inference: According to Siddha literature Neithal land which comprises Sea shore and its 
adjoining areas induce Vatha diseases. 
Though Marutham land is said to possess healthy leaving, now a day’s change in lifestyle 
and food habits may induce the diseases. 
7. Incidence with reference to Diet: 
Among the 40 cases observed  
· 38 (95%) cases were observed to have Non-vegetarian diet. 
· 2 (5%) cases were observed to have vegetarian diet. 
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Inference: Intake of Non Veg diet may lead to increased acid secretion in the stomach, 
which in turn may lead to the disease. 
 
8. Habits of Smoking and Alcohol: 
Among the 40 cases observed   
· 8 (20%) cases were found to be with the habit of Smoking and Alcohol 
· 1 (2.5%).case was found to have the habit of Smoking alone.  
Inference:  In 9(22.5%) cases the onset of disease may be due to the habit of smoking 
and alchol. 
9. Occupation status: 
Among the 40 cases observed   
· 24 cases( 60%) were doing Field work  
· 8 cases (20%) were doing Desk work and  
· 8 cases (20%) were found to be with other works 
10. Incidence with reference of Socio-economic status: 
Among the 40 cases observed   
· 27 (67.5 %) cases belonging to Middle class. 
· 13 (32.5 %) cases belonging to lower class. 
Inference: The incidence of the disease was found to be higher 27 (67.5 %) in Middle 
class. 
11. Incidence due to familial involvement history: 
Among the 40 cases observed   
· 4 (10%) cases had the incidence of the disease in their first degree relationship. 
· 36 (90%) cases did not have any family history for the incidence of the disease.  
Inference: In this study only few patients had familial history related to the disease. 
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12. Incidence with reference to chronicity of illness: 
Among the 40 cases observed, 
· In 21 (52.5%) of the cases the chronicity of illness was between 2 – 5 years. 
· In 4 (10%) of the cases the chronicity of illness was within 6 months. 
· In 4 (10%) of the cases the chronicity of illness was between 6 months-1 year. 
· In 4 (10%) of the cases the chronicity of illness was between 5-10 years. 
· In 4 (10%) of the cases the chronicity of illness was more than 10 years. 
· In 3 (7.5%) cases the chronicity of illness was between 1 – 2 years. 
 
Inference: The chronicity of illness before recruitment for the study was more in 
21(52.5%) cases who were between the time intervals of two years to five years.  
 
CONDITION OF MUKKUTTRAM: 
13.  Derangement in Vadha kutram: 
Among the 40 cases, 
· Pranan was affected in 40 (100%) cases which resulted in indigestion. 
· Abanan was affected in 19 (47.5%) cases which resulted in constipation in 16 
patients and Diarrhea in 3 Patients.. 
· Samanan was affected in all 40 (100%) cases as a result of epigastric pain, 
flatulence, indigestion and abdominal discomfort. 
· Udhanan was affected in 32 (80%) of cases which resulted in Nausea and 
vomiting. 
· Viyanan was affected in 3 (7.5 %) cases resulted in body pain. 
· Kirukaran was affected in 4 (10%) cases resulted in excess salaivation. 
· Naagan, Koorman, Devadhathan and Dhananjeyan were remained normal in all 40 
cases. 
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14.  Derangement in Pitha Kutram: 
Among 40 cases, 
· All 40 (100%) cases Anarpitham was affected, which resulted in loss of appetite, 
indigestion and abdominal discomfort  
· In 3 (7.5%) cases Ranjaga pitham was affected resulted in pallor of conjunctiva.  
· In 1 (2.5%) case Prasaga pitham was affected resulted in reduced glowing of skin. 
 
15. Derangement in Kabha kutram: 
Among 40 cases, 
· Avalambagam was affected in 40 (100%) cases, due to the derangement of 
Kilethagam. 
· Klethagam was affected in 40 (100%) cases resulted in digestive disorders. 
· Pothagam was affected in 2 (5%) cases resulted in tastelessness. 
· Santhigam was affected in 1 (2.5%) case resulted in joint pain. 
16. Incidence with reference to the Gnanendrium: 
Among 40 cases, 
· Mei was affected in all 40 (100%) cases (epi gastric tenderness was felt)  
· Vai was affected in 8 (20%) cases (Stomatitis) 
· Kan was affected in  3 (7.5%) cases (pallor of the conjunctiva) 
 
17. Incidence with reference to the Kanmendrium: 
Among 40 cases, 
· Kai (Upper limb) and Kal (Lower limb) were affected in 1(2.5%) (pain in the 
joints) 
· Vai (Mouth) was affected in 8 (20%) cases (stomatitis)  
· Eruvai was affected in 19(47.5%) cases (constipation in 16 and diarrhea in 3 
patients) 
· Karuvai was affected in 1(2.5%) patient (white discharge) 
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8. KOSANGAL: 
Among the 40 cases 
· Annamaya kosam was affected in all 40 cases (epigastric pain, flatulence, 
vomiting, indigestion and gripping abdominal pain)  
· In 1 (2.5%) case Vignanamaya kosam was affected ( pain in joints) 
· In 1 (2.5%) case Manomaya kosam was affected ( mental depression) 
· In 1 (2.5%) case Ananthamaya kosam was affected ( presence of white discharge) 
19. Incidence with reference to the Udal thathukkal: 
Among 40 cases, 
· Saaram was affected in all 40 (100%) cases that produced the symptoms like 
Generalised weakness and tiredness. 
· Senneer was affected in 3 (7.5%) cases that produced the signs like pale 
conjunctiva of the eyes.  
· Oon was affected in 3 (7.5%) cases that lead to weight loss. 
· Enbu was affected in 1 (2.5%) cases that produced the symptoms like joint pain. 
· Suronitham was affected in 1 (2.5%) case with white discharge. 
20. Incidence with reference to the Envagai thervugal: 
Among 40 cases, 
· Naadi: Under this study of naadi, all the 40 cases showed Vaatham 30(75%) and 
its tontham with Pitham (25%). 
· Naa was affected in 25(62.5%) cases as it showed coating of tongue in 18 (45%) 
and coating and fissured in 7(17.5%). 
· Niram was affected in 8(20%) case as it was observed by pallor and yellowish 
discolouration of the skin. 
· Mozhi was affected in 8 (20 %) cases as it leads to reduction of voice due to 
epigastric pain. 
· Vizhi was affected in 16 (42.5%) cases as it showed pale in 3(7.5%) and Yellow 
discolourisation of conjunctiva in 13(32.5%).  
· Sparisam was affected in 26 (65%) cases (warm feel on touching) 
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· Malam was affected in 19 (47.5%) cases, leading to constipation in 16(40%) and 
Diarrhea in 3(7.5%) of cases. 
· Moothiram was found to be affected in 2 (5%) patient with burning sensation 
during urination. 
20. a. Incidence with reference to the Naadi type: 
Majority of the cases 30 (75%) revealed Vatha naadi and 10 (25%) with Vatha 
pitha tontha naadi. 
20. b. Incidence with reference to the Naa changes: 
Among the total of 40 patients  
Coated tongue is noted in 18 (45%) of cases and coated with fissured tongue was 
noted in 7 (17.5%). Remaining 15 (37.5%) cases were found to be normal. 
20. c. Incidence with reference to the Vizhi: 
Among the total of 40 patients  
Yellow conjunctiva is noted in 13 (32.5%) of cases and Pale colored conjunctiva   
was noted in 3 (7.5%) and normal Vizhi was observed in 23 (57.5%) of cases. 
20. d. Incidence with reference to the Malam: 
Among the total of 40 patients  
Constipation is noted in 16 (40%) of cases and Diarrhea was noted in 3 (7.5%) 
cases. Remaining 21(52.5%) had normal bowel habits. 
20. e. Incidence with reference to the Neikuri: 
Among the 40 patients,  
· Vaatha neer was observed in 28(70%) of cases,  
· Pitha neer was observed in 8(20%) cases, 
· Kabha neer was observed in 4(10%) of cases.  
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OUTCOME MEASURES: 
21. CLINICAL FEATURES: 
Observation with reference to Clinical symptoms: 
1. Indigestion 
Among 40 patients all are found to have Indigestion. 
· In 34(85%) cases complete relief was found.  
· In 6(15%) cases there was reduction in symptom was present. 
 
2. Vomiting with residues of food 
Among 40 patients, 33 (82.5%) patients were found to have Vomiting with 
residues of food. Out of the 33 cases, 
· In 30(91%) cases complete relief was found.  
· In 3(9%) cases there was reduction in symptom was present. 
 
3. Aversion to food 
Among 40 patients all were found to have the symptom aversion to food. Out of 
them, 
· In 36(90%) cases complete relief was found.  
· In 4(10%) cases there was reduction in symptom was present. 
 
4. Griping epigastric pain 
Among 40 patients all were found to have the symptom of Griping epigastric pain. 
Out of them,  
· In 34 (85%) cases complete relief was found. 
· In 4 (10%) cases reduction in symptom was present. 
· In 2 (5%) cases there was no improvement. 
 
5. Flatulence 
Among 40 patients 31 (77.5%) were found to have the Flatulence. Out of 31 
patients,  
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· In 28 (90%) cases complete relief was found. 
· In 2 (6.5%) cases reduction in symptom was present. 
· In 1 (3.5%) case there was no improvement. 
 
6. Fatigue 
Among 40 patients, 28 (70%) patients were found to have Fatigue. Out of the 28 
patients, 
· In 26(93 %) cases complete relief was found. 
· In 2(7 %)  cases there was reduction in symptom was present. 
 
7. Generalized weakness 
Among 40 patients 39(97.5%) were found to have generalized weakness. After 
treatment all are found to have complete relief.  
 
8. Sweating 
Among  40 patients only 2(5%) were found to have sweating. Out of them, One 
was found to have complete relief and in the other there was no impact. 
 
9. Excessive thirst 
Among 40 patients only 3 (7.5%) were found to have the symptom of excessive 
thirst. After treatment all are found to have complete relief.  
 
10. Headache 
Among 40 patients 9 (22.5%) patients were found to have Headache. Out of the 9 
patients, 
· In 8(89 %) cases complete relief was found.  
· In 1(11 %) case there was reduction in symptom was present. 
 
11. Loss of weight 
Among 40 patients only 3 (7.5%) were found to have Loss of weight. Out of the 
three patients, after treatment 2 patients (67%) showed weight gain and 1patient 
(33%) showed no further weight loss. 
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12. Regurgitation 
Among 40 patients, 6 (15%) patients were found to have Regurgitation.. Out of 
the 6 patients 
In 4(67 %) cases complete relief was found.  
In 2(33 %) cases there was reduction in symptom was present. 
22. Incidence with Blood grouping: 
Among the 40 patients included in the study  
· 18(45%) belongs to the O+ Blood group,  
· 11(27.5%) belongs to the A+ Blood group,  
· 8(20%) belongs to the B+ Blood group and  
· 1(2.5%) each belongs to the blood groups AB+, A- and O- respectively 
 
23. Observation with reference to symptom score according to vaezl , Grading and 
Staging in Gastroenterology. 
Among the 40 patients 
· 1(2.5%) patient was found to be in level 2 and 39 (97.5%) patients were found to 
be in Level 3 during the induction for treatment.  
· After treatment 28 (70%) patients were in level 1, 7(17.5%) patients were in Level 
2 and 5(12.5%) patients were in Level 3.  
· This reduction in score after the treatment reveals the efficacy of the drug in the 
treatment of Vaayu Kunmam. 
 
24. STATISTICAL ANALYSIS 
I. SYMPTOM SCORE BEFORE AND AFTER TREATMENT. 
BIO STATISTICAL ANALYSIS 
 The clinical trials of the drug Vediyuppu kattu (Internal) is differentiated in terms 
of percentages. The effectiveness of the drug is assessed by using paired comparison test 
(paired t test). The responses of the patients to the drug are analyzed.  
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Assessment of the effectiveness of drug: 
 The effectiveness of the drug was assessed by the relief of the patients from 
clinical symptoms, and which is measured using symptom score. 
 Inference: The test drug was statistically significant (p>0.001) it shows its effectiveness 
in the treatment of Vaayu kunmam (Gastritis). 
 
25. ENDOSCOPIC EVALUATION 
Among the 5 patients with endoscopic evaluation 
Before the treatment 2 patients had the impression of Gastritis, 1 patient with 
Antral Gastritis, 1 patient with Gastritis associated with inflammation in the body of 
stomach and 1 patient with Gastritis associated with Duodenal ulcers and Deodenitis.  
 After the treatment all the 5 patients showed considerable improvement in 
the endoscopic evaluation and found to have normal endoscopic study. 
 
BIOCHEMICAL ANALYSIS: 
v Qualitative analysis of Vediyuppu kattu done in NIS biochemical lab revealed that 
it contains inevitable constituents like calcium, Iron and sulphate  
v Quantitative analysis  revealed that it contains chiefly 
« 2.325 mg/L of Sulphur. 
« 8.654 mg/L of Phosphorous. 
« 5.231 mg/L of Aluminium 
« 15.45 mg/L of Sodium 
« 200.528 mg/L of Potasium. 
« 9.564 mg/L of Silicate 
v The SEM is carried out by using FEI-Quanta FEG 200-High Resolution 
Instrument the PPM (PARTICLE PER MILLION) size seems to be 0.5 - 2µ.  
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TOXICITY STUDY: 
ACUTE TOXICITY: 
Acute toxicity studies done in National Institute of Siddha, as per WHO guide 
lines revealed the safety of the drug in oral dose (28.8mg/animal for mice) as it did not 
produce any adverse effects in the animals. There were no abnormalities detected in the 
internal organs on necropsy.  
CHRONIC TOXICITY:  
Chronic toxicity- Long term toxicity studies done in National Institute of Siddha, 
as per WHO guide lines did not reveal any adverse effects in the animal. Animal 
behavior, metabolic functions (food and water intake, defaecation, urination etc) did not 
reveal any abnormality. Blood investigation parameters and histopathological 
examination did not show any abnormal variations. 
Hence it can be concluded from the study that up to maximum dose (288 
mg/animal for wister rat) the drug was proved to be safe. 
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SUMMARY 
 
v The aim of the study was to evaluate the safty and efficacy of the drug Vediyuppu 
Kattu in the treatment of Vaayu Gunmam. 
v Before initiating the clinical trial, approval was got from the Institutional Animal 
Ethical Committee IAEC : 1248/ac/09/CPCSEA/4-06/2011 – 6 Dt. 20.12.2011and 
Institutional Ethical Committee IEC : NIS/IEC/2011/3/06 – Dt. 24.12.2011 for 
conducting the pre clinical studies and clinical studies respectively by submitting 
the well defined protocol and proforma. 
v The raw drugs were authenticated by the concerned department and the trial drug 
was prepared in the Gunapadam lab of National Institute of Siddha as per the 
Standard Operating Procedure mentioned in the protocol. 
v The medicine was then subjected to toxicity studies (Acute and long term toxicity 
studies) as per the protocol and the safety of the drug was ensured. 
v The qualitative and quantitative bio chemical studies were done at the bio 
chemistry lab of National Institute of Siddha. 
v  SEM analysis and trace metals detection were done at Sophisticated Analytical 
Instrument Facility, IIT, Chennai. 
v Among the 70 cases screened at the OPD of department of Maruthuvam NIS, 40 
cases were recruited for the trial as per the inclusion and exclusion criteria. 
v Clinical diagnosis of Vaayu Gunmam was made by Siddha and Modern 
methodology. 
v Before inducement into the trial informed consent was obtained from the patients. 
Out of the 40 cases 28 cases were treated in OPD and 12 cases in IPD. 
v A day before the trial drug administration, puragation was given to correct the 
elevated Vatha thathu and bring other two deranged thathus to equilibrium. 
v The clinical trial was conducted with the trial medicine Vediyuppu Kattu 800 mg 
b.i.d  with Thiri Kadugu Chooranam 400mg internal, for a period of 48 days, 
referred under the Siddha literature Yaakoobu Vaidhiya Chinthamani 700 
respectively..  
v Diet restriction was strictly followed during the period of drug administration. as 
per noted in the form IV E (Dietary advice form).  
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v Required lab investigations were carried out before and after the treatment and the 
concerned data was recorded in the proforma.  
v Clinical assessment was done daily in all the IP patients and in OP patients it was 
assessed once in 7 days. 
v During the study period, there was no event of any adverse reactions owing to the 
drug or disease. 
v In these studies out of 40 cases, 35 cases (87.5%) were found to be relieved from 
the clinical symptoms. In 3 cases (7.5%) the clinical symptoms were found to be 
reduced and no reduction was found in 2 cases (5%).  
v As per the Siddha Literature and modern science reviews and research articles, the 
ingredients of the trial drugs were found to have the property of controlling the 
disease Vaayu Gunmam. 
v Endoscopic evaluation of the patients before and after treatment shows the 
reduction of inflammation in the stomach. This showed the therapeutic effect of 
the drug in controlling the disease to a greater extent. 
v Statistical analysis showed significant reduction in symptoms and health 
assessment score assessed before and after the treatment (P< 0.010). Statistical 
analysis on lab parameters and toxicity studies also showed significant outcome. 
v Oral toxicity studies conducted ensured the safety usage of the drug to animals up 
to a maximum dose of 28.8 mg/animal for mice and 288mg/animal for wister rat.  
v Bio chemical analysis showed the presence of inevitable constituents like 
Calcium, Iron, Sulphate which plays a role in repairing and preventing the Gastric 
mucosal damage and inflammation in the disease.  
v The minimum particle size (0.5 - 2µ) unveiled in the (Particle Per Million size) 
PPM analysis shows the existence of the drug in micro particle size which 
contributes its therapeutic effect by the increased bio availability. 
 122 
 
CONCLUSION 
 
Ø The safety studies (the acute toxicity and long term toxicity) conducted revealed 
that the trial drug was safe even at higher dosage of 28.8 mg/animal for mice and 
288mg/animal for wister rat. There were no abnormalities found in blood 
investigation and histopathological examination. Hence it can be reasonably 
assumed that the drug is safe for human. 
Ø Clinical study revealed the therapeutic efficacy of the trial drug by showing, 
complete relief in 87.5% (35) cases and reduction of symptoms in 3 (7.5%) cases 
out of 40 cases.  
Ø Improvement was noted in the Endoscopic evaluation of patients after the 
treatment when compared with before, revealing the control of the disease. 
Ø There were no adverse reactions observed during the trial. 
Ø Because of the encouraging clinical outcome, the study may be further carried out 
with the same drug in a large number of cases of Vaayu kunmam.     
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BIO -CHEMICAL ANALYSIS OF VEDIYUPPU KATTU 
ANALYSED AT NATIONAL INSTITUTE OF SIDDHA 
S.No EXPERIMENT OBSERVATION INFERENCE 
1.  Physical Appearance of sample White in colour  
2. Solubility: 
a. A little (500mg) of the sample 
is shaken well with distilled water. 
b. A little (500mg) of the sample 
is shaken well with con. HCl/Con. 
H2So4. 
Completely soluble Absence of Silicate 
3. Action of Heat: 
   A small amount (500mg) of the 
sample is taken in a dry test tube and 
heated gently at first and then strong. 
 
White fumes   
evolved 
 
Presence of Carbonate 
4. Flame Test: 
  A small amount (500mg) of the 
sample is made into a paste with con. 
HCl in a watch glass and introduced 
into non-luminous part of the Bunsen 
flame. 
 No Bluish green 
flame appeared. 
Absence of Copper 
5. Ash Test:s  
   A filter paper is soaked into a 
mixture of sample and dil. cobalt 
nitrate solution and introduced into the 
Bunsen flame and ignited 
 No Yellow colour 
flame 
Absence of Sodium 
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Preparation of Extract:   
5gm of Vediyuppu Kattu is weighed accurately and placed in a 250ml clean 
beaker and added with 50ml of distilled water. Then it is boiled well for about 10 
minutes. Then it is cooled and filtered in a 100ml volumetric flask and made up to 100ml 
with distilled water. 
S.No EXPERIMENT OBSERVATION INFERENCE 
 I. Test For Acid Radicals   
1.  Test For Sulphate: 
2ml of the above prepared extract is taken in a test 
tube to this added 2ml of 4% dil ammonium 
oxalate solution. 
 Cloudy 
appearance 
present 
Present 
2. Test For Chloride: 
2ml of the above prepared extracts is added with 
2ml of dil-HCl is added until the effervescence 
ceases off. 
No Cloudy 
appearance 
present 
Absent 
3. Test For Phosphate: 
2ml of the extract is treated with 2ml of 
dil.ammonium molybdate solution and 2ml of 
con.HNo3. 
No Yellow 
appearance 
present 
Absent 
4.  Test For Carbonate: 
2ml of the extract is treated with 2mldil. 
magnesium sulphate solution. 
No Cloudy 
appearance 
present 
 
Absent  
5. Test For Nitrate: 
1gm of the substance is heated with copper turning 
and concentrated H2So4 and viewed the test tube 
vertically down. 
No Brown gas is 
evolved 
Absent 
6. Test For Sulphide: 
1gm of the substance is treated with 2ml of con. 
HCL 
No Rotten Egg 
Smelling gas 
evolved 
Absent 
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7. Test For Fluoride & Oxalate: 
2ml of extract is added with 2ml of dil. Acetic acid 
and 2ml dil.calcium chloride solution and heated. 
No Cloudy         
appearance 
Absent 
8. Test For Nitrite: 
3drops of the extract is placed on a filter paper, on 
that-2 drops of dil.acetic acid and 2 drops of dil. 
Benzidine solution is placed. 
No 
Characteristic 
changes 
Absent 
9. Test For Borate: 
  2 Pinches (50mg) of the substance is made into 
paste by using dil.sulphuric acid and alcohol 
(95%) and introduced into the blue flame. 
Bluish green 
colour flame not 
appeared 
   Absent 
 II. Test For Basic Radicals   
1. Test For Lead: 
2ml of the extract is added with 2ml of 
dil.potassium iodine solution. 
No Yellow 
Precipitate is 
obtained. 
Absent 
2. Test For Copper: 
a. One pinch(50mg) of substance is made into 
paste with con. HClin a watch glass and 
introduced into the non-luminuous part of the 
flame. 
No Blue colour 
flame 
No Blue colour 
precipitate 
formed. 
Absent 
3. Test For Aluminium: 
To the 2ml of extract dil.sodium hydroxide is 
added in 5 drops to excess. 
No Yellow 
colour appeared 
  Absent 
4. Test For Iron: 
a.To the 2ml of extract add 2ml of dil.ammonium 
solution 
b.To the 2ml of extract 2ml  thiocyanate solution 
and 2ml  of con HNo3 is added 
 
Mild Red colour 
appeared 
 
Present 
5. Test For Zinc:       To 2ml of the extract 
dil.sodium hydroxide solution is added in 5 drops 
to excess and dil.ammonium chloride is added.  
White precipitate 
is   not formed 
  Absent 
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6. Test For Calcium:  
2ml of the extract is added with 2ml of 4% 
dil.ammonium oxalate solution  
 Cloudy 
appearance and 
white precipitate 
is obtained 
   Present 
7. Test For Magnesium:  
To 2ml of extract dil.sodium hydroxide solution is 
added in drops to excess. 
No White 
precipitate is  
obtained 
   Absent 
8. Test For Ammonium: 
  To 2ml of extract 1 ml of Nessler's reagent and 
excess of dil.sodium hydroxide solution are added. 
  No Brown 
colour appeared 
     Absent 
9. Test For Potassium:  
   A pinch (25mg) of substance is treated of with 
2ml of dil.sodium nitrite solution and then treated 
with 2ml of dil.cobalt nitrate in 30% dil.glacial 
acetic acid. 
 
No Yellowish 
precipitate is 
obtained. 
 
Absent 
10. Test For Sodium: 
    2 pinches (50mg) of the substance is made into 
paste by using HCl and introduced into the blue 
flame of Bunsen burner. 
 No Yellow 
colour flame 
appeared 
 Absent 
11. Test For Mercury:  
   2ml of the extract is treated with 2ml of 
dil.sodium hydroxide solution.  
No yellow 
precipitate is 
obtained 
  Absent 
12. Test For Arsenic:  
   2ml of the extract is treated with 2ml of 
dil.sodium hydroxide solution. 
No brownish red 
precipitate is 
obtained 
Absent 
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III. Miscellaneous 
 
 
 
 
1.
  
Test For Starch:  
2ml of extract is treated with weak dil.iodine 
solution  
 No Blue colour 
developed 
Present 
2.
  
Test For Reducing Sugar:  
    5ml of Benedict's qualitative solution is taken in 
a test tube and allowed to boil for 2 minutes and 
added 8 to 10 drops of the extract and again boil it 
for 2 minutes. The colour changes are noted. 
Brick red colour 
not developed 
Absent 
3.
  
Test For The Alkaloids: 
a) 2ml of the extract is treated with 2ml of 
dil.potassium lodide solution. 
b)  2ml of the extract is treated with 2ml of 
dil.picric acid. 
c)  2ml of the extract is treated with 2ml of 
dil.phosphotungstic acid. 
 
. 
  
No Yellow 
colour developed 
 
- 
 
  Absent 
4.
  
Test For Tannic Acid:  
  2ml of extract is treated with 2ml of dil.ferric 
chloride solution  
 No black 
precipitate is 
obtained 
    Present 
5.
  
Test For Unsaturated Compound: 
  To the 2ml of extract 2ml of dil.Potassium 
permanganate solution is added.  
Potassium 
permanganate is 
not decolourised 
   Absent 
6.
  
Test For Amino Acid: 
    2 drops of the extract is placed on a filter paper 
and dried well. 20ml of  Biurette reagent is added. 
 
No Violet colour 
developed 
   Absent 
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7. Test For Type Of Compound: 
    2ml of the extract is treated with 2 ml of 
dil.ferric chloride solution.  
No green colour 
developed 
 
 
No red colour 
developed 
 
 
No violet colour 
developed 
 
 
No blue colour 
developed 
Absence of 
oxy quinole 
pinephrine 
and pyro 
catechol. 
Anti pyrine, 
Aliphatic 
amino acids 
and meconic 
acid are 
absent  
Apomorphin
e salicylate 
and 
Resorcinol 
are absent. 
 Morphine, 
Phenol cresol 
and 
hydrouinone
are absent 
 
 
Preliminary Qualitative Phyto chemical tests procedure and  
Interpretation of results 
S.NO CONSITUENTS INFERENCE 
1. Silicate Absent 
2. Carbonate Absent 
3. Copper Absent 
4. Sodium Absent 
5. Sulphate Present 
6. Chloride Absent 
7. Phosphate Absent 
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8. Carbonate Absent 
9. Fluoride  Absent 
10. Oxalate Absent 
11. Nitrate Absent 
12. Sulphide Absent 
13. Nitrite Absent 
14. Borate Absent 
15. Lead Absent 
16. Copper Absent 
17. Aluminium Absent 
18. Iron  Present 
19. Zinc Absent 
20. Calcium Present 
21. Magnesium Absent 
22. Ammonium Absent 
23. Sodium Absent 
24. Mercury Absent 
25. Arsenic Absent 
26. Starch Present 
27. Reducing Sugar Absent 
28. Alkaloids Absent 
29. Tannic acid Present 
30. Unsaturated 
Compound 
Absent 
31. Amino acids Absent 
 
162 
 
SOPHISTICATED ANALYTICAL INSTRUMENT FACILITY 
IITM, CHENNAI-36 
Table-1 
Colour characters of  Vediyuppu Kattu. 
S No Solvent used Under ordinary light Under ultra violet light 
1 PM White White 
PM-Powdered material 
 
Table-2 
Physicochemical properties of Vediyuppu Kattu. 
S. No. Parameters Values obtained 
(%w/w) 
Heavy/ toxic metals 
1 Total ash value 9.66 Lead BDL 
2 Acid insoluble ash 0.84 Cadmium BDL 
3 Water soluble ash 5.26 Mercury BDL 
4 Moisture content 10.47 Arsenic BDL 
BDL-Below detection limit 
 
Table-3 
Colour, nature and percent yields of extracts of Vediyuppu Kattu. 
S.No. Extract 
Solvents 
Colour Nature % 
Yield(w/w) 
 
SEM-Micro 
graph partical 
size range in 
micron 
pH 
1. Water White Solid 48 0.5 – 2 micron 8.9 – 9.1 
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SOPHISTICATED ANALYTICAL INSTRUMENT FACILITY 
IITM, CHENNAI-36 
INDUCTIVELY COUPLED PLASMA OPTICAL EMISSION SPECTROMETRY 
Introduction  
Inductively coupled plasma optical emission spectrometry (ICP-OES), is an 
analytical technique used for the detection of trace metals. It is a type of emission 
spectroscopy that uses the inductively coupled plasma to produce excited atoms and ions 
that emit electromagnetic radiation at wavelengths characteristic of a particular element. 
The intensity of this emission is indicative of the concentration of the element within the 
sample. 
Principle 
A Perkin-Elmer Optima ICP spectrometer is used for routine ICP-OES analysis. 
First, a high-energy radio frequency field is impinged upon a stream of argon gas. Then, a 
spark is used to ionize the argon gas, which forms a sustained plasma due to inductive 
coupling with the high energy radio frequency field and the continuous supply of fresh 
argon to the plasma torch. This plasma has solutions passed into it in the form of a fine 
aerosol. The aerosol is dried, the dried particles broken apart, and the individual elements 
are excited by interaction with the excited state argon in the plasma. As each atom returns 
to its ground state from the excited state, they emit light at wavelengths characteristic of 
the elements from which they originate. The emission intensity for each element is 
monitored for each standard solution and a calibration curve of emission intensity versus 
element concentration can be constructed. 
Extraction of information 
Obtaining qualitative information, i.e., what elements are present in the sample, 
involves identifying the presence of emission at the wavelengths characteristic of the 
elements of interest.  Obtaining quantitative information, i.e., how much of an element is 
in the sample, can be accomplished using plots of emission intensity versus concentration 
called calibration curves. Typical calibration graph is illustrated below 
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Typical ICP Calibration curve 
Experimental Procedure: Done at SAIF, IIT Madras, Chennai-36 
Perkin Elmer Oplima 5300DV  
40 M Hz RF generator 
Range: 165-782 nm;  
Detection limit: upto ppb level using SCD detector 
 Sample preparation – Microwave Digestion   
· Weigh 0.25g of test sample and transfer into a liner provided with the instrument. 
· Slowly add 9ml of Nitric acid or Sulphuric acid such that no piece of sample 
sticks on the slides. 
· Mix thoroughly and allow reacting for few minutes. 
· Place the liner in the vessel jacket. 
· Close the screw cap hand-tight in clockwise direction. 
· Seal the vessel and place in the rotor fixed in microwave. 
· Set temperature to 180°C for 5 minutes; hold at 180°C for least 10 minutes. 
· Allow the vessels to cool down to a vessel interior temperature below 60°C and to 
a vessel surface temperature (IR) below 50°C before removing the rotor. 
· The digested sample was made upto 100ml with millipore water. 
· If visible insoluble particles exist, solution could be filtered through whatmann 
filter paper. 
· Transfer the digested solution into plastic containers and label them properly. 
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Advantages: 
Good general-purpose technique 
Good dynamic range 
Accommodates organic solvents 
Multi-elemental technique 
Disadvantages 
Cost of the instrument 
Limits of detection 
Sample volume requirements 
Spectral interferences for unknown/complicated matrices 
Sample description: Vediyuppu Kattu 
Instrument            :  PERKIN ELMER OPTIMA 5300DV ICP-OES 
 Analyte Mean 
As 193.696 BDL 
Al 308.215 5.231 mg/L 
Ca 317.933 BDL 
Cd 226.502 BDL 
Cu 324.754 BDL 
Hg 253.652 BDL  
Fe 238.204 BDL  
K 766.491 200.528 mg/L 
Na 588.995 15.4526 mg/L 
Mg 257.610 BDL 
P 214.914 8.654 mg/L 
Pb 230.204 BDL 
S 181.975 2.325 mg/L 
Si 251.611 9.564 mg/L 
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SOPHISTICATED ANALYTICAL INSTRUMENT FACILITY 
IITM, CHENNAI-36 
HR SEM-METHODOLOGY: 
An SEM is essentially a high magnification microscope, which uses a focussed 
scanned electron beam to produce images of the sample, both top-down and, with the 
necessary sample preparation, cross-sections. The primary electron beam interacts with 
the sample in a number of key ways:- 
· Primary electrons generate low energy secondary electrons, which tend to 
emphasize the topographic nature of the specimen.  
· Primary electrons can be backscattered which produces images with a high 
degree of atomic number (Z) contrast.  
· Ionized atoms can relax by electron shell-to-shell transitions, which lead to 
either X-ray emission or Auger electron ejection. The X-rays emitted are 
characteristic of the elements in the top few μm of the sample.  
SAMPLE PREPARATION: 
Sample preparation can be minimal or elaborate for SEM analysis, depending on 
the nature of the samples and the data required. Minimal preparation includes acquisition 
of a sample that will fit into the SEM chamber and some accommodation to prevent 
charge build-up on electrically insulating samples. Most electrically insulating samples 
are coated with a thin layer of conducting material, commonly carbon, gold, or some 
other metal or alloy. The choice of material for conductive coatings depends on the data 
to be acquired: carbon is most desirable if elemental analysis is a priority, while metal 
coatings are most effective for high resolution electron imaging applications. 
Alternatively, an electrically insulating sample can be examined without a conductive 
coating in an instrument capable of "low vacuum" operation.  
 The SEM is carried out by using FEI-Quanta FEG 200-High Resolution 
Instrument. 
 
Resolution : 1.2 nm gold particle separation on a carbon substrate 
Magnification: From a min of 12x to greater than 1, 00,000 X 
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Application : To evaluate grain size, particle size distributions, material homogeneity   
   and inter metallic distributions. 
Experimental Procedure: Done at SAIF, IIT Madras, Chennai-36 
Sample preparation: 
                Sample preparation can be minimal or elaborate for SEM analysis, depending 
on the nature of the samples and the data required. Minimal preparation includes 
acquisition of a sample that will fit into the SEM chamber and some accommodation to 
prevent charge build-up on electrically insulating samples. Most electrically insulating 
samples are coated with a thin layer of conducting material, commonly carbon, gold, or 
some other metal or alloy. The choice of material for conductive coatings depends on the 
data to be acquired: carbon is most desirable if elemental analysis is a priority, while 
metal coatings are most effective for high resolution electron imaging applications. 
Alternatively, an electrically insulating sample can be examined without a conductive 
coating in an instrument capable of "low vacuum" operation.  
 
PARTICLE PER MILLION SIZE OF VEDIYUPPU KATTU 
                                                                 
 
PARTICLE PER MILLION SIZE 0.5 - 2 MICRON 
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TOXICOLOGICAL EVALUVATION OF VEDIYUPPU KATTU 
ACUTE TOXICITY STUDY OF VEDIYUPPU KATTU   
[WHO guidelines, 1993] 
Principle: 
Acute toxicity was carried out in Swiss albino mice with a single exposure of 10 
times of the recommended therapeutic dose of test compound. The study duration was 14 
days. 
Animal species  : Swiss albino mice 
Age / Weight / Size  :  6 weeks.  Mice-20-25 gms. 
Gender   :   Both male and female 
Number of Animals   : Mice: 20 
Acclimatization Period : 7 Days 
 
S.No Group No of mice 
1 Vehicle control 10  (5 male, 5 female) 
2 Toxic dose 10X therapeutic dose (28.8 mg) 10  (5 male, 5 female) 
 
Test Animals  
Test animals were obtained from the animal laboratory of the King institute, 
Chennai and stocked at Animal house, National institute of Siddha, Chennai. All the 
animals were kept under standard environmental condition (27+ or – 2 degree c).The 
animals had free access to water and standard pellet diet (Sai meera foods pvt.ltd, 
Bangalore).The principles of laboratory animal care were followed and the  Institutional 
Animal ethical committee approved the use of animals and the study design. 
(1248/ac/09/CPCSEA/4-06/2011 – 6 Dt. 20.12.2011). 
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Route of administration: 
Oral route was selected, because it is the normal route of clinical administration. 
Test substance and vehicle 
The test substance (Vediyuppu kattu & Thirikadugu Chooranam) was insoluble in 
water.  In order to obtain and ensure the uniformity in drug distribution, the drug was 
dissolved by aqueous Tween 80 solution (7 %).  
Administration of doses: 
The test substance was suspended in aqueous Tween 80 solution (7%), with 
uniform mixing and it was administered to the groups in a single oral dose. The control 
groups received equal volume of the vehicle. The animals were weighed before giving the 
drug. The dose level was calculated according to body weight, and surface area. Since the 
clinical dose was 800 mg\day. It was converted to animal dose (28.8 mg) and then 
administered. The principle of laboratory animal care was followed. 
Observations 
Observations were made and recorded systematically and continuously observed 
as per the guideline after substance administration. Animals were observed individually. 
Visual observations included skin changes, alertness, grooming, aggressiveness, 
sensitivity to sound, touch and pain, restlessness, tremors, convulsion, righting reflex, 
gripping reflex, pinna reflex, corneal reflex, writhing reflex, papillary reflex, urination, 
salivation, lacrimation for first 4 hrs, then periodically during the first 24 hrs. Animals 
were observed for body weight and mortality for 14 days. If animals dye during the 
period of study, the animals were sacrificed. At the end of the 14th day all animals were 
sacrificed and necroscopy was done. 
Body Weight 
Individual weights of animals were determined before the test substance was 
administered and daily for 14 days. Weight changes were calculated and recorded. At the 
end of the test surviving animals were weighed and sacrificed. 
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Results: Vediyuppu Kattu at the dose 28.8mg/animal did not exhibit any mortality in 
mice. 
No behavior changes were noted for the first 4 hours and for the next 24 hours and 
throughout the study period of 14 days. No weight reduction was noted before and after 
the acute study duration. Reflexes were found to be normal before and after the study. All 
other observations were found to be normal before and after the study. In Necropsy, the 
organs of the animal such as Liver, Heart, Lungs, Pancreas, Spleen, Stomach, Intestine, 
Kidney, Urinary bladder, Uterus all appeared normal. 
 
LONG TERM TOXICITY STUDY OF VEDIYUPPU KATTU: 
Animals             : Male and Female Wistar albino rats 
Age                     : 6-8 weeks 
Weight   : 150-200 gms 
Gender   :   Both male and female 
Number of animals   : Rat: 40 
Acclimatization period : 7 Days 
Clinical duration  : 90 days 
 
Animal source:      
Test animals were obtained from the animal laboratory of the King institute, 
Chennai, and stocked at Animal house, National Institute of Siddha, Chennai. All the 
animals were kept under standard environmental condition (27+ or – 2 degree c) .The 
animals had free access to water and standard pellet diet (Sai meera foods pvt.ltd, 
Bangalore). The principles of laboratory animal care were followed and the Institutional 
S. No Group No of Rats 
1 Vehicle control 10 (5male,5 female) 
2 1XTherapeutic dose (28.8 mg) 10 (5male,5 female) 
3 5XTherapeutic dose (144 mg) 10 (5male,5 female) 
4 10XTherapeutic dose(288 mg) 10(5male, 5 female) 
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Animal ethical committee approved the use of animals and the study design. 
(1248/ac/09/CPCSEA/4-06/2011 – 6 Dt. 20.12.2011). 
Identification of animal: 
By cage number, animal number and individual marking on fur. 
Housing & Environment: 
The animals were housed in polypropylene cages provided with bedding of husk 
.Dark and light cycle each of 12 hours. 
Administration period: 
The period of administration of the test substance to animals depends on the 
expected period of clinical use. Since the clinical dose of the test drug is 48 days and as 
per WHO guidelines the administration period is reported to be 90 days. 
Dose selection: 
The results of acute toxicity studies in Swiss albino mice indicated that 
Vediyuppu Kattu was non toxic and no behavioral changes, mortality was observed. On 
the basis of these results, the doses were selected for the study as per WHO guidelines.  
Preparation and administration of dose:        
The test substance Vediyuppu Kattu & Tirikadugu Chooranam was suspended in 
aqueous twin 80 solution (7%). It was administered to animals at dose levels of 
1Xtherapeutic dose (28.8 mg), 5XTherapeutic dose (144 mg) and 10XTherapeutic dose 
(288 mg).The control animals were administered vehicle only. Administration was by 
oral (gavage) once a day for 90 days. 
METHODOLODY: 
Randomization, numbering and grouping of animal: 
The animals were randomly divided into four groups for dosing up to 90days. 
Each group consist of 10 animals (5 per sex in each group) were allowed acclimatization 
period of 7 days to laboratory conditions prior to the initiation of treatment. Each animal 
was fur marked with picric acid. The females were nulliparous and non pregnant. 
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OBSERVATION: 
Experimental animals were kept under observation throughout the course of study 
for the following:         
Body weight:  
Weight of each rat was recorded on day 1 and at weekly intervals throughout the 
course of study and at termination to calculate relative organ weights. From the data mean 
body weights and percent body gain were calculated. 
Food and water consumption: 
The quantity of food consumed by groups consisting of an animal for different 
doses were recorded at weekly intervals. Food consumed per animal was calculated for 
control and the treated dose groups. 
Clinical sings 
All animals were observed daily for clinical signs. The time of onset, intensity and 
duration of the symptom if any were recorded. 
Mortality: 
All animals were observed twice daily for any mortality during entire course of 
study. 
TERMINAL STUDIES: 
 LABORATORY INVESTIGATIONS: 
Following laboratory investigations were carried out on day 91 in animals fasted 
over night. Blood samples were collected by cardiac puncture using sodium heparin (200 
IU\ml) for blood chemistry and potassium EDTA (1.5 mg/ml) for hematology 
anticoagulant. Blood sample were centrifuged at 3000 r. p .m for 10 minutes. 
Hematological investigations: 
Hematological parameters were determined by manual methods at the Tami Nadu 
Veterinary & Animal Sciences University, Chennai.  
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 Biochemical investigations: 
The effect of Vediyuppu Kattu on certain biochemical parameters were examined 
and compared with those of the control group. The blood samples collected with 
heparinized bottles were centrifuged at 5000 rpm for 10 minutes to obtain clear serum for 
the following investigation. Glucose was estimated using commercial Glucose estimation 
kit (Span Diagnostics) by the method of Barham et al., (1972) and Tenscher. et al., 
(1971).Haemoglobin PCV,RBC,Erythocyte count was estimated by Hemocytometer 
method of Ghai (1995). Total Leukocyte Count was estimated by Hemocytometer method 
of John (1972).Total (bilirubin test kid- malloy& evelyn 1937) direct and indirect 
bilirubin were determined.Alkaline phosphatase,Alanine  amino tranferase (ALT) and 
Aspartate amino transferase (AST) were measured by using ALT and AST test kit (kind 
& king) .Total protein TP concentration was determined.Albumin was determined based 
on its reaction with bromocresol green (binding method) .Urea was determined according 
to urease – berthelot method and plasma creatinine was estimated using jaffe rection. 
Results of biochemical investigations conducted on day 91 revealed significant changes 
in the values of different parameters studied when compared with those of respective 
controls. 
Statistical analysis done for the above said biochemical investigations did not 
reveal any significant difference in values between the control groups and test groups 
stating that the provided test drug is non toxic. 
NECROPSY:  
All the animals were sacrificed on day 91 under ether anesthesia. Necropsy of all 
animals was carried out and the weights of the organs including liver, kidneys, brain, 
stomach, heart, and lungs were recorded.  
HISTOPATHOLOGY: 
  Tissue samples of organs from control and treated animals were preserved in 10% 
formalin for preparation of sections using microtome. The organs included liver, kidneys, 
heart, lungs and stomach of the animals were preserved and they were subjected to histo 
pathological examination. 
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The organ pieces (3-5 micron) were fixed in 10% formalin for 24 hours and 
washed in running water for 24 hours .Samples were dehydrated in tissue processor and 
then cleaned in benzene to remove absolute alcohol. Embedding  was done by passing the 
cleared sample through three cups containing molten paraffin at 50 degree c and then a 
cubical block of paraffin made by the L moulds it was followed by microtome and the 
slides were stained with haematoxylin–eosin stain .Stained sections of each organ were 
examined under light microscope at high (40X) power magnification. All the histo 
pathological slides were prepared at Dept of. Veterinary Pathology, Tamil Nadu 
Veterinary & Animal Science University, 
Results:   
GROUP - I – Control   
Liver: Multifocal mononuclear cell infiltration. 
Lung:  Pulmonary congestion, peribronchial and interstitial mononuclear 
cell infiltration. 
Kidney: Shows normal appearing tubules and glomeruli. 
Stomach: Shows gastric mucosa with glands lined by tall columnar cell. 
Heart: No abnormality detected. 
Spleen: No abnormality detected. 
Impression: Normal study. 
 
GROUP - II – 1 X Therapeutic Dose (28.8 mg) 
Liver: Shows central veins with radiating cords of hepatocytes, portal 
trials and kupfer cells appear normal. 
Lungs: Shows bronchioles, alveoli , the alveolar septa with normal 
histology 
Kidney: Shows normal appearing tubules and glomeruli. 
Stomach: Shows gastric mucosa with glands lined by tall columnar cell 
Heart: No abnormality detected. 
Spleen: No abnormality detected. 
Impression: Normal study. 
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GROUP - III – 5 X Therapeutic Dose (144 mg) 
Liver:  Multifocal mononuclear cell infiltration. 
Lung:  Pulmonary congestion, peribronchial and interstitial mononuclear 
cell infiltration. 
Kidney: Mild tubular epithelial cell degeneration. 
Stomach: Non – glandular stomach; Neutrophilic and mononuclear cell 
infiltration in the lamina propria.  
Heart: No abnormality detected. 
Spleen: No abnormality detected. 
Impression: Normal study 
 
GROUP - IV – 10 X Therapeutic Dose (288 mg) 
Liver:  Multifocal mononuclear cell infiltration and mild periportal 
mononuclear cell infiltration. 
Lung:  Pulmonary congestion, peribronchial and interstitial mononuclear 
cell infiltration. 
Kidney: Tubular epithelial cell degeneration. 
Stomach: Non – glandular stomach; Neutrophilic and mononuclear cell 
infiltration in the lamina propria.  
Heart: No abnormality detected. 
Spleen: Haemosiderosis. 
Impression: Normal study. 
The histopathological studies did not reveal any abnormalities in the animals in 
both control and test groups stating that the drug is non toxic.  
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Hematological parameters after 90 days treatment with Vediyuppu Kattu in rats. 
Parameter Group I Group II Group III Group IV 
RBC (X106/µL) 8.20±0.63 8.72±0.80 9.22±1.10 9.03±0.52 
HB (%) 14.16±1.24 15.10±1.22 15.84±0.99 15.12±1.18 
Leukocyte (X103/µL ) 7.37±1.32 7.50±1.31 6.89±0.93 6.62±0.54 
Platelets (X103/µL) 840.4±80.42 816.25±87.74 837.1±87.14 780.76±70.32 
MCV (gl) 51.24±5.08 50.16±4.32 51.60±5.41 56.14±4.86 
N 23.22±2.16 22.53±3.70 24.74±3.62 25.18±3.11 
L 69.82±6.15 67.46±6.55 66.24±6.28 66.12±3.18 
M 2.0±0.34 2.0±0.35 2.24±0.28 2.32±0.26 
E 1.42±0.54 1.61±0.60 1.28±0.42 1.00±0.11 
B 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
ESR(mm) 1±00 1±00 1±00 1±00 
PCV 42.10±1.02 44.6±3.7 44.04±2.2 45±1.8 
Values are mean ± S.E.M. (Dunnett's test). *P<0.05; **P<0.01. N=6. 
Lipid Profile 
Parameter Group I Group II Group III Group IV 
Total 
cholestrol(mg/dL) 
75.28±4.4 78.10±7.6 82.20±8.10 82.64±6.2 
HDL(mg/dL) 114.5±0.47 161.57±0.38** 150.39±0.49** 140.02±0.37** 
LDL(mg/dL) 32.40±4.71 95.62±0.64 71.70±3.52** 86.43±0.57** 
VLDL(mg/dl) 16.32±2.42 15.27±2.24 16.10±1.44 15.06±1.11 
Triglycerides (mg/dl) 66.56±1.50 83.29±1.04** 118.30±1.02** 113.15±1.05** 
Blood glucose(mg/dl) 90.77±0.48 81.16±0.32** 58.56±0.45** 52.00±1.00** 
Values are mean ± S.E.M. (Dunnett's test). *P<0.05; **P<0.01. Vs. control   
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Effect of Vediyuppu Kattu biochemical parameters. 
Parameter Group I Group II Group III Group IV 
Total Bilirubin 
(µmol/l) 
17.12±2.16 16.70±1.10 15.12±1.15 20.66±1.35 
Bilirubin direct 
(µmol/l) 
13.64±1.21 11.74±1.04 10.78±0.86 10.12±0.73* 
ALP (U/L) 60.11±3.12 85.11±2.62** 102.10±1.92** 105.45±2.31** 
SGOT (U/L) 84.02±6.2 90.16±8.45 87.52±6.31 96.2±7.52 
SGPT(U/L) 71.72±7.2 74.31±6.2 82.2±7.10 93.5±7.50 
Total Protein(g/dl) 8.21±0.25 7.55±0.23 7.55±0.72 7.18±0.61 
Albumin(g/dl) 2.62±0.18 2.54±0.17 2.52±0.16 2.65±0.10 
Globulin(g/dl) 6.82±0.28 5.18±0.28** 4.78±0.22** 4.73±0.30** 
Urea(mg/dL) 6.35±0.25 7.30±0.19* 7.58±0.25** 8.85±0.22** 
Creatinine (mg/dL) 0.17±0.04 0.22±0.05 0.50±0.05** 0.52±0.04** 
Uric acid (mg/dL) 1.92±0.07 2.12±0.08 1.39±0.08** 1.29±0.07** 
Na m.mol 148.00±1.10 147.36±1.12 146.28±0.54 145.20±0.50 
K m.mol 6.12±0.88 5.90±1.00 5.68±0.78 5.82±0.69 
Cl m.mol 100.05±4.26 101.27±5.51 99.82±4.72 100.14±5.10 
Values are mean ± S.E.M. (Dunnett's test). *P<0.05; **P<0.01. Vs. control   
 
 
 
 
   
Lab Parameters Before Treatment 
     D.C  %  Blood Sugar (mg/dl) Serum Cholesterol  (mg/dl) 
S.No OPD/ 
IPD  No 
Hb 
g/dl 
T.Rbc 
Mil/cu 
ESR 
½ - 1hr 
T.Count 
Cells/cu 
P L M E B Plt 
Lak 
F PP R Total HDL LDL VLDL TGL 
1. C 73051 16.2 5.1 2/6 8800 54 45 - 1 - 2.4 - - 103 199 63 84 52 256 
2. C73216 15.2 5.1 2/6 5100 37 62 - 1 - 1.9 86   220 36 133 51 253 
3. C 73371 14.3 4.9 4/8 8900 67 32 - 1 - 3.1 - - 117 221 38 127 56 279 
4. C 73442 14.0 4.9 4/8 11000 60 38 - 2 - 3.2 78 - - 135 36 78 21 103 
5. C73666 14.1 4.8 2/6 5300 65 28 - 7 - 2.6 80 - - 203 34 109 36 162 
6. C 73671 16.0 5.1 2/6 11000 60 34 - 6 - 2.4 85 - - 190 54 38 33 120 
7. C 73826 14.2 5.0 6/12 7700 60 36 - 4 - 2.9 81 - - 209 55 42 66 124 
8. C 73822 12.4 3.8 8/18 9300 54 40 2 4 - 3.2 99 - - 178 38 56 48 66 
9. C 73988 16.3 5.4 2/4 7400 59 39 - 2 - 2.5 79 - - 210 42 56 60 875 
10. C 74492 17.1 4.7 2/4 8500 65 29 - 6 - 2.8 96 - - 247 68 120 66 325 
11. C 75067 14.4 4.9 2/10 10600 50 44 2 4 - 1.9 101 - - 203 46 145 42 263 
12. C 76023 13.2 4.7 6/14 6800 65 30 - 5 - 2.6 94 - - 158 35 106 17 85 
13. C 75948 14.4 4.6 4/8 4500 63 32 - 5 - 1.8 76 - - 165 40 110 15 75 
14. C 76327 15.9 4.8 4/8 10500 68 30 - 2 - 2.2 101 - - 164 30 124 10 50 
15. C 76329 14.4 4.6 4/8 6400 58 40 - 2 - 1.8 105 - - 236 49 174 13 66 
16. C 76330 14.8 4.7 4/8 6100 44 52 - 4 - 2.2 94 - - 179 30 139 10 50 
17. C 76467 13.8 5.2 4/8 8200 62 35 - 3 - 3.1 - - 108 188 35 119 34 170 
18. C 75970 15.5 5.4 18/36 5500 44 50 1 5 - 1.4 - - 103 125 30 87 8 40 
19. C 77289 10.9 4.0 6/14 6700 45 49 - 6 - 2.6 82 - - 182 30 142 10 50 
20. C 77311 10.7 3.5 4/10 6800 59 36 - 5 - 2.6 83 - - 179 30 129 20 100 
  
 
Lab Parameters Before Treatment 
     D.C  %  Blood Sugar (mg/dl) Serum Cholesterol  (mg/dl) 
S.No OPD/ 
IPD  No 
Hb 
g/dl 
T.Rbc 
Mil/cu 
ESR 
½ - 1hr 
T.Count 
Cells/cu 
P L M E B Plt 
Lak 
F PP R Total HDL LDL VLDL TGL 
21. C 77487 12.0 3.9 2/6 5600 50 43 2 5 - 3.9 98 - - 180 31 135 14 72 
22. C 77703 14.4 4.3 2/3 107000 64 31 - 5 - 2.7 - - 110 151 30 85 36 183 
23. C 77718 13.3 4.3 4/8 5500 60 33 1 6 - 1.5 88 - - 156 37 103 16 81 
24. C 77719 12.1 3.7 2/4 6500 68 29 - 3 - 2.1 87 - - 197 30 153 14 74 
25. C 84062 14.4 4.5 4/8 6600 62 33 - 5 - 2.5 79 - - 155 24 143 21 105 
26. C 84584 14.4 4.7 2/4 5800 55 36 1 8 - 2.3 - - 121 149 30 103 69 345 
27. C 86714 9.8 3.6 2/16 7500 62 33 - 5 - 2.6 100 - - 132 24 78 16 81 
28. C 86747 12.4 4.1 4/8 6000 65 32 - 3 - 2.4 83 - - 143 26 80 22 114 
29. C 75922 16.6 3.9 6/17 9500 43 46 1 10 - 3.0 84 - - 149 30 126 12 63 
30. C 95104 12 4.5 6/18 5300 50 40 2 8 - 2.1 101 - - 124 30 42 67 239 
31. C 73542 12.3 4.0 6/14 9400 65 26 - 9 -  89 - - 185 38 119 28 138 
32. C 74676 13.5 4.6 2/8 7500 61 34 - 5 - 3.2 91 - - 167 39 111 47 185 
33. C 75699 13.4 4.7 6/12 5800 59 35 1 5 - 2.5 68 - - 210 45 129 136 182 
34. C 93380 13.3 4.7 8/18 10300 60 34 - 6 - 2.9 106 - - 139 32 100 28 141 
35. C 64949 14.8 5.0 2/8 6400 73 21 - 5 - 2.4 91 104 - 180 41 88 39 197 
36. C 95029 12.4 4.3 6/20 6800 57 33 1 9 - 2.4 97 - - 110 27 35 10 50 
37. C 94846 13.4 4.6 12/24 6700 49 47 - 4 - 2.0 92 - - 114 27 88 19 97 
38. C 93333 16.5 5.2 2/10 6700 64 32 - 4 - 2.4 97 131 - 129 30 77 34 170 
39. C 95846 10 3.4 2/12 7000 55 40 - 5 - 3.6 93 - - 205 43 97 31 157 
40. D 01526 15.4 4.7 2/4 8500 54 34 - 2 - 2.9 80 - - 198 37 87 20 101 
  
Lab Parameters Before Treatment 
  Blood 
Group 
RFT (mg/dl) LFT (mg/dl) Serum  (gm/dl) (IU/L) 
S.NO OPD/ IPD  
No 
Rh 
Type 
Urea Creat U.acid T.Bil Dir Ind Tota
l 
Alb Glb Cal Phos OT PT ALKP 
1. C 73051 O - 21 0.6 6.6 0.6 0.4 0.2 7.6 5.5 2.1 - - 33 41 155 
2. C73216 O + 15 0.6 5.1 0.8 0.5 0.3 7.3 5.2 2.1 - - 36 38 180 
3. C 73371 O + 29 0.7 9.7 0.6 0.4 0.2 6.9 5.2 1.7 - - 29 37 144 
4. C 73442 O + 17 0.6 3.9 0.5 0.3 0.2 7.9 5.5 2.4 - - 18 14 159 
5. C73666 O + 23 0.6 - 0.6 0.3 0.3 7.8 5.4 2.4 - - 23 41 183 
6. C 73671 O + 38 0.8 - 0.6 0.3 0.3 8.1 5.8 2.3 - - 20 17 187 
7. C 73826 A + 24 0.7 - 0.5 0.3 0.2 7.7 5.0 2.7 - - 35 31 116 
8. C 73822 B + 16 0.7 - 0.4 0.2 0.2 7.8 4.6 3.2 - - 20 15 193 
9. C 73988 B + 24 0.6 - 0.6 0.3 0.3 7.1 4.0 3.1 - - 29 30 163 
10. C 74492 A + 28 0.7 - 0.9 0.6 0.3 6.7 3.5 3.2 - - 34 39 154 
11. C 75067 A + 14 0.5 - 0.4 0.2 0.2 7.9 4.9 3.0 - - 23 25 152 
12. C 76023 O + 29 0.8 - 1.0 0.4 0.6 6.3 4.6 1.7 - - 23 25 164 
13. C 75948 B + 16 0.5 - 0.6 0.2 0.4 6.4 4.9 1.5 - - 24 26 170 
14. C 76327 A + 20 0.6 - 0.9 0.4 0.5 6.2 4.9 1.3 - - 30 28 184 
15. C 76329 B + 21 0.7 - 1.4 0.6 0.8 6.9 4.9 2.0 - - 18 20 185 
16. C 76330 B + 24 0.8 - 0.8 0.2 0.6 6.9 4.0 2.9 - - 13 15 183 
17. C 76467 A + 21 0.7 - 0.4 0.2 0.2 7.7 5.1 2.6 9.9 2.8 28 30 204 
18. C 75970 A + 16 0.5 - 1.1 0.5 0.6 6.7 4.7 2.0 - - 19 22 189 
19. C 77289 O + 18 0.5 5.5 0.4 0.2 0.2 7.0 5.0 2.0 - - 32 33 168 
20. C 77311 AB + 20 0.6 - 0.4 0.2 0.2 7.1 4.4 2.7 - - 13 15 170 
 
  
Lab Parameters Before Treatment 
  Blood 
Group 
RFT (mg/dl) LFT (mg/dl) Serum  (gm/dl) (IU/L) 
S.NO OPD/ IPD  
No 
Rh 
Type 
Urea Creat U.acid T.Bil Dir Ind Tota
l 
Alb Glb Cal Phos OT PT ALKP 
21. C 77487 O + 23 0.7 6.0 0.4 0.2 0.2 7.0 5.0 2.0 - - 27 30 194 
22. C 77703 O + 17 0.5 6.0 0.6 0.3 0.3 7.2 4.8 2.4 - - 25 29 222 
23. C 77718 B + 19 0.6 6.7 0.6 0.2 0.4 7.0 4.9 2.1 - - 18 20 138 
24. C 77719 A + 28 0.8 6.0 0.9 0.3 0.6 6.8 4.0 2.8 - - 34 24 152 
25. C 84062 O + 24 0.7 4.2 0.4 0.2 0.2 5.8 3.4 2.4 - - 22 23 180 
26. C 84584 B + 24 0.7 6.2 0.6 0.2 0.4 7.6 5.0 2.6 10.6 2.9 12 14 132 
27. C 86714 A + 20 0.6 4.0 0.6 0.2 0.4 7.0 5.0 2.0 11 3.0 19 20 160 
28. C 86747 A + 14 0.4 5.9 0.5 0.2 0.3 6.0 4.0 2.0 10.5 3.0 17 18 150 
29. C 75922 O + 25 0.8 5 0.5 0.2 0.3 6.9 4.3 2.6 - - 18 20 135 
30. C 95104 B + 19 0.6 5.6 0.4 0.2 0.2 6.2 3.8 2.4 - - 22 23 160 
31. C 73542 O + 20 0.7 2.9 0.6 0.4 0.2 7.1 5.1 2.0 10.7 3.9 27 26 146 
32. C 74676 O + 18 0.7 - 0.4 0.2 0.2 6.1 4.6 1.5 - - 18 20 136 
33. C 75699 O + 23 0.7 - 0.6 0.2 0.4 6.9 4.5 2.4 - - 11 13 156 
34. C 93380 O + 16 0.5 3.7 0.5 0.2 0.3 6.5 3.6 2.9 11 3.1 25 26 246 
35. C 64949 A1 - 38 1.0 2.9 0.7 0.3 0.4 7.1 4.7 2.4 10.6 2.9 17 19 216 
36. C 95029 O + 22 0.6 4.1 0.5 0.2 0.3 5.2 3.2 2.0 - - 18 19 142 
37. C 94846 O + 20 0.6 3.5 0.5 0.2 0.3 7.4 4.0 3.4 10.4 3.0 17 18 184 
38. C 93333 A1 + 25 0.6 3.1 0.4 0.2 0.2 6.6 3.7 2.9 11.0 3.1 26 28 195 
39. C 95846 O + 19 0.5 3.0 0.4 0.2 0.2 6.6 4.0 2.6 11 3.0 36 27 166 
40. D 01526 A + 16 0.5 3.6 0.4 0.2 0.2 7.0 4.0 3.0 10.6 2.8 12 13 160 
 
 Lab Parameters Before Treatment 
S.NO OPD  / IPD  
No 
URINE Motion 
AlB Sug Pus Epi B.S B.P Ova Cyst Occult Blood 
1. C 73051 NIL NIL 1 - 2 2 - 3 NIL NEG NIL NIL NIL 
2. C73216 NIL NIL 2 – 3 2 - 3 NIL NEG NIL NIL NIL 
3. C 73371 NIL NIL 3 – 4 3 – 4 NIL NEG NIL NIL NIL 
4. C 73442 NIL NIL 2 – 3 2 – 3 NIL NEG NIL NIL NIL 
5. C73666 NIL NIL 2 – 4 2 – 4 NIL NEG NIL NIL NIL 
6. C 73671 NIL NIL 2 – 3 2 – 3 NIL NEG NIL NIL NIL 
7. C 73826 NIL NIL 1 – 2 1 – 2 NIL NEG NIL NIL NIL 
8. C 73822 NIL NIL 1 – 2 1 – 2 NIL NEG NIL NIL NIL 
9. C 73988 NIL NIL 1 – 2 1 – 2 NIL NEG NIL NIL NIL 
10. C 74492 TRACE NIL 1 – 2 1 – 2 NIL NEG NIL NIL NIL 
11. C 75067 NIL NIL 1 – 2 2 – 3 NIL NEG NIL NIL NIL 
12. C 76023 NIL NIL 2 – 3 2 – 3 NIL NEG NIL NIL NIL 
13. C 75948 NIL NIL 2 – 3 2 - 3 NIL NEG NIL NIL NIL 
14. C 76327 NIL NIL 1 – 2 1 – 2 NIL NEG NIL NIL NIL 
15. C 76329 NIL NIL 0 - 1 1 – 2 NIL NEG NIL NIL NIL 
16. C 76330 NIL NIL 1 – 2 0 - 1 NIL NEG NIL NIL NIL 
17. C 76467 NIL NIL 2 – 3 5 - 6 NIL NEG NIL NIL NIL 
18. C 75970 NIL NIL 2 – 3 2 - 3 NIL NEG NIL NIL NIL 
19. C 77289 NIL NIL 2 – 4 2 – 4 NIL NEG NIL NIL NIL 
20. C 77311 NIL NIL 1 – 2 1 – 2 NIL NEG NIL NIL NIL 
 
 
 
  
 
 
 
Lab Parameters Before Treatment 
S.NO OPD  / IPD  
No 
URINE Motion 
AlB Sug Pus Epi B.S B.P Ova Cyst Occult Blood 
21. C 77487 NIL NIL 1 – 2 2 - 3 NIL NEG NIL NIL NIL 
22. C 77703 NIL NIL 1 – 2 2 - 3 NIL NEG NIL NIL NIL 
23. C 77718 NIL NIL 1 – 2 1 – 2 NIL NEG NIL NIL NIL 
24. C 77719 NIL NIL 2 – 4 2 - 4 NIL NEG NIL NIL NIL 
25. C 84062 NIL NIL 1 – 2 2 - 3 NIL NEG NIL NIL NIL 
26. C 84584 NIL NIL 2 – 4 2 - 4 NIL NEG NIL NIL NIL 
27. C 86714 NIL NIL 3 - 4 3 - 4 NIL NEG NIL NIL NIL 
28. C 86747 NIL NIL 2 – 3 2 - 3 NIL NEG NIL NIL NIL 
29. C 75922 NIL NIL 2 - 3 1 – 2 NIL NEG NIL NIL NIL 
30. C 95104 NIL NIL 2 – 4 2 - 4 NIL NEG NIL NIL NIL 
31. C 73542 NIL NIL 4 – 5 5 - 6 NIL NEG NIL NIL NIL 
32. C 74676 NIL NIL 1 – 2 1 – 2 NIL NEG NIL NIL NIL 
33. C 75699 NIL NIL 0 - 1 2 - 4 NIL NEG NIL NIL NIL 
34. C 93380 NIL NIL 2 – 4 2 - 4 NIL NEG NIL NIL NIL 
35. C 64949 NIL NIL 2 – 4 2 - 4 NIL NEG NIL NIL NIL 
36. C 95029 NIL NIL 1 – 2 2 - 3 NIL NEG NIL NIL NIL 
37. C 94846 NIL NIL 4 – 5 4 – 5 NIL NEG NIL NIL NIL 
38. C 93333 NIL NIL 2 - 3 1 – 2 NIL NEG NIL NIL NIL 
39. C 95846 NIL NIL 2 – 4 2 - 4 NIL NEG NIL NIL NIL 
40. D 01526 NIL NIL 2 – 4 2 - 4 NIL NEG NIL NIL NIL 
  
Lab Parameters  After  Treatment 
     D.C  %  Blood Sugar (mg/dl) Serum Cholesterol  (mg/dl) 
S.No OPD/ 
IPD  No 
Hb 
g/dl 
T.Rbc 
Mil/cu 
ESR 
½ - 1hr 
T.Count 
Cells/cu 
P L M E B Plt 
Lak 
F PP R Total HDL LDL VLDL TGL 
1. C 73051 16.2 5.1 4/10 9700 52 40 3 5 - 2.0 86 101 - 142 28 71 30 154 
2. C73216 16.4 5.2 2/6 9500 56 38 3 3  2.3 88 106  150 32 70 33 160 
3. C 73371 13.3 4.5 2/4 9400 74 20 6 - - 3.1 - 156 - 208 26 97 68 315 
4. C 73442 16.2 5.4 2/4 6100 40 49 2 9 - 2.7 87 - - 177 30 141 37 174 
5. C73666 13.8 4.8 2/4 5500 60 35 - 5 - 2.7 84 - - 160 34 101 23 116 
6. C 73671 14.3 4.7 20/40 10500 61 31 - 8 - 2.4 77 - - 131 27 102 31 156 
7. C 73826 14.1 5.1 8/16 8100 59 25 1 15 - 3.2 88 - - 145 30 102 30 164 
8. C 73822 17.1 5.2 6/12 4600 65 33 - 2 - 1.5 102 - - 191 35 82 137 185 
9. C 73988 17.4 5.8 2/4 7500 61 36 - 3 - 2.8 74 - - 193 36 169 55 278 
10. C 74492 16.9 4.8 6/14 7800 58 33 - 9 - 3.0 82 - - 210 45 128 68 342 
11. C 75067 16.2 5.1 8/18 8800 60 32 1 7 - 2.0 82 - - 132 25 88 52 264 
12. C 76023 13.6 4.7 2/12 8100 66 22 2 10 - 2.5 104 - - 138 24 76 21 108 
13. C 75948 14.7 4.4 2/6 6100 58 34 - 3 - 2.6 94 - - 152 32 96 34 174 
14. C 76327 16.9 5.1 2/4 10400 74 23 - 3 - 2.7 - - 109 140 31 60 25 128 
15. C 76329 14.2 4.7 4/10 7300 55 40 - 5 - 2.0 96 163  146 33 68 28 144 
16. C 76330 15.1 4.9 2/10 10200 63 33 - 4 - 3.0 - - 113 200 34 131 26 130 
17. C 76467 12.2 4.5 6/18 9300 62 33 - 5 - 3.3 80 - - 132 26 86 41 208 
18. C 75970 16.5 5.6 2/4 4300 49 41 4 9 - 1.5 77 - - 126 27 50 24 123 
19. C 77289 12.9 4.4 10/22 6200 55 42 - 3 - 2.3 98 - - 152 34 68 54 272 
20. C 77311 14.3 3.9 6/12 5500 54 41 - 5 - 2.3 90 - - 182 36 120 32 112 
  
Lab Parameters  After  Treatment 
     D.C  %  Blood Sugar (mg/dl) Serum Cholesterol  (mg/dl) 
S.No OPD/ 
IPD  No 
Hb 
g/dl 
T.Rbc 
Mil/cu 
ESR 
½ - 1hr 
T.Count 
Cells/cu 
P L M E B Plt 
Lak 
F PP R Total HDL LDL VLDL TGL 
21. C 77487 17.6 5.2 2/4 9700 66 22 - 8 4 3.8 101 - - 168 34 106 36 184 
22. C 77703 17.2 5.3 4/8 11100 64 32 - 4 - 3.4 - - 116 123 28 98 48 244 
23. C 77718 16.3 5.2 2/6 6600 63 30 1 6 - 1.3 102 - - 146 30 102 19 97 
24. C 77719 13.1 3.5 2/4 4200 66 30 - 4 - 1.4 81 - - 200 34 160 30 90 
25. C 84062 15.1 4.6 2/4 6300 65 30 - 5 - 2.3 77 - - 146 38 100 23 115 
26. C 84584 14.6 4.7 2/4 5800 55 36 1 8 - 2.3 - - 121 149 30 103 69 345 
27. C 86714 10.6 3.9 4/10 7800 60 35 - 5 - 2.6 92 - - 108 30 52 16 83 
28. C 86747 12.5 4.0 2/10 6600 65 32 - 3 - 2.9 104 - - 188 42 82 53 266 
29. C 75922 17.3 5.5 2/6 5200 52 39 1 8 - 2.1 85 - - 191 30 102 21 108 
30. C 95104 11.5 4.4 2/6 6000 62 33 - 5 - 2.2 106 - - 231 38 101 22 110 
31. C 73542 12.8 3.9 6/12 7600 41 49 1 10 - - 83 - - 165 30 70 19 98 
32. C 74676 12.9 4.6 2/4 8800 64 30 - 6 - - - - 91 169 27 98 44 220 
33. C 75699 13.1 4.5 2/6 5500 50 40 2 8 - 1.8 70 - - 169 34 80 58 290 
34. C 93380 11.5 4.7 2/4 11200 62 33 - 5 - 2.5 - 123 - 138 33 72 37 185 
35. C 64949 15.2 5.2 2/4 4800 60 35 - - 5 1.6 91 - - 158 34 78 40 485 
36. C 95029 11.8 4.6 3/6 9500 50 45 - 5 - 3.0 95 - - 176 32 102 39 198 
37. C 94846 11.9 4.6 6/12 7100 43 45 - 12 - 2.4 104 - - 177 36 82 34 173 
38. C 93333 16.3 5.2 2/4 4900 55 40 - 5 - 2.2 88 - - 154 32 76 12 63 
39. C 95846 12.7 3.3 4/6 7100 55 38 - 7 - 3.2 86 - - 225 43 112 16 83 
40. D 01526 16 4.8 2/4 8400 56 32 - 2 - 3.2 84 - - 200 36 88 24 90 
 Lab Parameters  After  Treatment 
  RFT (mg/dl) LFT (mg/dl) Serum  (gm/dl) (IU/L) 
S.NO OPD/ IPD  
No 
Urea Creat U.acid T.Bil Dir Ind Tota
l 
Alb Glb Cal Phos OT PT ALKP 
1. C 73051 16 0.8 4.7 0.4 0.2 0.2 6.9 4.5 2.4 - - 20 24 164 
2. C73216 15 0.7 4.5 0.5 0.3 0.2 6.6 4.5 2.1 - - 20 21 154 
3. C 73371 25 0.8 8.6 0.4 0.2 0.2 6.8 3.1 3.6 - - 50 48 146 
4. C 73442 25 0.7 6.7 1.0 0.5 0.5 6.6 4.0 2.6 - - 15 16 176 
5. C73666 21 0.7 - 0.6 0.2 0.4 6.4 4.2 2.2 - - 20 25 194 
6. C 73671 25 0.8 - 0.6 0.2 0.4 6.9 3.9 3.0 - - 7 8 243 
7. C 73826 17 0.6 - 0.5 0.3 0.2 7.0 5.0 2.0 - - 22 24 213 
8. C 73822 14 0.5 - 0.4 0.2 0.2 6.8 4.8 2.0 - - 4.-0 26 196 
9. C 73988 29 0.8 6.0 0.7 0.3 0.4 6.9 4.0 2.9 - - 29 30 160 
10. C 74492 21 0.6 5.0 0.4 0.2 0.2 7.6 3.4 4.2 - - 27 28 180 
11. C 75067 21 0.6 5.8 1.3 0.6 0.7 7.2 4.1 3.1 12 3.6 14 15 142 
12. C 76023 18 0.5 5.4 0.5 0.2 0.3 5.6 3.6 2.0 11 3.0 11 12 156 
13. C 75948 18 0.5 5.7 0.5 0.2 0.3 7.3 5.2 2.1 11.7 3.2 18 19 166 
14. C 76327 15 0.5 5.8 1.5 0.6 0.9 6.2 4.2 2.0 10.0 3.1 28 29 170 
15. C 76329 23 0.7 8.6 0.5 0.2 0.3 7.7 5.1 2.6 11.4 3.4 22 23 164 
16. C 76330 31 0.9 6.1 0.6 0.3 0.3 7.1 5.1 2.0 11.9 3.5 36 28 195 
17. C 76467 24 0.7 3.0 0.6 0.2 0.4 7.0 5.0 2.0 11.0 3.2 10 11 145 
18. C 75970 14 0.6 4.7 1.4 0.9 0.5 7.4 4.4 3.0 10.0 3.2 25 26 165 
19. C 77289 24 0.8 5.9 0.5 0.2 0.3 7.2 5.2 2.0 11.3 3.0 29 30 178 
20. C 77311 14 0.4 3.0 0.3 0.1 0.2 6.7 4.7 2.0 10 3 21 31 166 
 
 
 Lab Parameters  After  Treatment 
  RFT (mg/dl) LFT (mg/dl) Serum  (gm/dl) (IU/L) 
S.NO OPD/ IPD  
No 
Urea Creat U.acid T.Bil Dir Ind Tota
l 
Alb Glb Cal Phos OT PT ALKP 
21. C 77487 14 0.4 5.9 0.6 0.2 0.4 7.0 5.0 2.0 11.0 3.0 11 12 150 
22. C 77703 14 0.4 5.9 0.5 0.2 0.3 5.5 3.2 2.3 10.2 3.1 15 16 156 
23. C 77718 14 0.4 6.5 0.5 0.2 0.3 7.0 5.0 2.0 10.9 3.0 22 19 168 
24. C 77719 14 0.4 6.2 0.4 0.2 0.2 6.5 4.5 2.0 12 3.5 19 20 165 
25. C 84062 19 0.5 3.2 0.4 0.2 0.2 6.0 3.4 2.6 10.6 3.2 17 19 149 
26. C 84584 20 0.6 5.0 0.5 0.2 0.3 5.6 2.8 2.8 10.8 2.9 13 15 146 
27. C 86714 14 0.4 3.1 0.4 0.2 0.2 6.1 4.1 2.0 11.5 3.1 12 15 182 
28. C 86747 23 0.7 3.4 0.6 0.2 0.4 5.7 3.4 2.4 10.6 3.6 13 15 145 
29. C 75922 15 0.6 4.9 0.6 0.2 0.4 7.4 4.0 3.4 10.1 3.9 19 20 168 
30. C 95104 14 0.6 4.1 0.6 0.2 0.4 6.7 4.3 2.4 10.8 2.9 16 18 170 
31. C 73542 22 0.7 2.3 0.4 0.2 0.2 6.8 4.2 2.6 - - 29 30 196 
32. C 74676 21 0.7 6.0 0.6 0.2 0.4 5.6 3.1 2.5 - - 15 16 150 
33. C 75699 14 0.4 2.6 0.7 0.3 0.4 7.4 4.8 2.6 10.4 3.0 13 14 149 
34. C 93380 14 0.5 3.2 0.8 0.3 0.5 6.0 3.9 2.1 10.7 3.0 12 14 152 
35. C 64949 15 0.5 4.2 0.4 0.2 0.2 6.3 4.1 2.2 10.7 2.7 49 42 215 
36. C 95029 15 0.4 4.1 0.5 0.2 0.3 5.1 3.0 2.1 10 2.9 28 30 194 
37. C 94846 15 0.5 4.3 0.6 0.2 0.4 6.2 4.0 2.2 10.9 3.4 20 22 180 
38. C 93333 14 0.5 3.3 0.5 0.2 0.3 6.3 4.2 2.1 10.2 3.3 24 26 185 
39. C 95846 16 0.6 3.0 0.5 0.2 0.3 5.9 3.3 2.6 10.0 2.8 26 28 183 
40. D 01526 16 0.4 3.8 0.4 0.2 0.2 7.2 4.1 3.1 10 2.6 14 16 170 
 
 
  
Lab Parameters After Treatment 
S.NO OPD  / IPD  
No 
URINE Motion 
AlB Sug Pus Epi B.S B.P Ova Cyst Occult Blood 
1. C 73051 NIL NIL 2 – 4 2 – 4 NIL NEG NIL NIL NIL 
2. C73216 NIL NIL 1 - 2 2 - 3 NIL NEG NIL NIL NIL 
3. C 73371 NIL NIL 2 – 4 2 – 4 NIL NEG NIL NIL NIL 
4. C 73442 NIL NIL 1 - 2 2 - 3 NIL NEG NIL NIL NIL 
5. C73666 NIL NIL 1 – 3 3 – 4 NIL NEG NIL NIL NIL 
6. C 73671 NIL NIL 2 – 3 2 - 3 NIL NEG NIL NIL NIL 
7. C 73826 NIL NIL 1 – 2 1 - 2 NIL NEG NIL NIL NIL 
8. C 73822 NIL NIL 2 – 3 2 - 3 NIL NEG NIL NIL NIL 
9. C 73988 NIL NIL 1 – 2 1 - 2 NIL NEG NIL NIL NIL 
10. C 74492 NIL NIL 3 – 4 2 - 3 NIL NEG NIL NIL NIL 
11. C 75067 NIL NIL 2 – 4 2 – 4 NIL NEG NIL NIL NIL 
12. C 76023 NIL NIL 2 – 4 2 – 4 NIL NEG NIL NIL NIL 
13. C 75948 NIL NIL 1 – 2 1 - 2 NIL NEG NIL NIL NIL 
14. C 76327 NIL NIL 2 – 4 2 – 4 NIL NEG NIL NIL NIL 
15. C 76329 NIL NIL 2 – 4 2 – 4 NIL NEG NIL NIL NIL 
16. C 76330 NIL NIL 2 – 3 2 - 3 NIL NEG NIL NIL NIL 
17. C 76467 NIL NIL 2 – 4 2 – 4 NIL NEG NIL NIL NIL 
18. C 75970 NIL NIL 1 – 2 2 - 3 NIL NEG NIL NIL NIL 
19. C 77289 NIL NIL 1 -  2 1 -  2 NIL NEG NIL NIL NIL 
20. C 77311 NIL NIL 2 – 4 2 – 4 NIL NEG NIL NIL NIL 
 
 
  
Lab Parameters After  Treatment 
S.NO OPD  / IPD  
No 
URINE Motion 
AlB Sug Pus Epi B.S B.P Ova Cyst Occult Blood 
21. C 77487 NIL NIL 1 – 2 1 – 2 NIL NEG NIL NIL NIL 
22. C 77703 NIL NIL 1 – 2 1 – 2 NIL NEG NIL NIL NIL 
23. C 77718 NIL NIL 1 – 2 1 – 2 NIL NEG NIL NIL NIL 
24. C 77719 NIL NIL 1 – 2 1 – 2 NIL NEG NIL NIL NIL 
25. C 84062 NIL NIL 2 – 3 2 – 3 NIL NEG NIL NIL NIL 
26. C 84584 NIL NIL 1 – 2 1 – 2 NIL NEG NIL NIL NIL 
27. C 86714 NIL NIL 8 – 10 10 - 12 NIL NEG NIL NIL NIL 
28. C 86747 NIL NIL 4 – 5 2 – 3 NIL NEG NIL NIL NIL 
29. C 75922 NIL NIL 1 – 2 1 – 2 NIL NEG NIL NIL NIL 
30. C 95104 NIL NIL 2 – 4 2 - 4 NIL NEG NIL NIL NIL 
31. C 73542 NIL NIL 1 – 2 2 - 3 NIL NEG NIL NIL NIL 
32. C 74676 NIL NIL 1 – 2 3 – 4 NIL NEG NIL NIL NIL 
33. C 75699 NIL NIL 1 – 2 1 – 2 NIL NEG NIL NIL NIL 
34. C 93380 NIL NIL 10 – 15 8 - 10 NIL NEG NIL NIL NIL 
35. C 64949 NIL NIL 2 – 4 3 – 6 NIL NEG NIL NIL NIL 
36. C 95029 NIL NIL 2 – 3 2 – 3 NIL NEG NIL NIL NIL 
37. C 94846 NIL NIL 2 – 4 2 - 4 NIL NEG NIL NIL NIL 
38. C 93333 NIL NIL 2 – 4 2 - 4 NIL NEG NIL NIL NIL 
39. C 95846 NIL NIL 2 – 4 2 - 4 NIL NEG NIL NIL NIL 
40. D 01526 NIL NIL 1 – 2 1 – 2 NIL NEG NIL NIL NIL 
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 CERTIFICATE 
Certified that the mineral drug Vediyuppu kattu formulated by 
Dr.S.Senthil  Karunakaran, Dept of Maruthuvam, National Institute of Siddha, 
Tambaram Sanatorium, Chennai – 47 was analyzed (Quantitative) by Physico- 
Chemical, SEM,ICP and Phyto chemical methods at SAIF, IITM, Chennai – 
36 during October 2012. 
 
